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SUMMARY  
 
Despite the advent of highly effective combined antiretroviral therapy (cART), HIV remains a major 
global health concern, for which we still do not have a cure. The major barrier to curing HIV is a 
long-lived reservoir of latently infected cells. Latently infected cells in patients are very rare (1/106 
CD4+ T cells) and cannot be clearly distinguished from their uninfected counterparts as we lack a 
ubiquitous cell surface marker to identify them. Reservoir cells are impervious to host immune 
surveillance and cART, and most importantly, they can be induced to re-establish a systemic 
infection upon cART interruption. Thus, currently the gold standard in management of HIV is life-
long cART, which besides being associated with important health, economic and social burdens, is 
available to only about half of HIV-infected individuals and millions of new infections occurring 
every year globally reflects reality. To halt the HIV pandemic, a cure is needed. To this end, one of 
the main approaches involves purging the latent HIV reservoir. However, progress in this field is 
hindered by the difficulty in studying HIV latency ex vivo and the lack of truly representative in vitro 
models. Another major approach to HIV cure is vaccination. However, HIV’s propensity to rapidly 
diversify within its host confers it with an immense evolutionary potential that enables HIV to evade 
immune recognition and develop drug resistances, and has thus far thwarted efforts in vaccine 
development. Thus, HIV diversification within its host is another major barrier to HIV eradication. 
The work in this thesis focuses on two features of HIV that preclude its eradication, namely, HIV 
latency and HIV diversification.  
 
Our first aim was to develop a HIV reporter humanized mouse model in which genuine latently 
infected cells can be identified, characterized and isolated. Such a model would provide valuable 
insights into the nature of the cells harboring latent HIV, as well as the mechanism that support 
latency, which are necessary for development of effective strategies to purge the latent reservoir. 
As humanized mice (hu-mice) provide a uniquely mutable system in which HIV infection can be 
studied in the context of a functional human immune system, we hypothesized that they would 
serve as a good basis for developing a HIV reporter model particularly suited to studying HIV 
latency. Thus, we introduced a Cre recombinase (Cre) inducible fluorescent transgene into the 
NSG humanized mouse model and used a recombinant HIV strain that encodes Cre for the 
infections. The concept behind this design is that when a cell carrying the inducible fluorescent 
transgene is infected with a HIV encoding Cre, the Cre subsequently present in the cell mediates 
recombination at loxP sites flanking the fluorescent reporter gene, resulting in the thereafter-
constitutive expression of the fluorescent protein. Thus, in the model, infected cells are marked in 
vivo and can be isolated based on the expression of the fluorescent reporter gene. Then, by 
treating infected reporter hu-mice with cART, latently infected cells can be studied and isolated 
from various deep tissues. We demonstrated that our HIV reporter hu-mouse model is functional, 
as we could specifically recognize and isolate productively infected cells in our model by flow 
cytometry and fluorescence-activated cell sorting. However when used in a latency scenario, the 
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resolution of our model was not high enough to enable the unambiguous detection and purification 
of latently infected cells based on the expression of the reporter gene. Thus, further optimizations 
must be implemented to make our model more suitable for studying HIV latency.  
 
Our second aim was to dissect the contribution of the host deaminase APOBEC3G (A3G) to HIV 
diversification. A3G is a component of the host innate anti-viral immune system and a potent 
restriction factor of HIV. A3G introduces extensive G-to-A mutations into the HIV genome, which 
generally render the virus defective. However, HIV effectively counteracts A3G with its accessory 
proteins Vif, which targets A3G for proteasomal degradation. Although Vif is indispensable for 
replication of HIV in vivo, Vif alleles with suboptimal A3G-neutralization abilities have been isolated 
from patients and are associated with HIV diversification and cART failure. Thus, we hypothesized 
that A3G-induced mutagenesis can enhance HIV diversification and HIV’s ability to adapt to 
selective pressures. To this end, we infected hu-mice with isogenic HIV clones differing only in 
their ability to counteract A3G and characterized the phenotype and genotype of the different 
viruses either in natural infections or in the context of an antiretroviral drug (3TC) to impose a 
selective pressure on our system. We found that in the absence of a selective pressure, the HIV 
clone with only partial activity against A3G was attenuated over time compared to wild type HIV, 
however it displayed a superior 3TC-adaptation phenotype. We show that these phenotypes are 
supported by increased viral diversity characterized by an A3G-mutational footprint and the faster 
emergence of a 3TC-resistance mutation that results from a G-to-A mutation in a dinucleotide 
context favored by A3G. Our results support the notion that sublethal A3G activity can enhance the 
evolutionary potential of HIV in vivo.  
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ZUSAMMENFASSUNG 
 
Die HIV Pandemie ist, trotz den heute verfügbaren hochaktiven antiretroviralen Therapien (ART), 
die sehr wirksam die HIV assoziierte Morbidität und Mortalität verringern, nicht unter Kontrolle und 
bleibt vor allen in Afrika ein immenses Problem für die dortige Bevölkerung. Diese ART vermögen 
zwar die HIV Vermehrung im Patienten zu unterdrücken, führen aber zu keiner Heilung. Eine der 
essentiellen Hürden für eine Heilung stellt das latente HIV Reservoir dar, d.h. HIV kann in 
bestimmten Zelltypen jahrelang überdauern. Zudem gibt es nur sehr wenig latent HIV infizierte 
Zellen in einem Patienten; Schätzwerte gehen von ca. einer latent HIV infizierten Zelle auf 106 
CD4+ T-Lymphozyten aus. Diese latent infizierten Zellen sind von anderen nicht-infizierten Zellen 
nicht aktuell unterscheidbar, da kein Zelloberflächen Marker existiert, der diese latent HIV-infizierte 
Zellen eindeutig identifizieren könnte. Diese latent infizierten Zellen sind auch nicht für das 
Immunsystem (Abwehrsystem) nicht erkennbar. Wie oben erwähnt, sind auch die herkömmlichen 
antiretroviralen Therapien unwirksam, da diese rein die produktive HIV Vermehrung unterdrücken, 
aber keinen Effekt auf das latente HIV Reservoir haben. Dieses führt nach Absetzen der ART zu 
einer erneuten HIV Infektion und entsprechend zu Fortschreiten der HIV Erkrankung. 
Entsprechend muss ART von den HIV-infizierten Patienten lebenslang eingenommen werden. 
Diese Therapien sind eine enorme gesundheitliche und soziale Belastung für die Patienten sowie 
eine Last für die Volkswirtschaft eines Landes. Des Weiteren ist ART aktuell nur für ca. die Hälfte 
aller HIV-infizierte Menschen verfügbar und es infizieren sich immer noch jährlich Millionen von 
Menschen weltweit neu mit HIV. Eine Heilung ist daher notwendig um die HIV Pandemie zu 
besiegen. Seit längeren wird studiert wie man dieses latente HIV Reservoir angreifen kann. Der 
Wissensgewinn in diesem Gebiet ist jedoch limitiert, da das Studium der HIV Latenz in vivo 
aufgrund der Seltenheit und fehlenden Markern der latent HIV-infizierten Zellen sehr schwierig ist, 
und in vitro Modelle nur beschränkt die HIV Latenz simulieren können.  
 
Unser erstes Ziel war es, ein Mausmodell zu generieren, das es ermöglicht, latent HIV-infizierte 
Zellen anhand eines Reporters zu identifizieren und diese dann zu charakterisieren und isolieren. 
Ein solches Modell wäre sehr wertvoll, um die die Latenz mechanistisch zu erforschen und ist 
zudem eine Notwendigkeit für die Entwicklung effizienter Therapien, die das latente HIV Reservoir 
zu eliminieren können. Das lymphatische Immunsystem in humanisierten Mäusen ist mittlerweile 
sehr gut manipulierbar und wir haben entsprechend humanisierte Mäuse eingesetzt, um ein 
solches Mausmodell für das Studium der HIV-1 Latenz zu entwickeln. Um dies zu erreichen haben 
wir ein Cre Recombinase (Cre) induzierbares Reportergen in die lymphatischen Zellen der 
humanisierten Mäuse eingebracht, welches nach Infektion mit einem rekombinanten HIV-Stamm, 
dass das Cre in seinem Genom enthält und in infizierten Zellen exprimiert, aufleuchtet. So ist 
dieses Reportergen flankiert von loxP Elementen, welche durch die Cre erkannt werden. Daraufhin 
kommt es zu einer sequenzspezifischen Rekombination des Reportergens und dieses kann dann 
in den infizierten Zellen exprimiert werden, in anderen Worten, nur Zellen die mit dem HIV infiziert 
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werden, leuchten auf. Der Promoter für die Expression des Reportgens ist konstitutiv aktiv und 
führt zu einer Transkription des Reportergens unabhängig ob es sich um eine produktive oder 
latente Infektion handelt. Die konstitutive Expression des Reportergens sollte dann auch die 
Isolation latent HIV infizierten Zellen erlauben, nachdem die virale Replikation unterdrückt ist. 
Somit wäre ein Mausmodell verfügbar, das mit ART behandelt werden kann, und in dem nur noch 
latent HIV-infizierte Zellen vorhanden sind. Wir konnten zeigen, dass das Mausmodell basierend 
auf diesem Reportersystem funktionierte und es uns möglich war mittels des Reportergens 
produktiv infizierte Zellen mittels Durchflusszytometrie zu identifizieren und zu isolieren. Leider war 
dieses Reportersystem nicht robust genug, um in humanisierten Mäuse, die mit ART behandelt 
wurden, eindeutig latent HIV-infizierten Zellen zu identifizieren und isolieren. Daher muss dieses 
System noch weiter für das in vivo Studium latent infizierter Zellen optimiert werden.  
 
Ein zweites Ziel dieser Arbeit war das Studium der Deaminase APOBEC3G (A3G), das in 
Wirtszellen exprimiert wird, inwieweit diese zur Diversifikation von HIV beiträgt. A3G ist eine 
Komponente des angeborenen Immunsystems und ein potenter HIV Restriktionsfaktor. In akut 
infizierten Zellen führt A3G zu Guanin-zu-Adenosin (G-zu-A) Mutationen im HI-viralen Genom, 
welche zu replikationsdefekten HI-viralen Virionen führen, die sich nicht mehr vermehren können. 
HIV kann jedoch den Effekt von A3G mittels eines viralen, akzessorischen Proteins namens Vif 
kompensieren. Vif führt zum proteosomalen Abbau von A3G in der infizierten Zelle und ist daher 
essentiell für die virale Replikation. Es wurden aber auch Vif Varianten in HIV-1 Patienten 
identifiziert, die nur mässig A3G neutralisieren können und diese korrelierten waren mit einer 
verstärkten HIV Diversifikation und einem Therapieversagen. Bekanntlich führt eine erhöhte 
Diversifikation der HI-viralen Proteine eher zu einem Therapieversagen. Entsprechend war die 
Arbeitshypothese, das A3G-induzierte Mutagenese zu einer erhöhten Mutationsrate mit erhöhter 
Diversifikation führt und somit dem Selektionsdruck einer antiretroviralen Monotherapie standhält. 
Um dieser Frage nach zu gehen, haben wir humanisierte Mäuse mit isogenen HIV Stämmen 
infiziert, die sich nur in der Vif basierten Eigenschaft A3G zu neutralisieren, unterscheiden. Wir 
haben dann in diesen Mäusen die viralen Phäno- und Genotypen entweder ohne Therapie oder 
unter Therapie mit der antiretroviralen Substanz 3TC untersucht. 3TC wurde hier verabreicht, um, 
wie oben ausgeführt, den Selektionsdruck auf das Virus zu erhöhen. Wir konnten experimentell 
nachweisen, dass der HIV-Stamm mit einer partiellen Vif basierten anti-A3G Aktivität im Vergleich 
zu dem Wildtyp-Stamm in unbehandelten Mäusen, inhibiert war. Jedoch war die partielle Vif 
Aktivität vorteilhaft sobald die Mäuse mit 3TC behandelt wurden. So konnten wir zeigen, dass der 
HIV-Stamm mit einer partiellen Vif Aktivität zu einer A3G basierten, höheren Diversifikation der HI 
Viren führte und damit zu einem schnelleren 3TC-Therapieversagen, das auf die favorisierte A3G 
induzierte G-zu-A Mutation zurückzuführen war. Die Ergebnisse dieser Arbeit unterstützen die 
These, dass eine subletale A3G Aktivität die Diversität und damit das evolutionäre Potenzial von 
HIV in vivo fördert.  
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1. INTRODUCTION 
 
1.1. The HIV pandemic and current treatment strategies 
In 1981, a series of clinical case reports of Pneumocystis carinii pneumonia (PCP) and Kaposi 
sarcomas (KS) primarily in young and apparently healthy homosexual men and intravenous drug 
abusers living in New York and California, rose the suspicion of a new retrovirus causing severe 
immunodeficiency [1]. PCP and KS are rare diseases that occur otherwise only in severely 
immunosuppressed patients. By 1983, the human immunodeficiency virus (HIV) type 1 (HIV-1, 
hereon forth simply referred to as HIV) was discovered as the causative agent [2, 3] and has 
become a major global health concern, with a death toll of at least 35 million individuals so far [4]. 
HIV originated in Africa from numerous cross-species transmissions of simian immunodeficiency 
virus (SIV) strains from their natural hosts, African nonhuman primates, to humans [5]. According 
to the World Health Organization (WHO), in 2016 there were approximately 36.7 million HIV-
infected individuals and 1.8 million new infections globally, with sub-Saharan African countries 
suffering the greatest HIV/AIDS burden [4]. 
 
HIV is a complex retrovirus that primarily infects CD4+ T lymphocytes and left untreated, it leads to 
a complex immune system dysfunction with chronic immune activation and inflammation, 
characterized by progressive depletion of the CD4+ T cells. This progressive immunodeficiency 
eventually culminates in the acquired immunodeficiency syndrome (AIDS) within 2 to 15 years in 
the majority of infected individuals [6]. AIDS is a severe state of immune system dysfunction, 
characterized by CD4+ T cell counts below 200 cells/ml of blood, high susceptibility to 
opportunistic infections and the development of AIDS-associated cancers and a fatal outcome in 
all patients.  
 
The advent of antiretroviral drugs (ARVs) and development of combination antiretroviral therapy 
(cART) in 1996 were major medical breakthroughs for the management of HIV infection, drastically 
curbing HIV transmission, mortality and morbidity [7, 8]. cART effectively suppresses viral 
replication and currently is the only effective treatment against HIV‐associated immunodeficiency, 
yet it cannot eradicate HIV. This is due to the rapid seeding of a latent HIV reservoir that persists 
despite prolonged viral suppression with cART [9-14], evidenced by the rapid reemergence of 
infectious virus upon treatment interruption [15, 16]. The major barrier to HIV eradication, and 
therefore HIV cure, is this latent reservoir. Without the complete elimination of the latent reservoir, 
cART must be taken lifelong, which is associated with a number of problems, such as adverse 
events, high costs, access to HIV clinics and care, social stigmatism, and emergence of drug-
resistances in case of non‐adherence [17, 18]. In addition, the WHO reports that in 2016 only 53% 
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of HIV-infected individuals received cART [19], owing mainly to the difficulty in provision and 
access to HIV-testing and care in Sub-Saharan Africa.  
 
The other major barrier to HIV eradication is HIV’s immense evolutionary potential, driven mostly 
by exceptionally high mutation and replication rates [20, 21] and recombination between co-
packaged genomes [22, 23]. Indeed, although HIV transmission is usually established by a single 
founder virus, within a very short period of time the HIV strains in the newly infected host become 
genetically distinguishable from one another, resulting in a highly heterogeneous pool of viral 
quasispecies. In this context, HIV has an exceptional ability to escape immune recognition, to 
adapt to environmental and antiretroviral drug pressures, and renders universal vaccination 
strategies ineffective [24, 25]. Therefore, a greater understanding of HIV latency, as well as HIV’s 
mechanisms of diversification will be crucial in developing effective novel eradication and 
vaccination strategies. 
 
As current cART and vaccination strategies cannot eradicate HIV, a cure is urgently needed to halt 
the HIV pandemic. Currently three main strategies are being explored: i) vaccines against HIV 
(reviewed in [26]); ii) gene therapies aiming to either excise integrated provirus from host cells or 
render host cells resistant to HIV infection (reviewed in [27]); and iii) drugs to purge or fully block 
the latent reservoir using latency reversing or latency-inducing agents, respectively (reviewed in 
[28, 29]). The latter will be discussed in more detail in section 1.5.4. HIV cure strategies can be 
subdivided into two categories, based on the aspired end goal. Sterile cure approaches aim to 
eradicate all cells harboring replication-competent HIV, whilst functional cure strategies aim to 
achieve sustained viral control in the absence of cART by, for example, boosting and 
supplementing the host immune system. 
 
1.2. HIV structure and genome 
HIV is a human-tropic lentivirus, belonging to the Retroviridae family. Distinguishing features of 
retroviruses are their pseudodiploid single-stranded RNA genomes and the necessity for 
chromosomal integration of their viral genetic material for productive viral replication. The viral 
RNA genome is reverse transcribed into double-stranded DNA by a viral reverse transcriptase 
(RT) and a viral integrase (IN) then catalyzes its permanent integration into the host genome. 
Thereafter the proviral genome (i.e. provirus) serves as a template for the synthesis of viral 
mRNAs and proteins required for production of progeny virions, which is orchestrated by cellular 
and viral proteins. Besides the three essential polyproteins Gag, Pol and Env, which encoding 
structural gene products common to all retroviruses, the HIV genome also encodes six accessory 
proteins: Tat (transactivator of transcription), Rev (regulator of expression of viral proteins), Nef 
(negative factor), Vpr (viral protein r), Vif (viral infectivity factor), and Vpu (viral protein unique) 
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(Figure 1). Therefore, HIV is categorized as a complex retrovirus. The entire length of the HIV 
genome is approximately 9.7kb. Gag codes for structural proteins necessary to the assembly of 
the virion infrastructure: the matrix (MA), capsid (CA, i.e. p24), nucleocapsid (NC), and p6. Pol 
codes for enzymes essential to replication and virion maturation: the RT, IN and protease (PR). 
Env encodes the surface and transmembrane glycoproteins (gp), gp120 and gp41, respectively, 
that are part of the viral envelope and necessary for binding and entry into target cells. HIV’s 
accessory proteins are multifunctional and essential to virus infectivity and propagation in vivo 
(reviewed in [30]). Briefly, regulatory proteins Tat and Rev are essential for viral replication and 
virion production, meditating efficient transcription of full-length viral mRNAs and nuclear export of 
unspliced and partially spliced viral mRNAs, respectively. Vpr is primarily responsible for the 
nuclear import of the viral complementary DNA (cDNA) (i.e. as part of the preintegration complex 
(PIC)), causes G2 phase cell cycle arrest and enables viral replication in non-dividing cells. Vpu 
and Nef both modulate, via distinct pathways, cell surface levels of the CD4 molecule, tetherin and 
MHC-class I, thereby preventing superinfection and antibody-dependent cell-mediated cytotoxicity 
(ADCC), as well as promoting virion release and supporting immune escape. Importantly, Nef also 
enhances viral infectivity by counteracting the host restriction factor SERINC5 [31] and facilitates 
viral assembly. Vif is primarily responsible for counteracting a set of host restriction factors, the 
APOBEC3 deaminases, which are part of the human antiviral innate immunity. 
 
Figure 1. HIV-1 genome. 
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1.3. HIV replication 
All the viral proteins are encoded as a single proviral transcription unit under the control of the HIV 
enhancer and promoter, called the long-terminal repeat (LTR). The LTR contains binding sites for 
numerous host factors that mediate the recruitment of the host RNA polymerase II machinery and 
cellular proteins that support low-level, poorly processive transcription. This basal transcription 
mainly gives rise to short (~60 base pairs (bp)) and thus incomplete viral transcripts, as well as a 
few full-length early transcripts [32]. Efficient, processive HIV transcription, which is crucial for viral 
replication, additionally necessitates the interaction of Tat with the transactivation response 
element (TAR) in the LTR and the host positive transcription elongation factor b (P-TEFb). 
Synthesis of Tat from rare full-length early transcripts fuels an auto-stimulatory transcription loop 
that sustains high levels of genome replication (reviewed in [33]). 
 
A mature HIV virion consists of a lipid envelope, derived from the cytoplasmic membrane of the 
producer cell, and viral glycoproteins, enclosing a conical capsid that contains two copies of the 
viral RNA genome, as well as RT, IN, PR, Vif, Nef, and Vpr molecules. HIV enters a target cell via 
the engagement of the viral glycoproteins on the surface of the virion with its main cellular surface 
receptor CD4, and one of its chemokine co-receptors, CCR5 or CXCR4, which enables fusion of 
the virion’s lipid envelope with the target cell’s plasma membrane and release of the viral capsid 
into the cytoplasm. The co-receptor usage of a given HIV strain permits its classification as either 
R5- or X4-tropic, and more importantly, dictates the permissiveness of CD4+ lymphocyte subsets 
to the virus [34]. Other molecules have been implicated in viral entry, however their relevance in 
vivo is debated (reviewed in [35]). After entry, the viral genome is reverse transcribed into double-
stranded DNA and imported along with IN and host factors within the PIC into the nucleus, where 
the proviral DNA is then preferentially integrated into actively transcribed host genes [36]. The fate 
of the integrated provirus is then largely dictated by the activation state and availability of host 
transcription factors in the host cell [37]. If the necessary host transcription initiation factors are 
available for proviral transcription, such as NF-κB, NFAT and AP1, replication of the provirus takes 
place, i.e. viral proteins and new viral RNA genomes are synthesized and assembled at the host 
cell membrane into virus-like particles, that become infectious (mature) virions after budding and 
PR-mediated activity (reviewed in [38]). The budding of progeny virions may lead to cell-lysis. 
However, innate immune sensing of viral nucleic acids, recognition and lysis by cytotoxic T 
lymphocytes (CTLs) and the cytotoxic effect of viral proteins are the main mechanisms associated 
with death of infected cells [39, 40]. As a result, generally, productively infected cells have a short 
life span of about two to four days in vivo [41, 42]. This means that viral burden in an infected 
individual is dynamic and involves continuous rounds of de novo infection and replication, offset by 
a rapid turnover of productively infected cells and cell-free virus (i.e. virions), due to viral cytopathic 
effects and clearance by HIV-specific CTLs [41]. Alternatively, the provirus may become inactive 
after integration and thereby persist in a non-immunogenic, latent state in the host cell (discussed 
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in more detail in section 1.5). Virus production and latency can be seen as alternative and dynamic 
states of replication-competent proviral HIV DNA, dictated by HIV’s cellular tropism and 
dependence on specific cellular host factors for replication. In their productive state, proviruses 
ensure sustained viremia as well as viral evolution, dissemination and transmission. Whereas in 
their latent state, proviruses allow for immune evasion and long-term survival in the host, serving 
as archives of viral quasispecies that may resurface when conditions are fitting. 
 
Viral replication is commonly measured by quantification of viral RNA by qPCR, or the viral p24 
antigen by ELISA, in a HIV-infected sample (e.g. blood from a HIV infected patient or cell culture 
supernatant) [43-45]. In the clinics, a patient’s viral load is quantified using the former method, 
whereby viral RNA is isolated from patient plasma (i.e. cell-free plasma virus), reverse transcribed 
and then quantified by qPCR, providing a value for plasma viral load in copies per milliliter.  
 
As mentioned earlier, HIV requires the human CD4 receptor and CXCR4/CCR5 co-receptor for 
entry into the cells, so its cellular tropisms is intrinsically limited to cell subsets that express these 
surface receptors. However, cells that allow HIV entry may not be permissive to viral replication, 
either due to blocks imposed by innate immune mechanisms or the cell’s activation state [37, 46]. 
Indeed, studies analyzing HIV DNA in peripheral blood mononuclear cells (PBMCs) from viremic 
HIV-patients revealed that the majority of infected cells harbor unintegrated or defective viruses 
[47], with <0.01% harboring replication-competent HIV [48]. Yet the relevance of cells harboring 
replication-incompetent virus for HIV pathogenesis and persistence is disputable [49, 50]. Owing to 
their permissiveness to productive infection, CD4+ T lymphocytes and macrophages are the main 
targets and producers of HIV. Other cell types that have been shown to harbor HIV in vivo, include 
monocytes, microglia, dendritic cells, Langerhans cells and hematopoietic progenitor cells 
(reviewed in [35, 46]). The main sites of viral replication are the (secondary) lymphoid tissues, 
including gut-associated lymphoid tissue (GALT) [51], which are also compartments harboring high 
frequencies of CD4+ T lymphocytes and macrophages. As different tissues are characterized by 
different cellular, immune and structural environments, and ARV drug distribution and metabolism 
are tissue-specific, viral diversity and replication can vary substantially between tissues and cells 
types, which is referred to as HIV compartmentalization [52, 53]. 
 
CD4+ T lymphocytes consists of a heterogeneous population of cells, with distinct transcriptional 
profiles, CXCR4/CCR5 expression levels and homing capabilities, which are dependent on their 
antigen-experience, activation and metabolic states, as well as anatomical compartmentalization 
[34, 54, 55]. In addition, HIV DNA and RNA are differentially and dynamically distributed across 
CD4+ T cell subsets and anatomical compartments [56, 57]. Namely, activated effector CD4+ T 
cells are the most amenable to reverse transcription and proviral gene expression and are the 
main producers of HIV in acute infection, whereas in chronic infection viral entry and replication are 
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predominantly observed in activated central or effector memory subsets [48, 57-59]. In addition, 
specific memory subsets have been identified as major sites of viral replication in particular 
tissues, such as T follicular helper (Tfh) cells and T helper 17 (Th17) cells in lymph nodes and 
gastrointestinal tract, respectively [60, 61]. On the other hand, infection of and replication in resting 
(both memory and naïve) CD4+ T cells is rare and inefficient [57, 62], owing primarily to blocks to 
viral entry and reverse transcription, as well as the presence of the host restriction factor SAMHD1 
(reviewed in [63]). Furthermore, the ability of macrophages to sustain long-term productive 
infection and migrate throughout the body, as well as their longevity, make macrophages key 
players in HIV pathogenesis and likely physiologically relevant components of HIV persistence 
[64]. In non-lymphoid compartments, such as the brain, viral load is predominantly sustained by 
macrophages [65]. 
 
1.4. Combined antiretroviral therapy  
ARVs have turned HIV-infection from a death-sentence into a manageable chronic disease, as 
they can effectively block viral replication and de novo infections, thereby curbing disease 
progression. Different classes of ARVs have been developed over the years, targeting key steps of 
the HIV life cycle. The main ARVs used in cART are: i) Nucleoside reverse transcriptase inhibitors 
(NRTIs) and non‐nucleoside reverse transcriptase inhibitors (NNRTI), which interfere with reverse 
transcription by inducing chain-termination when incorporated by the RT, or by direct allosteric 
binding to the RT, respectively. ii) Integrase strand transfer inhibitors (INSTI), which block proviral 
DNA integration by rendering the IN catalytically inactive. iii) Protease inhibitors (PI), which hinder 
virion maturation by blocking proteolytic cleavage, resulting in the production of non-infectious 
virions. In addition, virion fusion inhibitors and co-receptor agonists (i.e. entry inhibitors) are other 
classes of less common ARVs. cART is made up of at least two classes of ARVs, such that 
multiple steps of the viral life cycle are simultaneously targeted, reducing the risk of emergence of 
drug-resistant strains [18]. 
 
The decay of viremia to undetectable levels (typically 20-50 copies/mL with ultrasensitive assays 
[45]) resulting from cART observed in treatment-naïve HIV-patients occurs in two phases [41], 
reflecting the contribution of different infected cell populations to viral production. The first phase is 
characterized by a rapid (exponential) decline in viremia within two to four weeks of treatment 
initiation, attributable to the clearance of cell-free plasma virus and virus-producing CD4+ T cells, 
which have half-lives of about seven hours and two days, respectively [41, 42]. The second phase 
is distinguished by a slower decay in viremia resulting from the elimination of productively infected 
cells with longer half-lives, such as macrophages, or with a lower activation state, such as partially 
activated CD4+ T lymphocytes [56].  
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1.5. HIV latency 
1.5.1. Characteristics and establishment of HIV latency 
The crux of HIV is its ability to exist in a very small portion of cells in a reversibly non-productive 
state, known as HIV latency. cART brought great hope for HIV eradication, as the rapid virologic 
control resulting from therapy suggested viral pools could be eliminated within 3 years of effective 
therapy [66]. However, the recovery of replication-competent HIV in long-lived resting memory 
CD4+ T lymphocytes of aviremic patients [9-11], accompanied by the detection of archival and 
non-evolving low-level residual viremia [67], highlighted the persistence of HIV despite prolonged 
viral suppression. Ultimately, the rebound in viremia in patients within weeks of cART interruption 
explicitly proved the presence of a latent HIV reservoir [13, 16], and revealed that cART cannot 
cure HIV. HIV persistence is achieved by the seeding of a latent reservoir in diverse cell types and 
anatomical compartments early after transmission [12, 13], that can be induced to produce 
infectious particles upon antigen recognition or exposure to T-cell-activating stimuli, and can 
thereby re-establish a disseminated infection in the absence of cART [10, 68]. Latently infected 
cells produce only low levels of viral RNAs and no viral proteins, making these cells 
immunologically indistinguishable from uninfected counterparts and therefore impervious to host 
immune surveillance [69-71]. Despite reports of markers that identify CD4+ T cell subsets enriched 
in HIV DNA in aviremic patients, such as CD2 [72] and CD32a [73], there is still no ubiquitous 
phenotypic method to unequivocally identify latently infected cells. Furthermore, studies in non-
human primates (NHP) and humanized mice or with patient samples revealed that the HIV 
reservoir is essentially unperturbed by existing cART and cART intensification, LRAs and broadly 
neutralizing antibodies (bnAbs) [11, 74-79]. The main reservoir is found in resting memory CD4+ T 
lymphocytes in lymphoid tissues and has been evaluated to occur at a frequency on the order of 
one in a million resting CD4+ T lymphocyte [9, 11, 48, 51]. For this reason, most research on HIV 
latency and latency models are focused on this cell type. Macrophages have also been identified 
as reservoirs of HIV persistence, along with other cell types such as dendritic cells, monocytes and 
microglia, yet whether they persist under cART and their relative contributions to viral rebound 
upon cART interruption remain uncertain and controversial [64, 65, 80-84]. Due to the intrinsic 
longevity of memory CD4+ T lymphocytes, and the stable integration of HIV DNA in its host, the 
HIV reservoir is incredibly stable, with an estimated half-life of about 44 months [74]. Thus, despite 
the latent reservoir being very small, its stability and imperviousness to cART and anti-viral 
immune mechanisms, make it the major barrier to HIV eradication. 
 
Strikingly, long-lived latently infected lymphocytes can sustain the HIV reservoir through clonal 
expansion and homeostatic proliferation without viral production [85-87]. The homeostatic 
maintenance of latently infected cells has important implications for eradication strategies aiming at 
purging the reservoir and underlines the difficulties that lie ahead with developing such strategies, 
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especially with regards to the required depth of purging and expectations linked to decay of the 
reservoir. Furthermore, in depth characterization of residual viremia (i.e. trace levels of cell-free 
plasma virus) in cART treated patients revealed that a homogenous population of plasma clones 
predominated, suggesting that under cART, virus is released due to activation of a small number of 
latently infected cells [88]. These predominant plasma clones (PPC) were rarely found in resting 
CD4+ T cells from the blood [88], implying that the circulating pool of resting CD4+ T cells, or any 
blood cell type, is unlikely to be the source of these PPC. These findings emphasize how viral and 
lymphocyte dynamics, as well as cellular reservoirs in the blood compartment, may not be 
representative of those in lymphoid tissues [51, 82, 89-94], but also that mixing and spreading can 
occur between compartments; highlighting the importance of studying HIV latency beyond the 
blood compartment. 
 
The stable integration of retroviral genomes into the chromosomes of the cells they infect is an 
obligate step of retroviral life cycle and intrinsically confers the ability to persist for the lifespan of 
the cellular host. However, why and how HIV latency is established in vivo is not completely 
understood and still debated, especially as evidence is largely based on in vitro models. Clearly, 
HIV latency allows HIV to evade elimination by cART, but cART is a modern intervention and yet in 
rhesus macaques, latent SIV reservoirs are established within 3 days post-inoculation, before SIV-
specific immune responses can be mounted [12]. Thus, latency must serve another, evolutionarily 
conserved, purpose. In addition, although the latent proviral landscapes in aviremic chronic HIV-
patients are dominated (>98%) by CTL escape variants [69], ultimately HIV’s capacity to rapidly 
evolve is what enables it to avoid recognition by neutralizing antibodies and CTLs [95]. Taken 
together these findings imply that escape from the host immune system may not be the key role of 
latency, but rather that HIV latency may be a deterministic evolutionary strategy to enhance viral 
transmission across mucosa (i.e. most common exposure route) [96, 97]. Specifically, long-lived 
latently infected cells could help HIV survive in its host during initial mucosal infection, a phase 
characterized by high rates of viral extinction [98]. In fact, it has been estimated that the probability 
of HIV-transmission is below 0.5% [99]. 
 
The establishment of HIV latency in resting memory CD4+ lymphocytes has yet to be fully 
elucidated, however two main mechanisms are favored. Either, HIV may directly infect and 
integrate its DNA into resting CD4+ T lymphocytes, which by virtue of their quiescent state result in 
silencing of the provirus [37, 100, 101]. Resting lymphocytes are largely refractory to HIV infection 
because their low CCR5 expression [34, 57, 62] makes for poor viral entry, and their low 
cytoplasmic deoxynucleoside triphosphates (dNTP) levels greatly limit reverse transcription of HIV 
RNA [102]. Nevertheless, infection of both memory and naïve resting CD4+ T lymphocytes has 
been achieved in vitro [103, 104], particularly in those with a memory phenotype or isolated from 
lymphoid tissues, where the microenvironment seems to skew these cells into a state more 
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favorable to HIV entry and integration [91, 105]. Alternatively, proviral latency is established in 
resting CD4+ T lymphocytes when productively infected activated memory precursor cells survive 
viral cytopathic and host cytolytic effects long enough to revert to a long-lived resting memory state 
[9, 25, 100]. This mechanism is particularly plausible given that activated CD4+ T lymphocytes are 
supportive of all steps of the HIV life cycle and that transition between different cellular activation 
and functional states, characterized by different gene expression profiles, is part of normal T cell 
memory generation [54]. Recently Shan et al. explicitly demonstrated that HIV infection can 
become latent as a consequence of the unique transcriptional state of CD4+ T lymphocytes 
undergoing effector-to-memory transition that makes these cells permissive to infection, but not 
conductive to viral production [57]. In either case, what appears to drive HIV infection into a latent 
state is the activation status (and associated gene expression profile) of the infected cell. 
Additional mechanisms may then play a role in enforcing latency.  
 
1.5.2. Molecular mechanisms of HIV latency establishment and maintenance 
A number of incompletely understood and overlapping molecular mechanisms, involving numerous 
host and viral proteins, mediate the establishment and maintenance of HIV latency, of which two 
forms have been observed: pre-integration and post-integration latency. Most of these 
mechanisms were discovered using in vitro models of HIV latency. Pre-integration latency arises 
due to defects in reverse transcription, inhibition of nuclear import of the viral PIC or incomplete 
integration of the proviral DNA, resulting in the formation of labile short-lived unintegrated forms of 
virus in the cytoplasm of infected cells [106]. As this form of latency is responsible for short-term 
latent reservoirs, it is of minor clinical importance [50, 107]. On the other hand, post-integration 
latency is responsible for the stable persistence of HIV in its host and results from a multitude of 
viral and cellular molecular mechanisms (reviewed in [108]). Briefly, the main mechanisms of post-
integration latency establishment and maintenance (i.e. silencing of the provirus) involve 
transcriptional repression or post-transcriptional blocks. As discussed earlier, proviral transcription 
requires and is regulated by a number of inducible host transcription initiation factors (e.g. NF-κB, 
NFAT), whilst binding of Tat and cellular cofactors for HIV transcription (e.g. P-TEFb) to the viral 
promoter are required to relieve transcriptional blockade and achieve processive transcription. 
Thus, the cytoplasmic sequestration of key transcription factors, their presence in inactive 
conformations or inhibitory complexes, as is seen in resting cells (i.e. cells with low metabolic 
activity), and absence of Tat, prohibit efficient transcription. This underlines how the activation 
status of the infected cell greatly affects the fate of the provirus. Moreover, the site of proviral 
integration and chromatin environment of the LTR may lead to proviral silencing. Although HIV 
integrates non-randomly in actively transcribed genes [36], proviral latency may be reinforced by 
transcriptional interference during expression of neighboring host genes. In addition, the consistent 
positioning of two nucleosomes (nuc-0, nuc-1) in the LTR mediated by histone deacetylases 
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(HDACs), epigenetically restrict transcriptional elongation from the LTR [109]. Removal of this 
epigenetic block by hyperacetylation and remodeling of nuc-1 mediated by histone 
acetyltransferases (HATs), has been induced by Tat, NF-κB and various stimuli, including 
cytokines and phorbol esters [109]. Finally, post-transcriptional blocks affecting nuclear export, 
splicing and translation of viral mRNA may further suppress viral replication. For example, binding 
of mature host miRNAs to viral mRNAs can lead to their degradation or translational inhibition 
[110, 111], whereas viral miRNAs have been observed to contribute to latency maintenance via 
miRNA-mediated gene-regulation [112].  
 
1.5.3. Measuring the HIV latent reservoir  
Quantifying the HIV latent reservoir has been instrumental to identifying cellular reservoir [9], 
appreciating its stability [14], as well as understanding the effects of early cART [113], cART 
intensification [79] and latency purging strategies (discussed below), on the reservoir. As 
definitions of the HIV reservoir vary greatly, particularly depending on which forms of persistent 
virus are considered [50]. Herein we consider that the HIV reservoir denotes any cell type stably 
harboring replication-competent HIV DNA (i.e. intact proviral genomes) that can be induced to 
produce infectious viral particles. The last part of this definition is the pivotal characteristic of 
reservoir cells that makes them clinically relevant, yet it can be difficult to verify ex vivo [114]. 
Nevertheless, cells harboring unintegrated, defective, or uninduced persistence forms of HIV have 
also been implicated in HIV pathogenesis, evolution and persistence [49, 50, 114, 115].  
 
Commonly reservoir size in aviremic patients is determined using ex vivo assays, performed on the 
patients’ PBMCs or purified CD4+ T cells that aim to either quantify the frequency of cells that i) 
harbor HIV DNA; or ii) can be induced to produce HIV ex vivo [48]. The latter assay is commonly 
referred to as the quantitative viral outgrowth assay (qVOA), and is considered the gold standard 
for measuring the size of the replication-competent inducible HIV reservoir. Briefly, purified resting 
CD4+ cells from the peripheral blood of cART-suppressed patients are co-cultured in limiting 
dilution with permissive cells to propagate (amplify) released virus, and activated with 
phytohaemagglutinin (PHA) and allogenic irradiated PBMCs [48]. The common readout of the 
qVOA is p24 concentration in the culture supernatants, detected by ELISA. Over the years, a 
number of different VOAs have been developed using different permissive cells for co-culture or T-
cell-activating stimuli and regimes [114, 116, 117], as well as alternative and more sensitive 
readouts to detect viral replication in the cultures [118, 119] (reviewed in [120]). The reactivated 
viral clones can also be harvested from the cultures for further characterization [86]. qVOAs have 
also been helpful in assessing the therapeutic potential of drug candidates to reduce the frequency 
of latently infected cells. On the other hand, measurement of cell-associated HIV DNA is achieved 
by highly sensitive and generally more standardized and simple qPCR assays. Importantly, the 
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qPCR assay design will impact what types of cell-associated HIV DNA are measured, such as total 
[115], integrated [121], or near-full-length [85] viral genomes and will also measure defective or 
replication-incompetent viruses. Accordingly, viral outgrowth and PCR-based HIV DNA assays 
provide different estimates of the frequency of latently infected cells in a patient, with the latter 
generally yielding estimates that are at least two logs higher [122] (reviewed in [123]). 
 
1.5.4. HIV latency reversal  
As mentioned earlier, latency reversal is the critical characteristic of latent proviruses that makes 
latency relevant to HIV pathogenesis and persistence. If a latent provirus lacks the ability to revert 
to a productive state, whereby it produces infectious virus, then post-integration latency would be a 
dead-end for HIV, with little overt clinical importance. Reversal of latency in patients on 
suppressive cART has been proposed as a strategy towards HIV eradication and major efforts are 
being devoted to finding latency reversing agents (LRAs) that can specifically reactivate latent HIV 
DNA and thereby purge the latent reservoir. This strategy is often referred to as “shock and kill” 
and the idea is to administer LRAs to patients on cART to activate virus production in latently 
infected cells, which may trigger their clearance due to viral cytopathic effects and CTLs, whilst 
cART protects against de novo infections [17, 124].  
 
Various compounds have been proposed as putative LRAs owing to their biological activities 
associated with antagonism of mechanisms of latency maintenance (described in section 1.5.2). 
The main classes of LRAs include compounds that either alleviate epigenetic silencing of the LTR, 
such as HDAC inhibitors, or promote T cell activation, proliferation and signaling, such as protein 
kinase C (PKC) agonists, cytokines (e.g. IL-2, IL-7, TNF-alpha) and Toll-like receptor (TLR) 
agonists (reviewed in [125]). These compounds induce HIV transcription in latently infected cells in 
vitro or ex vivo. A limited number of LRAs have been tested in clinical trials, including the HDAC 
inhibitors valproic acid, vorinostat [77, 126, 127], panobinostat [128] and romidepsin [76], as well 
as disulfiram (thought to activate NF-κB) [129, 130], TLR9 agonist [131], bryostatin (PKC agonist, 
activates NF-κB) [75], cyclophosphamide (alkylating agent that interferes with DNA replication) 
[132], IL-7 [133] and several types of IL-2 based treatments (IL-2 alone, IL-2 plus IFN-gamma, IL-2 
plus OKT3 antibody (reviewed in [134])). Except for bryostatin, all these compounds, induced 
measurable increases in cell-associated HIV RNA in the test subjects, nevertheless none resulted 
in a significant clinical benefit in that they either failed to reduce the size of the reservoir, or 
rebound in viremia after cART interruption was neither inhibited nor delayed. Of note, in vivo 
assessments of valproic acid’s effect on reservoir size have yielded contradictory results. In a first 
clinical trial, valproic acid was administered for three months to four patients on intensified cART 
and a small but significant decrease in the frequency of infected resting CD4+ T cells in the 
peripheral blood of three of the four subjects was observed by the end of the treatment [135]. 
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However, since then no other in vivo study of valproic acid found an effect of this HDAC inhibitor 
on reservoir size [136-139]. 
 
Ultimately, research in this area seems to be hindered by the lack of a convenient, physiologically 
representative HIV latency model that would allow more telling screens of LRA candidates before 
transition to clinical trials. Moreover, the notion that to be effective, latency reversal strategies will 
also require additional interventions to get efficient clearing of reactivated reservoir cells, such as 
boosting of virus-specific immune mechanisms [140, 141], immunomodulatory agents [142, 143] or 
compounds that induce apoptosis [125], is gaining attention and being investigated. Purging of the 
entire reservoir is very likely to require combinations of LRAs targeting different mechanisms of 
latency maintenance [144]. Such insights and combinatorial approaches may lead to the 
development of effective eradication strategies. Nevertheless, in order to develop new therapies 
targeting the latent reservoir, it is imperative to further characterize the cells that harbor replication-
competent latent provirus, elucidate their contribution to HIV persistence, as well as clarify the 
mechanisms governing latency establishment, maintenance and reactivation in vivo. The 
extremely low frequency of latently infected cells, the fact that these do not produce viral proteins 
and that no surface markers exist for identifying latently infected cells, make HIV latency very 
difficult to study. The situation is exacerbated by the limited availability of patient samples, largely 
confining the ex vivo study of HIV latency to the peripheral blood compartment, shallow lymph 
nodes, and sometimes cerebrospinal fluid and small intestinal biopsies, which as discussed earlier, 
may dramatically limit our understanding of HIV latency in the human body.  
 
1.6. In vitro models of HIV latency  
As HIV is unable to replicate in nonhuman cells and studying latently infected resting CD4+ T 
lymphocytes ex vivo is very difficult (see above), HIV latency has largely been studied using in vitro 
models. The various in vitro models of HIV latency (reviewed in [107, 145]) can be subdivided into 
two groups: chronically infected immortalized T cell lines and latently infected primary cells. Briefly, 
the first in vitro models of latency consisted of chronically HIV-infected immortalized T cell lines 
that constitutively express minimal amounts of HIV mRNA and proteins. Viral gene expression can 
be induced in these cell lines with mitogens or cytokines, providing the first indications of the 
contribution of LTR activity and chromatin environment, and proviral integration site to latency. 
However, ultimately the proliferative and clonal nature of immortalized cell lines do not recapitulate 
the quiescent nature of, nor the proviral integration site heterogeneity observed in resting primary 
reservoir cells. In addition, establishment of HIV latency in these cell lines was found to be a 
consequence of mutations in the viral genome or integration site, further questioning the relevance 
of these models for elucidating the in vivo mechanisms of HIV latency. Therefore, various groups 
developed more physiological models of latently infected resting memory CD4+ T cells by using 
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fresh primary CD4+ T cells from healthy donors. As it remains unclear whether in vivo latency in 
resting memory CD4+ T lymphocytes arises from infection of activated lymphocytes during 
effector-to-memory transition or direct infection of resting lymphocytes, models exist for both 
approaches. In addition, models differ in the types of primary CD4+ T cells, culture conditions and 
HIV variants used, which has given rise to a variety of primary cell models, representing different 
T-cell subsets, with different proviral silencing characteristics and reactivation responses [145]. 
 
To recapitulate latency establishment due to reversion of an infected activated lymphocytes to a 
resting state, the common approach involves activation of primary CD4+ T lymphocytes via T-cell 
receptor (TCR) stimulation and cytokines, infection and then culture for several weeks in the 
absence of T-cell stimulation to allow the infected cells to transition back to a resting state [146-
150]. These models can yield high numbers of cells harboring integrated latent provirus [151], 
however the short life span of lymphocytes in culture in the absence of stimulatory signals is 
problematic. Thus, during the transition to a resting state, the primary cells are often cultured in the 
presence of low doses of cytokines (e.g. IL-2, IL-7, IL-15 [147, 152]) sufficient to promote cell 
survival without inducing T-cell activation. Alternatively, to maintain the infected primary CD4+ T 
lymphocytes in culture long enough for reversion to a resting state in the absence of T-cell stimuli 
some groups transduce the primary cells with anti-apoptotic proteins (e.g. Bcl-2 [148, 150]), or co-
culture with feeder cells (e.g. H80 cells [149]). Possible caveats of these models is that the ensuing 
latently infected cells may not be truly quiescent as they continue to express markers of activation 
[149, 153], display an altered morphology [147] and often do not encompass all different CD4+ T 
cell memory subsets shown to harbor latent virus in vivo [107]. Alternatively, resting primary CD4+ 
T lymphocytes, which can consist of either purified or mixtures of naïve, central memory, and 
effector memory subsets, are directly infected ex vivo using chemokines to render the cells 
susceptible to infection [104], or spinoculation [103, 154], however the latter is not very 
physiological and may result in a substantial amount of cells carrying unintegrated genomes. 
 
In addition, the genetic composition of the latent proviruses in the various models differ greatly, 
ranging from wild-type to HIV-derived reporter viruses, replication-competent to pseudotyped 
viruses. Replication-competent viruses encoding all or the majority of viral genes may result in 
more representative states of latency, but may reduce yields of latently infected cells due to 
cytotoxic effects, and require the use of ARVs in reactivation assays, endorsing the use of less 
physiological replication-incompetent or defective viruses. Furthermore, reporter viruses are 
advantageous in that they allow a simple means to distinguish productive and latent infection and 
quantify latency reversal. Yet, defective, pseudotyped and reporter viruses may display altered 
behaviors, affecting latency establishment, maintenance and reversal.  
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These primary models have been pivotal to the study of HIV latency and related mechanisms, yet 
these ex vivo-generated latently infected cells and the state of latency therein may not be entirely 
representative of the in vivo situation. Namely, the latently infected cells in these models may not 
be truly quiescent, nor reflect the phenotypic heterogeneity of reservoir cells found in patients, 
whilst the long-term in vitro culture involved may affect the physiology of the primary cells and 
chromatin environment of the provirus [107]. Indeed, an in-depth comparison of proviral 
reactivation in a panel of established latency cell models in response to thirteen stimuli known to 
reactivate latent HIV, revealed that no single in vitro model of HIV latency could consistently and 
accurately recapitulate the ex vivo response characteristics of latently infected resting CD4+ T 
lymphocytes from aviremic HIV patients [145]. The non-physiologically high proportions of latent 
infections that arise after in vitro infections (see Table 1 in [151]), further highlight a divergence 
from the in vivo scenario. Finally, in vitro models of latency cannot capture the complex interplay 
between HIV and the host immune system, which has been shown to affect and shape the latent 
reservoir in patients [6, 69, 97]. Therefore, there is the need for a physiologically relevant in vivo 
model of HIV latency, which would allow the isolation and study of genuine latently infected cells 
from different tissue compartments, and be used to test the efficacy of latency-reversing strategies 
in purging reservoirs systemically. To this end, humanized mice (hu-mice) engrafted with a human 
immune system provide a unique opportunity to study HIV systematically and in the context of a 
functional immune response. Additionally, hu-mice are exceptionally customizable models, as the 
human system can be gene-engineered prior to engraftment.  
 
1.7. Humanized mice in HIV research 
Hu-mice are immunodeficient mouse models engrafted with functional human systems, allowing 
the study of diverse human pathologies and used as pre-clinical models for testing new 
pharmacological agent. To this end, various immunodeficient mouse models have been generated 
via the introduction of mutations associated with immunodeficiencies. The latest generation of 
immunodeficient mice, called NSG (NOD-scid IL2Rgammanull) mice, carry a mutation in Prkdc, 
causing the severe combined immunodeficiency syndrome (SCID), and knockout of the IL-2 
receptor common gamma-chain, abrogating reactivity to many essential cytokines. NSG mice lack 
mature lymphocytes, functional natural killer (NK) cells and other components of the innate 
immune system [155, 156]. They are also thereby highly amenable to the engraftment of human 
CD34+ hematopoietic stem and precursor cells (HSPCs), from which a functional lymphoid system 
of human origin (including T and B lymphocytes, NK cells, monocytes, macrophage, dendritic cells) 
is reconstituted in the mice [155-158]. Humanized NSG mice can be generated in different ways 
based on the source of the HSPCs (i.e. cord blood, fetal liver and thymus, or bone marrow), their 
route of administration (i.e. intrahepatic, intraperitoneal or intravenous), age of the recipient 
immunodeficient mice (i.e. newborn or adult), as well as whether pre-conditioning is used 
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(reviewed in [159]). In our group, we transplant irradiated, newborn NSG pups intrahepatically with 
cord blood-derived CD34+ hematopoietic stem and precursor cells (HSPCs).  
 
Hu-mice are cost and time effective, flexible models to study HIV latency (reviewed in [160, 161]), 
as they are highly susceptible to disseminated HIV-infection [162, 163], mount HIV-specific 
immune responses [164-167], harbor various tissue and cellular reservoirs (reviewed in [82]), 
which persist under cART regimes commonly used in the clinics and are resistant to immune 
clearance [69, 80, 163, 168-172]. New models of hu-mice, such as the T-cell only mice (ToM) and 
myeloid-only mice (MoM) ([161, 171]), are powerful tools for dissecting the contribution of different 
cell types to viral persistence and rebound after cART interruption. 
 
1.8. HIV evolutionary potential 
A critical feature of HIV is the accumulation of genetically diverse quasispecies during the course 
of infection [173]. This means that HIV exists in its host as a pool of incredibly diversified variants, 
rather than a homogenous viral population, responsible in part for the adaptive immune system’s 
inability to mount an effective and long-lasting response, and failures in vaccine development [24, 
25, 173]. HIV’s incredible evolutionary potential is attributed to the low fidelity of its reverse 
transcriptase (RT) (3 x 10-5 mutations/base pairs/cycle [20, 174, 175]), high viral replication rates 
(1010 – 1011 virions/day [21, 176]) and recombination between co-packaged genomes [22, 23]. Viral 
diversification in HIV patients is associated with increased fitness [177] and the rapid accumulation 
of variants resistant to recognition by CTLs and neutralizing antibodies, and ARVs [40, 42, 178], 
but can also result in the presence of drug-resistance variants prior to drug exposure [179].  
 
Another proposed driver of viral diversification is sublethal mutagenesis induced by host cytidine 
deaminases from the APOBEC3 (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like 3) family. APOBEC3s contribute to human innate antiviral immunity and some of the family 
members have been shown to be cellular restriction factors of HIV, restricting HIV replication to 
varying degrees [71, 180-183]. These cellular deaminases hypermutate the nascent HIV cDNA 
during reverse transcription, which results in G-to-A mutations in the viral genome [184]. However, 
the viral accessory protein Vif can efficiently counteract this restriction, by targeting the APOBEC3s 
for proteasomal degradation [185, 186]. Strikingly, HIV variants encoding vif alleles with only 
partial-APOBEC3 neutralizing activities have been identified and recovered from HIV infected 
patients [187-189] and associated with ART-failure [189, 190]. Nevertheless, the contribution of the 
APOBEC3-Vif axis to viral evolution is highly debated [176, 191, 192], with opponents maintaining 
that APOBEC3-mediated mutagenesis results in lethal mutagenesis of the provirus (i.e. introduces 
premature stop codons or other mutations that render the provirus defective) or is insignificant 
compared to RT-error [176, 193, 194].  
22 
 
AIMS OF THE THESIS  
 
The seeding of diverse cellular and anatomical latent HIV reservoirs throughout the body that 
persist under cART precludes HIV eradication with existing therapies. Strategies targeting the 
latent reservoir may enable the purging of persistent forms of HIV, and thereby eventually lead to 
cure of patients. However, specifically studying genuine latently infected cells seeded throughout 
the body is currently not feasible as these cells are largely phenotypically indistinguishable from 
their uninfected counterparts and access to patient samples is very limited and generally confined 
to the peripheral blood. These hurdles also limit our ability to effectively assess the efficacy of 
latency reversing pharmacological interventions. Indeed, despite inducing viral transcription in in 
vitro models of latently HIV infected cells, to date, all LRAs tested in clinical trials have failed to 
produce a measurable clinical benefit, highlighting the need for more representative models to 
screen putative LRAs. Therefore, there is a need for novel in vivo models of HIV that would allow 
the study of primary latently infected cells from diverse anatomical compartments and screening of 
novel therapeutic compounds.  
 
The first project in my thesis aims to address this technological need. Specifically, the first specific 
aim of my thesis (chapter 2) is to develop a HIV reporter hu-mouse model that allows the 
identification, isolation and characterization of primary latently HIV infected cells seeded 
throughout the host. Such a model must incorporate a means to specifically and unambiguously 
identify, and thereby recover, the extremely rare reservoir cells. Humanized mice provide a HIV 
infection model that can easily be manipulated. Thus, we hypothesized that introducing a HIV-
inducible reporter transgene into the NSG hu-mouse model would allow us to identify and sort 
genuine latently infected cells from diverse tissues in the hu-mice, based on their expression of the 
reporter gene. To this end, we collaborated with Professor Monsef Benkirane and Dr Gaël 
Petitjean (Institute of Human Genetics CNRS, Montpellier, FR), who had developed and validated 
an in vitro HIV fluorescent reporter system.  
 
Another characteristic of HIV that greatly impedes its eradication is the virus’s ability and 
propensity to diversify, helping it evade recognition by neutralizing antibodies and CTLs, and 
making vaccination strategies thus far ineffective. Although viral diversification is largely attributed 
to HIV’s high replication rates and error-prone RT, APOBEC3 deaminases may also play a 
significant role in HIV diversification due to their mutagenic activity on the viral genome. The 
second specific aim of my thesis (chapter 3) is to assess the contribution of APOBEC3G to HIV 
diversification and adaptability to an external selective pressure. We hypothesized that as 
partially-active Vif alleles can be found in the circulating viral pool in patients and are associated 
with cART failure, suboptimal APOBEC3G neutralization in vivo is not fatal for HIV as a population 
and benefits viral adaptation. For this study, we collaborated with Professor Viviana Simon (Icahn 
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School of Medicine at Mount Sinai, New York, USA) who have expertise in sequencing viral 
quasispecies.  
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2. CHAPTER 2 
 
 
Development of a HIV reporter hu-mouse model for 
studying HIV latency 
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2.1. Introduction 
The rapid seeding of a very small, yet heterogeneous, disseminated and long-lived latent HIV 
reservoir, which is unaffected by existing anti-HIV therapies (cART, LRAs, bnAbs [11, 74-78]) and 
host immune surveillance [69-71], precludes complete HIV eradication. Consequently, HIV 
infection remains an incurable chronic condition affecting more than 36 million people worldwide 
(WHO, 2016 statistics). Efforts directed towards developing a cure for HIV can generally be divided 
into two categories based on whether they aim to achieve a functional or a sterile cure. The former 
aims at achieving durable virologic control in the absence of cART, such as fully blocking viral 
production from latent proviruses to inhibit viral rebound upon cART interruption, also known as the 
“block and lock” strategy. The latter entails purging the entire replication-competent inducible latent 
reservoir using LRAs together with cART, a strategy commonly referred to as “shock and kill”. 
However, despite an extensive and growing body of research on HIV latency and the mechanisms 
that support viral persistence, a major barrier to effectively studying and targeting the HIV 
reservoir, irrespective of the approach pursued, is the lack of specific markers to identify all latently 
infected cells. Ultimately, this thwarts our ability to characterize latently infected cells, the provirus 
they harbor, as well as to understand the contribution of the different cellular and tissue HIV 
reservoirs to viral persistence.  
 
Moreover, as latently infected cells are extremely scarce (1/106 CD4+ T lymphocytes) and access 
to human tissues is very limited, studying latently infected cells from patients is very difficult and 
circuitous. Currently the gold standard for quantifying the HIV reservoir in patients is based on ex 
vivo analyses of resting CD4+ T cells from suppressed HIV-patients, which are then cultivated and 
stimulated in limiting dilutions with feeder cells (QVOA) or analyzed by qPCR for cell-associated 
HIV DNA [195]. Such assays are useful for assessing the effectiveness of eradication strategies, 
exploring other cellular subsets that serve as HIV reservoirs [57, 85, 196, 197], and have helped 
reveal the pivotal role of clonal expansion of infected cells in HIV persistence [57]. Nonetheless, ex 
vivo studies are limited to analysis of tissue samples that can readily be obtained from patients, i.e. 
peripheral blood and shallow lymph nodes, and sometimes cerebrospinal fluid and small intestinal 
biopsies, whereas HIV persistence has been documented in a wide variety of anatomical site, in 
association with distinct and diverse cell types [82]. For example, Tfh cells in lymph nodes [198, 
199], CD133+ hematopoietic progenitor cells in the bone marrow [200], CD4+ T cells as well as 
CD13+ myeloid cells and macrophages in GALT [82, 201-203], perivascular macrophages and 
microglia in the central nervous system [82], have all been found to harbor HIV DNA in aviremic 
treated patients. In this regard, the Last Gift Study, conducted at the University of California, San 
Diego, may provide unprecedented insights into HIV persistence in hard-to-reach anatomical 
compartments. The study aims to characterize the HIV reservoirs throughout the human body by 
rapid autopsy of full body donations from altruistic, terminally ill, HIV-infected individuals. 
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Although the value of such a project is evident, its implementation is too complex to fully replace 
the need for other approaches to study HIV latency. Moreover, for the rational design of new 
strategies effectively targeting persistent virus, qualitative characterization of genuine HIV reservoir 
cells and the latent proviruses they harbor is imperative. Using patient samples, this would 
ultimately require single-cell sequencing of millions of cells, as there are still no phenotypic means 
to unequivocally identifying latently infected cells. Therefore, there is a pressing need for 
physiologically relevant models of HIV latency.  
 
In vitro models of HIV latency, which consist of either chronically HIV-infected immortalized cell 
lines that produce no or only very low levels of viral proteins unless stimulated, or highly 
manipulated primary cells infected with reporter viruses (reviewed in [107, 145]) (see thesis 
introduction, section 1.6), have been key to our early understanding of the molecular mechanisms 
governing HIV latency. However, such in vitro models cannot capture the heterogeneity of proviral 
integration [204], nor the quiescent nature of long-lived memory CD4+ T cells harboring latent 
provirus. In addition, the method by which latently infected cells are generated in vitro influences 
the nature of latency and the reactivation profile in these cells, limiting the relevance of results 
ensuing from such models. By measuring HIV reactivation in five primary T cell models and four 
latently infected T cell lines (J-Lat cell models) in response to thirteen known latency-reversing 
stimuli, Spina et al. demonstrated that ultimately none of the tested models could consistently 
recapitulate the ex vivo response characteristics of resting CD4+ T cells isolated from aviremic 
HIV-infected patients [145]. Finally, in vitro models cannot capture the complex interplay between 
virus and the host immune system. On the other hand, non-human primate models infected with 
SIV do not suffer from such limitations and pathogenic SIV infections closely approximate HIV 
pathogenesis in humans [205, 206], making NHP models valuable tools in HIV research. However, 
NHP studies are expensive, laborious, and not permitted in all countries, and ultimately do not 
allow the direct study of HIV in the context of a human immune system. In this regard, humanized 
mice models provide a powerful tool to study HIV (reviewed in [160, 161]). Namely, as hu-mice 
have a functional lymphoid system of human origin [156, 158, 207] (see thesis introduction, section 
1.7), they are highly susceptible to HIV infection and recapitulate key features of HIV pathogenesis 
and persistence seen in patients [163, 168-170]. Moreover, hu-mice provide a highly mutable 
platform for studying HIV infection and persistence, as gene-engineered hu-mice (i.e. mice with a 
gene-engineered human immune system) are easily generated by lentiviral transduction of the 
human HSPCs used to reconstitute the immunodeficient mice [205, 208].  
 
Therefore, in this study we sought to address the unmet technological need for a convenient, yet 
physiologically relevant model to study HIV latency by developing a HIV reporter hu-mouse model 
in which infected cells are specifically marked in vivo, thereby allowing genuine latently infected 
cells to be isolated for ex vivo characterization (Figure 1). The model is based on introducing an 
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inducible HIV infection reporter transgene into the human hematopoietic stem and progenitor cells 
(HSPCs) used to humanize immunodeficient NSG mice [207], which gives rise to HIV susceptible 
mice with human leukocytes that express a fluorescent protein upon infection. The HIV reporter 
system, called HR4lox, was developed and tested in vitro by Gaël Petitjean (Institute of Human 
Genetics, CNRS, Montpellier FR) and employs a Cre-lox recombination system to achieve 
infection dependent expression of the reporter transgene, red fluorescent protein (RFP). The Cre-
lox system is a site-specific DNA recombination system derived from P1 bacteriophage and widely 
used in gene engineering and for conditional gene rearrangements, for example, to study gene 
functions, control gene expression and generate transgenic animal models [209, 210]. It involves 
two components, a Cre recombinase (Cre) and its specific DNA substrates, loxP sites. Cre is an 
enzyme that specifically recognizes two loxP sites and mediates rearrangement of the DNA that is 
flanked by these two loxP sites (commonly referred to as floxed DNA). If the loxP sites are in the 
same orientation, then the floxed DNA fragment will be excised, however if they are in the opposite 
orientations, then the floxed DNA will be inverted. Recombination is efficient in eukaryotic cells and 
does not require any accessory factors or specific DNA conformation [210]. Over the years, 
alternate loxP sites have been engineered, allowing for more complex gene rearrangements [211]. 
The HR4lox reporter system we use in our hu-mouse model is made up of two parts: a HIV 
reporter transgene containing a floxed RFP gene (HR4lox transgene) and a recombinant HIV that 
encodes a CMV promoter (CMV) and Cre cassette (CMV-Cre) that is called HOCC (Figure 1B). 
Specifically, the HIV reporter transgene contains a CMV-RFP cassette, in which the RFP gene is in 
antisense compared to the promoter and flanked by two sets of loxP sites (floxed-RFP), followed 
by a PGK promoter (PGK) and GFP cassette (PGK-GFP) (Figure 1A). This means that cells 
harboring the HIV reporter transgene (transgenic cells) are constitutively GFP+, but do not express 
RFP. RFP can only be expressed after two Cre-mediated recombination events take place at the 
loxP sites flanking the RFP gene. Thereafter, the upstream CMV promoter constitutively drives the 
expression of RFP. By using a HIV that encodes Cre for infections, in our model, Cre-lox 
recombination becomes dependent on HIV infection (Figure 1C). Thus, in our hu-mouse model, 
any transgenic cell infected with HOCC is specifically marked by its expression of RFP. This allows 
us to sort infected cells based on RFP expression using fluorescence-activated cell sorting 
(FACS). By treating HOCC-infected reporter hu-mice with cART, HIV latency and persistence can 
be explored in various deep tissues. We hypothesized that using this hu-model we could gain 
unprecedented access to genuine latently HIV-infected cells from a wide variety of tissues, 
allowing us to characterize these cells and gain further insight into the mechanisms driving latency 
establishment, maintenance and reactivation. We also envisaged using the model to evaluate the 
efficacy and potency of therapies aiming to purge the reservoir.  
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Figure 1. The HR4lox HIV-1 reporter mouse model and its components. A. Schematic of the HIV reporter 
transgene, called HR4lox. Two Cre-mediated recombination events (inversion and excision) at two distinct sets 
of loxP sites are required for RFP expression. B. Recombinant HIV encoding a Cre, called HOCC, used for 
infection. HOCC is derived from the complete HIV (NL4-3 strain) sequence with a truncated Nef for optimized 
functionality and a CMV-Cre cassette at the 3’ end. C. Schematic of the changes that occur when a cell 
carrying the HR4lox transgene is infected with a HIV encoding Cre. HR4lox transgenic cells constitutively 
express GFP from the PGK promoter and are only induced to express RFP upon infection, as only then is Cre 
present in the cells. Once Cre-lox recombination has occurred in a cell, RFP is constitutively expressed from 
the CMV promoter. D. Adult HR4lox hu-mice express the HR4lox transgene in CD34 lineage cells (represented 
as green cells) and upon infection with HOCC, these transgenic cells are induced to thereafter constitutively 
express RFP, allowing infected cells to be isolated by FACS based on the dual expression of GFP and RFP. 
To study the HIV reservoir, HOCC-infected HR4lox hu-mice are treated with cART and once they become 
aviremic, latently infected cells can also be identified and sorted based by gating on GFP+RFP+ cells. Parts A-
B were adapted with permission from a figure made by Dr. Petitjean. 
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2.2 Results 
2.2.1 Generation of a HIV Reporter hu-mouse model 
2.2.1.1. In vitro validation of the HIV reporter system 
This work is based on a collaboration between the labs of Prof. Benkirane and Prof. Speck.  
Dr. Petitjean assessed the functionality of the HR4lox reporter system in vitro, which we then 
implemented into hu-mice. For completeness, in this subsection I briefly summarize the results of 
these in vitro experiments.   
 
As the HR4lox reporter system makes use of a genetically modified HIV strain encoding a CMV-
Cre cassette, called HOCC, it was imperative to verify that this gene-engineered virus was 
genetically stable and remained functional over time during in vitro propagation [212]. Thus, firstly, 
the viability of HOCC and the stability of Cre expression were assessed by infecting MT4 cells 
expressing CCR5 (MT4C5 cells) and PHA/IL-2 activated PBMCs with the virus at a dose of 50-500 
ng p24 per million cells and then longitudinally collecting cells from the cultures for flow cytometry 
and qPCR analyses. Detection of intracellular HIV p24 antigen by flow cytometry (Figure 2A-B) 
and quantification of cell-associated HIV gag DNA by qPCR both confirmed that the virus could 
effectively infect and replicate in either cell type, albeit at lower levels than WT HIV in the cell line 
for at least 4 weeks (data not shown). Expression of Cre in infected cells (i.e. p24+ cells) was also 
confirmed by flow cytometry analyses, but expression levels decreased during in vitro propagation. 
Quantitative PCR analyses revealed that cre was stably maintained in the HOCC genome during in 
vitro propagation in both cells types. Specifically, normalized to the proportion of infected MT4C5 
cells or PBMCs, the average proportion of cells harboring cre was 80.86 ± 3.45% and 82.02 ± 
6.72%, respectively, with no significant differences between cell types (p= 0.3962) (Figure 2C). 
These results confirmed that modification of the HIV genome did not abrogate HOCC’s ability to 
infect and replicate in vitro and that Cre was expressed in infected cells. However they also 
highlighted that Cre’s expression and stability are compromised over time, likely as a result of 
mutagenesis within cre arising due to selective pressures for removing all unnecessary gene 
content within the viral genomes during in vitro propagation driven by HIV’s error-prone reverse 
transcriptase. These findings are in line with published work using recombinant HIVs [212].  
 
Secondly, the functionality and specificity of Cre encoded by HOCC were verified by infecting 
MT4C5 cells that were transduced beforehand with the HR4lox reporter vector (HR4lox-MT4C5 
cells), with HOCC or wild type (WT) HIV and then assessing GFP, RFP and intracellular p24 
expression by flow cytometry (Figure 2D). Cre functionality was demonstrated by the induction of 
RFP expression in HOCC-infected cells. As RFP was only detected in HOCC-infected reporter 
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cells (i.e. GFP+) these results also confirmed the specificity of RFP induction in the reporter 
system. As expected, the majority of GFP+RFP+ cells stained positive for intracellular p24. The 
lack of p24 signal in a small portion of RFP+ cells could be a result of differences in the timing of 
viral gene expression compared to the Cre, whose expression is independently driven by the CMV 
promoter, (see Figure 1B), as well as some level of non-productive infection. 
 
Lastly, it is crucial that Cre remains functional during serial passaging of HOCC to be of use for the 
in vivo model. Thus, Cre functional stability was assessed by co-culturing HR4lox-MT4C5 cells 
with MT4C5 cells or PBMCs that were infected with HOCC for 10 or 30 days, and then measuring 
RFP and p24 expression in the HR4lox-MT4C5 (i.e. GFP+) cells at 10 to 20 days post-infection 
(dpi). If the Cre in HOCC remains functional whilst replicating in MT4C5 cells and PBMCs, then 
infected HR4lox-MT4C5 cells should be induced to express RFP. RFP and p24 double positive 
HR4lox-MT4C5 cells could be detected in all co-cultures, indicating that the Cre encoded in the 
HOCC genome remained functional over up to 30 days of propagation in vitro (Figure 2E). These 
results are also depicted as the proportion of infected cells expressing RFP over the total 
proportion of infected cells in the co-cultures (i.e.: %RFP+ of p24+/ %p24+ cells) (Figure 2F), 
which provides a measure of the recombination efficiency in the reporter system. These results 
revealed that Cre maintained comparable levels of functionality when HOCC was propagated 10 or 
30 days in either cell type (p>0.05). In other words, recombination efficiencies were stable and 
comparable over time (p> 0.05) when using HOCC passaged on MT4C5 (36.21 ±0.52%) or 
PBMCs (47.59 ±6.08%), yet efficiencies were significantly lower compared to that obtained with 
virus stock (65.59 ±4.92%) (p<0.0001), which is in line with the differences in Cre stability 
observed in the previous assays. Importantly, these co-culture assays highlighted that even in vitro 
the Cre-lox recombination efficiency of the reporter system is well below 100%. Nevertheless, 
taken together these results showed that the HR4lox reporter system was stable in vitro and could 
be used to specifically mark infected cells, prompting us to implement it in vivo.  
 
2.2.1.2 Estimation of maximum readout obtainable with the HR4lox reporter system in 
vivo  
To get an impression of the readout we can expect with the HR4lox reporter system in vivo, I used 
the Cre-lox recombination efficiency measured in PBMCs (i.e. 47.59%) to assess the proportion of 
infection events we can expect to detect via RFP, given different levels of reporter transgene 
expression in the HR4lox hu-mice (see Table 1). Namely, considering proportions of CD4+ T cells 
carrying the HR4lox transgene ranging from 10-100%, at best, about 4.7 to 47% of infection events 
occurring in the HR4lox hu-mice could be detected with the system, respectively (Table 1, column 
2). Moreover, assuming 0.1-1% of CD4+ T cells are productively infected [6, 48, 213, 214] in the 
HIV reporter hu-mouse model, the number of CD4+ T cells that would need to be analyzed in order 
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to detect at least one infected cell was estimated. The results are summarized in Table 1 and 
reveal that depending on the level of transgene expression, between 2100 and 21000 CD4+ T 
lymphocytes need to be analyzed to detect a single infected cell based on the expression of RFP. 
Note that these are likely overestimations, as the true Cre-lox recombination efficiency in the 
reporter hu-mouse model is likely to be lower than observed in vitro. Nonetheless, this theoretical 
exercise highlighted the importance of achieving high levels of transgene expression in the hu-
mouse model in order to maximize the readout, and also that if the recombination efficiency of the 
reporter system is too low in vivo, marking of infected cells may ultimately be too infrequent for 
effective isolation of latently infected cells.  
Table 1. Estimation of reporter system readout in vivo. All calculations assume an in vivo recombination 
efficiency of 47.59%, as measured in vitro in PBMCs.  
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Figure 2. In vitro validation of the HR4lox reporter system and its components. A.-C. Stability of Cre 
expression in HOCC-infected (p24+) cells: Flow cytometric analysis of (A) MT4C5 cells and (B) PBMCs infected 
with HOCC at 8 and 30 days post infection (dpi), showing that the majority of infected cells concurrently express 
Cre. D. Functionality of reporter system in MT4C5 cells. RFP expression is only observed in HR4lox-MT4C5 
(GFP+) cells infected (p24+) with HOCC. E. Stability of Cre functionality in MT4C5 cells and PBMCs: Flow 
cytometric analysis of HR4lox-MT4C5 cells co-cultured with PBMCs infected with HOCC for 12 or 17 days. F. 
Recombination efficiency of reporter system in vitro, i.e. proportion of infected cells expressing RFP over the total 
proportion of infected cells in the co-cultures. G. Induction of RFP expression upon HOCC infection of CD34+ 
cells transduced with the HR4lox transgene. Figures based on data generated and collected by Dr. Petitjean.  
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2.2.1.3 Implementing and testing the stability of the HIV reporter system in vivo  
HR4lox hu-mice were generated as described in [163] using HSPCs that were transduced with the 
HR4lox transgene (see methods). Despite lentiviral transduction being well suited and widely used 
for the stable transgenesis of an extensive range of cell types, including non-dividing cells like 
HSPCs [215], it was imperative to verify that genetic engineering of the HSPCs did not 
compromise human immune system reconstitution, and if so, that transgene expression was stable 
over time. Flow cytometry analyses of PBMCs from three to four months old HR4lox hu-mice 
demonstrated that transduction of human HSPCs with the HR4lox lentivector did not impair human 
leukocyte reconstitution, as the engraftment of HR4lox hu-mice was comparable to that of regular 
hu-mice (i.e. transplanted with untransduced HSPCs) generated in our lab (Figure 3A). Moreover, 
as the HR4lox transgene constitutively expresses GFP, flow cytometry was used to assess the 
stability of the transgene in vivo. Flow cytometry analyses of cells from the peripheral blood, spleen 
and bone marrow of HR4lox hu-mice revealed that GFP was stably expressed from the HR4lox 
transgene in all probed anatomical compartments over time (Figure 3B), with GFP still detectable 
by flow cytometry in ten month-old HR4lox hu-mice. These results confirmed that the HR4lox-
HSPCs were genetically stably and could efficiently support hematopoiesis in the immunodeficient 
NSG mice. However, the mean proportion of CD4+ T cells in the periphery carrying the reporter 
transgene was only 15.5±21.64% (range 0.13 to 83.80%); a consequence of low transduction rates 
(14.5 to 50%) of the HSPCs used to reconstitute the HR4lox hu-mice. Effectively, this low 
proportion of transgenic CD4+ T lymphocytes meant that on average, in the periphery, we would 
only be able to identify about one fifth of infection events. However, given that the in vitro 
recombination efficiency of the reporter system was estimated at 47.59%, the proportion of 
infection events we could expect to track in these hu-mice fell below 8% (see Table 1). As our goal 
was to use this HIV-reporter hu-mouse model to identify and isolate extremely rare latently infected 
cells (frequency on the order of one in a million resting CD4+ T cells), we needed to increase the 
detection rate of infection events. To this end, we subjected the transduced HSPCs to FACS, in 
order to obtain almost pure populations of HR4lox+ HSPCs for generating the reporter hu-mice. As 
can be seen in Figure 3A-B, the HR4lox hu-mice reconstituted with transduced and FACS-sorted 
HSPCs displayed higher proportions of transgenic cells. However, although HR4lox hu-mice 
generated from FACS-sorted HSPCs displayed normal human immune system development and 
comparable levels of humanization (i.e. %CD54+ cells) (Figure 3A and C), the engraftment of the 
FACS-sorted HSPCs occurred in an all-or-nothing manner, i.e. all hu-mice transplanted with the 
same FACS-sorted HSPC sample either developed a human immune system or did not (gray bars 
in Figure 3C). The overall engraftment efficiency in hu-mice cohorts generated from transduced 
and FACS-sorted HSPCs was 30.8%, and Fischer’s exact test revealed this was a significantly 
lower proportion of successfully reconstituted mice compared to what we observed for WT (82.2%, 
p<0.0001) and solely transduced HSPCs (61.1%, p=0.011). Together these results indicated that 
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the HR4lox hu-mouse generated with a pure population of transgenic HSPCs constituted a stable 
reporter organism to use for the HIV reporter hu-mouse model. 
 
2.2.1.4 Testing the stability and functionality of the recombinant HIV encoding CMV-Cre 
in vivo 
Despite encouraging results of HOCC replication and functionality in vitro, the complexity of the 
human immune response to HIV made it imperative to verify that the recombinant virus retained its 
ability to replicate in vivo, whilst maintaining the Cre sequence in its genome. Infection of regular 
hu-mice with 4.4x105 TCID50 HOCC revealed that albeit slower kinetics, HOCC replicated 
efficiently in vivo and was able to establish disseminated infections in seven out of eight hu-mice. 
However, persistent high level viremia (i.e. >1000 copies/mL) was only detected in five of these 
mice and only three mice had viremias that rose above 104 copies/mL (Figure 3D). Thus, in order 
to increase HOCC infection rates and resulting viremia at early time points [216], in subsequent 
experiments we used infectious doses of 1.0 to 1.2x106 TCID50 per mouse. Furthermore, we 
confirmed by qPCR that the Cre sequence was maintained in the circulating viral pool, with Cre still 
detectable in plasma 8 weeks post-infection (Figure 3E). Together these experiments 
demonstrated that the recombinant HIV encoding Cre was suitable for use in the HIV reporter hu-
mouse model. 
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Figure 3. In vivo validation of reporter system components. A. Flow cytometric analysis of human 
immune system reconstitution in HR4lox hu-mice compared to standard hu-mice. Transduction of CD34+ 
cells with the HR4lox transgene does not impair human immune system reconstitution as evidenced by 
comparable (2-way ANOVA) engraftment levels between the different groups of hu-mice. Note only hu-
mice with ≥ 5% CD45+ are included in the subsequent downstream cell subsets. (Caption continued on 
next page.) 
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2.2.2 Testing the functionality of the HIV reporter hu-mouse model: Proof-of-principle 
experiments in HOCC-infected HR4lox hu-mice 
Having completed the in vivo implementation and validation of the HR4lox reporter system 
components, we proceeded to testing the functionality of the HIV reporter hu-mouse model; 
namely, whether HIV-infected cells could be expressly marked and detected in the HIV reporter 
hu-mouse model. As the frequency of productively infected cells is much higher than latently 
infected cells, as a proof of principle, we used a productive HIV infection scenario to test the model 
and we focused on CD 4 T lymphocytes, as these are the main cellular targets of HIV. To this end, 
cohorts of HR4lox hu-mice were infected with HOCC and once disseminated infection was 
confirmed by RT-qPCR, the animals were sacrificed and spleen, bone marrow, peripheral blood 
and, whenever possible, mesenteric lymph nodes were collected for analysis by flow cytometry, 
with a primary focus on GFP and RFP expression in these different compartments. In subsequent 
experiments, in order to characterize the RFP+ populations, we expanded the marker panel for 
flow cytometry to include phenotypic and activation markers. 
 
Figure 4A depicts the gating strategy used to identify infected CD4+ T lymphocytes in the different 
tissues studied. In line with good flow cytometry practices, in order to set the cutoffs for the GFP 
and RFP gates, regular or HR4lox hu-mice infected with WT HIV were used as controls. Regular 
hu-mice have no reporter cells, and thus were expected to have no GFP or RFP positive cells, 
whereas HR4lox hu-mice infected with WT virus have GFP+ cells, but these were expected to not 
express RFP due to absence of Cre required for induction of RFP expression. When analyzing 
flow cytometry data, for reliability I only considered results from gates that included at least one 
hundred cells, with the exception of the RFP+ gate. In addition, as we noticed that with the first 
HR4lox hu-mice cohorts we sometimes had too few cells in the tissues samples (especially 
PBMCs and lymph nodes) to have a robust detection of RFP+ cells, thereafter and whenever 
possible we pooled corresponding tissues from several HR4lox hu-mice for the flow cytometry 
analyses. Thus, in the majority of cases the results presented herein are from pooled samples.  
Figure 3 (cont.). B. Representative flow cytometry plots showing expression of GFP in CD4+ cells from 
peripheral blood, spleen and bone marrow of HR4lox hu-mice. GFP could readily be detect for up to 10 
months. C. Human engraftment levels measured by flow cytometry in HR4lox hu-mice transplanted with 
HSPCs that had been only transduced or transduced and FACS-sorted, compared to standard hu-mice 
(i.e. HSPCs not transduced). The light gray bars correspond to the proportion of transplanted mice in 
which a human immune system reconstitution could be detected (i.e. ≥ 5% CD45+ in peripheral blood). 
D. Replication kinetics of HOCC in 8 standard hu-mice. E. Results from HIV gag and cre qPCR assays 
carried out on plasma viral RNA.  
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Figure 4. Productive infection in HIV-1 reporter mouse model. A. Representative flow cytometry plots 
of spleen and bone marrow samples from HR4lox hu-mice infected either with HOCC or WT HIV. The 
upper panel shows the gating strategy used. B. Fluorescence microscopy images of splenocytes from a 
HOCC-infected HR4lox hu-mouse. C. Level of RFP expression in GFP+ CD4 T cells from different 
anatomical compartments of HOCC-infected HR4lox hu-mice. D. Phenotypic characterization of RFP+ 
splenocytes: representative flow cytometry plots are shown on the left and summary of results for all 
HOCC HR4lox hu-mice are shown in the right. 
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Flow cytometry analysis revealed that GFP+RFP+ cells could be detected in the majority of 
HR4lox hu-mice infected with the Cre-virus, in all probed anatomical compartments (i.e. spleen, 
bone marrow, peripheral blood, lymph nodes), expect lymph nodes for which we only had very few 
samples of limited size. Representative flow cytometry plots for stained splenocytes and bone 
marrow cells of HR4lox hu-mice infected either with HOCC or WT HIV (NL4-3) are depicted in 
Figure 4A. In addition, fluorescence microscopy of a small aliquot of splenocytes from a HOCC-
infected HR4lox hu-mouse confirmed expression of RFP in some of the GFP+ cells (Figure 4B). 
Marker expression derived from the flow cytometry analyses of the spleens of infected HR4lox hu-
mice are presented in Figure 4 C-D. As expected, the highest frequencies of GFP+RFP+ cells 
were observed in spleens, where on average 2.09% of GFP+ cells also expressed RFP (max. 
3.9%). In the bone marrows and PBMCs the average frequencies of RFP+ lymphocytes were 
1.46% and 0.51%, respectively. These results translate to an average of approximately 20900, 
14600 and 5100 infectious units per million (IUPM) GFP+ CD4+ T cells in the spleen, bone marrow 
and PBMC compartments respectively. Despite the relatively low fluorescence intensities of these 
RFP+ populations, RFP expression was only observed in conjunction with GFP positivity and 
RFP+ cells were not detected in uninfected HR4lox hu-mice or ones infected with WT HIV (see 
lower panels in Figure 4A). Furthermore, phenotypic characterization of total and GFP+RFP+ 
CD4+ T cells from infected HR4lox hu-mice samples by analysis of cell surface marker expression 
revealed that GFP+RFP+ CD4+ T cells from spleen, bone marrow, peripheral blood and lymph 
nodes were mainly activated cells (i.e. HLA-DR+) with a memory phenotype  (i.e. CD45RA- [217]) 
(Figure 4D). These results are in accord with findings that in HIV infected viremic patients, or in 
vivo HIV/SIV models, productive infection mainly occurs in activated memory CD4+ T lymphocytes 
[60, 90, 197, 218-221], with relatively few productively infected cells at any given time resulting 
from their rapid clearance by host immune responses or viral cytopathic effects [21, 41, 89, 213, 
214]. 
 
Despite low RFP intensities, together these results suggested that we were detecting infected cells 
marked in vivo rather than artefacts. Thus, we proceeded to isolating GFP+RFP+ cells from a new 
cohort of HOCC-infected HR4lox hu-mice by FACS, with the aim of using qPCR and a viral 
outgrowth assay (VOA) on these cells to confirm that indeed they harbored virus. As we expected 
a low yield of GFP+RFP+ cells from the FACS, in order to be able to run both assays in parallel 
with sufficient input material, whole genome amplification (WGA) was carried out on a small 
fraction of isolated cells destined for molecular analysis. The rest of the isolated cells were used for 
the VOA. The qPCR assay performed on amplified cell-associated DNA informs on the presence 
of the HIV gag, thus both defective and infectious proviruses are detected. On the other hand, the 
VOA informs on the presence of replication-competent virus via the detection of the viral p24 
protein (a proxy for viral replication) in culture supernatant quantified by an ultra-sensitive digital 
ELISA (Simoa technology from Quanterix) [119], however its execution is more complicated and 
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laborious. These two complementary assays were implemented in order to robustly evaluate 
whether RFP+ cells in the model were truly infected cells (i.e. carrying integrated provirus). It is 
important to note that as WGA is not uniform [222], the subsequent qPCR is not quantitative and 
the CT values were used simply to assess whether a sample was positive for HIV-Gag.  
 
FACS of pooled spleen, bone marrow and PBMC samples from productively infected HR4lox 
reporter hu-mice allowed us to identify and phenotypically characterize GFP+RFP+ cells, as well 
as to collect these cells for further downstream analyses. Along with the main CD4+GFP+RFP+ 
target population, CD45+CD4-GFP+RFP+ cells were also isolated in order to capture any infected 
monocyte-lineage cells that could harbor virus in the reporter hu-mouse model. In addition, the 
GFP+RFP- counterparts for both of these cell subsets were collected to get an idea of the 
proportion of infection events we were missing due to ineffective recombination catalyzed by Cre 
or poor RFP expression. The sorting strategy and RFP expression plots are displayed in Figure 
5A-B. Despite pooling of samples from several hu-mice and >66% of CD4+ T cells expressing the 
reporter transgene, as human engraftment levels were low, only 352, 14 and 4 CD4+GFP+RFP+ 
cells were isolated from the spleen, bone marrow and PBMC samples, respectively. The 
frequencies of RFP+ cells in the GFP+CD4+ T cell subset in these samples were 2.47%, 2.68% 
and 1.15%, respectively, and in line with our previous results and the literature. 
 
The VOA on the isolated cell populations revealed that p24 production (i.e. viral replication), 
quantified with an ultra-sensitive single molecule array (SIMOA) digital ELISA (Quanterix 
Corporation) could be detected in all GFP+RFP+ sorted populations, with exception of 
CD4+GFP+RFP+ cells from bone marrow (Figure 5C-D). The ultra-sensitive digital p24 ELISA 
used for quantification of p24 production in the VOA has a limit of detection (LOD) of 0.0025 pg/mL 
[119] and thereby is >200-fold more sensitive than conventional p24 ELISAs [223], and has been 
employed to detect p24 production from a single productively infected CD4+ T lymphocyte [224]. 
Specifically, Passaes C. P. et al were able to demonstrate that p24 production from single infected 
cells range from 0.096 to 0.36 pg/ml, levels not quantifiable with conventional p24 ELISA [224]. For 
our analyses, as done in the study by Passaes C. P. et al, we chose a conservative limit of 
quantification (LOQ) of 0.017 pg/mL, which corresponds to the lowest concentration used for 
generation of the standard curve. Although the maximum levels of p24 produced by 
CD4+GFP+RFP+ cells isolated from spleens and peripheral blood were very low (0.033 to 0.063 
pg/mL), the fact that few cells were used in the VOA and also that, at least for the splenocytes, the 
low p24 signal persisted over time – with the dips in p24 arising after each dilution of the well 
contents with fresh cells and medium – supported that this was not simply background noise. In 
addition, when large amounts of cells (n > 30000) were put in culture for the VOA, the p24 levels 
recorded in the culture supernatants were high (and sometimes above the range of quantification 
of the digital P24 ELISA), whereas with low input cell numbers, peak p24 levels in the 
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corresponding cultures were generally low. Furthermore, for the samples where DNA amplification 
was successful, the VOA results were corroborated by the Gag-qPCR results (see table in Figure 
5D). Of note, despite having optimized the WGA protocol for a low number of input cells, in some 
cases no DNA was detected after the amplification reaction. As I did not have a method to verify 
that the desired fraction of isolated cells had effectively been transferred to the WGA reaction 
tubes, the assumption is that when no DNA could be quantified after WGA, this was due to the 
absence of cells in the input sample.  
 
Viral replication and provirus were also measured in all the GFP+RFP- fractions, except in 
CD4+GFP+RFP- PBMCs where cell-associated HIV gag was not detected but p24 production was 
measured. The observation of viral replication and provirus in the RFP- subsets is not aberrant 
considering that Cre-lox recombination in the model is not 100% efficient, which entails that some 
infection events do not lead to the induction of RFP in GFP+ cells. However, these results revealed 
that in future sorts it would be pertinent to include an internal negative control population, such as 
CD19+GFP+ cells.  
 
Taken together, these experiments validated that with the HIV reporter hu-mouse model we could 
identify, phenotypically characterize and isolate productively infected cells based on the dual 
expression of GFP and RFP. Thus, we proceeded to testing whether the model would also allow 
us to identify and isolate in vivo latently infected cells using the reporter genes. 
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Figure 5. Isolation of RFP+ cells by FACS and subsequent characterization by VOA and 
HIV-gag qPCR. A. Actual gating strategy during FACS. B. RFP expression in splenocytes of 
HR4lox hu-mice infected with HOCC versus WT HIV (upper panels) and phenotypic 
characterization of RFP+ cells (lower panels). The upper panel shows the gating strategy used. 
C. Kinetics of p24 levels in VOA culture supernatants for the four cell populations collected 
from HOCC-infected HR4lox hu-mice. The thick horizontal dotted line corresponds to the 
minimum amount of p24 produced by one infected cell (Passaes C.P., J Virol., 2017). Arrows 
indicate when activated healthy donor CD4+ T cells were added to the cultures. D. Overview of 
maximum p24 reading in the VOA and HIV-gag qPCR results after WGA for each isolated cell 
population. WGA was considered successful (“+”) when DNA could be quantified by picogreen 
after the reaction and a sample. NA= not available. 
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2.2.3. Studying the HIV latent reservoir in our HIV reporter hu-mouse model 
To study HIV latency with the reporter hu-mouse model, viremic HOCC-infected HR4lox hu-mice 
were treated with a triple-drug ART until viral replication was suppressed below the limit of 
detection limit for a few weeks, as then, any GFP+RFP+ cell is a persistently infected cell that 
potentially contributes to the latent reservoir [168]. We assessed whether we could identify and 
isolate RFP+ cells persisting in different tissues from ART-suppressed HOCC-infected reporter hu-
mice by FACS and subsequently subjected these cells to molecular and viral outgrowth assays to 
verify they harbored provirus. These experiments aimed to validate the specificity of the RFP 
marker in identifying HIV reservoir cells. The cART used herein consisted of two reverse-
transcriptase inhibitors, Abacavir (ABC, 100 mg/kg per day) and Lamivudine (3TC, 150 mg/kg per 
day) and an integrase inhibitor, Dolutegravir (DTG, 15 mg/kg per day), dissolved in a sucralose 
solution replacing the normal drinking water [172]. This treatment regime was well tolerated by the 
animals and suppressed viremia below the limit of detection within 3-5 weeks. Moreover, gaining 
from our experience with the previous experiments, for these latency studies we modified the 
marker panel such as to include CD19 and thereby have a proper internal negative control. The 
new gating strategy used is depicted in Figure 6A.  
 
In the first two cohorts of cART-suppressed HOCC-infected HR4lox hu-mice, GFP+RFP+ 
splenocytes could be identified and phenotypically characterized by flow cytometry, mainly in the 
CD4+ cell subset, but also in CD3-CD19- cells (Figure 6B), which likely correspond to HIV 
reservoir macrophages  [80, 171]. Splenic and bone marrow RFP+ CD4+ T cells arose at a mean 
frequency of 0.204% (range 0.081 to 0.36%) and 0.680% (range 0.21 to 1.49%), respectively. 
Interestingly, the majority (~70%) of RFP+ cells in the hu-mouse model displayed a naïve 
phenotype (CD45RA+CCR7+), and to a lesser extent (~21%) central memory phenotype 
(CD45RA-CCR7+), whereas overall, effector memory cells were the most prevalent CD4+ T cell 
subset in the hu-mice (Figure 6B). This unexpected naïve phenotype may arise because 
humanized NSG mice do not fully recapitulate the T lymphocyte subsets found in human adults 
(see Table 2), and thus the higher prevalence of naïve T cells skews infection rates for this subset. 
Nonetheless, it would be of interest to elucidate what makes these CD45RA+CCR7+ cells 
susceptible to persistent infection. Alternatively, it could well be that the lymphatic reservoir is 
different from that found in the peripheral blood, especially considering that viral replication mainly 
occurs in lymphoid organs and GALT. Finally, new CD4+ T lymphocyte subsets are being 
identified as reservoirs, such as T helper follicular cells [60, 225, 226] and regulatory T cells (Treg) 
[218, 227]. Therefore the phenotype of the GFP+RFP+ cells in aviremic HR4lox hu-mice needs to 
be further evaluated by including additional markers in the staining panel, such as CD25 and 
CD127 (Treg), PD-1 and CXCR5 (Tfh). 
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Figure 6. Exploring latency in the HIV reporter hu-mouse model. A. FACS gating strategy for isolating 
latently infected (i.e. RFP+) cells. B. Representative flow cytometry plot of (left panels) RFP expression in 
splenocytes of cART-suppressed HOCC-infected HR4lox hu-mice compared to an uninfected counterpart 
and (right panels) phenotypic characterization of RFP+ cells. (Caption continued on next page.) 
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VOA on the isolated cells revealed that inducible, replication-competent provirus persisted in the 
splenic CD4+ and CD3-CD19- cell compartments (Figure 6C), however not in the rare 
CD4+GFP+RFP+ fraction. When available, these results were corroborated by HIV gag PCR on a 
small fraction of cells subjected to WGA (see table in Figure 6C). Noteworthy are the substantial 
differences in the number of cells used as input to the VOA between the different isolated 
populations, with only about 20 CD4+GFP+RFP+ cells available for VOA, compared to more than 
100’000 CD4+GFP+RFP- cells. Again, it must be noted that due to inefficient Cre-lox 
recombination, GFP+RFP- cells may harbor provirus. The lack of detectable viral replication in 
splenic CD4+GFP+RFP+ cells opened up a number of questions as to why we could not detect 
p24 in the culture supernatants. Namely, whether the reactivation stimuli used were insufficient to 
reverse latency in these cells [86, 114]; or whether reactivated latently infected cells only gave rise 
to abortive replication in the given culture conditions [224, 228]; or whether the isolated cells 
harbored defective provirus [195]. In addition, unexpectedly, the highest level of p24 production 
arising from VOA was seen for the CD19+GFP+RFP- splenocytes. The most plausible explanation 
for this was contamination during sorting arising as a result of the suboptimal anti-CD19 staining, 
which made distinguishing the CD19+ population from the CD19- difficult. Thus, it is possible that 
CD19- cells fell into the CD19+ sort gate. In addition, we realized that as we were pooling the 
HOCC-infected HR4lox hu-mice samples, we were actually analyzing a lot more cells for these 
samples than the control samples (i.e. tissue samples from a single hu-mouse), resulting in a 
greater amount of background noise in the experimental group compared to the control group. 
Therefore, we repeated the FACS of cells from a new cohort of cART-suppressed HR4lox hu-mice, 
a) using an optimized staining protocol yielding a better separation of the CD19 negative and 
positive populations, and b) acquiring an equivalent number of events for the control and 
experimental group samples. In addition, for the VOA, similar numbers of RFP+ and RFP- sorted 
cells were used for each population subset (Figure 6E). In this last proof-of-principle experiment 
aiming to assess if latently infected cells could be isolated from the HIV reporter hu-mouse model, 
flow cytometric analysis revealed that the RFP signal was too weak to detect persistently infected 
cells above background noise. This can be seen in Figure 6D from the lack of difference in RFP 
Figure 6 (cont.). C. Overview of maximum p24 readings in VOA culture supernatants for the different cell 
populations isolated from cART-suppressed HOCC-infected HR4lox hu-mice (i.e. from sort shown in B). D. 
RFP expression in pooled samples from a new cohort of cART-suppressed HOCC-infected HR4lox hu-mice 
compared WT HIV-infected counterparts, when analyzing comparable numbers of cells. E. Overview of 
maximum p24 readings in the VOA culture supernatants for the different cell populations isolated from cART-
suppressed HOCC-infected HR4lox hu-mice (i.e. from sort shown in D). F. Kinetics of p24 readings for the 
two VOA cultures that showed a single positive p24 read (blue and green lines), compared to the negative 
control (black) and the cultures containing the different isolated CD19+ cell populations (gray).  
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signal between the control and experimental groups when equivalent number of events were 
analyzed. The frequency of GFP+CD4+ spleen and bone marrow cells that expressed RFP was 
only 0.003% and 0.017%, respectively. Furthermore, VOA on the isolated cell fractions did not give 
rise to any persistent p24 signal. We also observed p24 readings above the LOQ (0.017 pg/ml) for 
the negative controls; with the highest p24 reading from wells containing just irradiated PBMCs 
and medium at 0.043 pg/ml and the highest p24 reading arising from CD19+ populations at 0.05 
5pg/ml (Figure 6E-F). Thus, using a revised threshold for p24 positivity, based on our negative 
controls, of 0.055 pg/ml, only CD4+GFP+RFP+ splenocytes and CD3-CD19-GFP+RFP+ bone 
marrow cells gave rise to a single positive p24 reading of 7.42 and 0.589 pg/ml, respectively. As in 
the case of the CD4+GFP+RFP+ splenocytes the positive p24 reading was measured at the very 
last assay time point, it is impossible to comment on whether this signal would of been sustained 
or have grown over time (Figure 6E). However for the CD3-CD19-GFP+RFP+ bone marrow cells, 
it is feasible that the signal arose due to p24 released from an insufficiently reactivated provirus or 
abortive viral reactivation, as the positive p24 reading appeared in the first sampling time point. 
Thus despite a low resolution, making the distinction of RFP+ cells from background noise very 
difficult, the analyses carried out on the isolated cells support that these cells contained replication-
competent provirus. In any case, in hindsight the results from the first latency studies in the HIV 
reporter hu-mouse model depicted in Figure 6B-C are likely erroneous, and should not be 
considered. 
Table 2. CD4 T lymphocyte subsets in humans compared to adult NSG hu-mice. Data extracted from 
publications as indicated in the last column. 
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2.3 Discussion and Outlook 
2.3.1 Discussion 
Although cART can effectively suppress HIV replication and thereby dramatically decrease 
morbidity and mortality of HIV-infected patients, it is not curative. The major barrier to cure is HIV’s 
ability to hide in a latent form in various cell types and tissues despite years of successful cART. 
Upon treatment interruption, a disseminated infection is rapidly re-established from these latently 
infected cells. Consequently, cART must be taken lifelong, which is associated with numerous 
drawbacks, amongst which an elevated risk of emergence of drug resistances. In addition, a 
significant proportion of the HIV-infected individuals do not have access to cART [19]. Therefore, 
new therapeutic curative approaches are needed. Our knowledge of HIV reservoir cells remains 
fragmentary, primarily because of the difficulty in isolating latently infected cells from patients, 
which are only present at extremely low frequencies (~1/106 lymphocytes). Qualitative profiling of 
primary latently infected cells seeded throughout the human body may bring to light ways of 
specifically eliminating these cells, for example by effectively inducing the provirus they harbor (i.e. 
“shock and kill” approach), or ways to permanently block the latent proviruses (i.e. “block and lock” 
approach). As no ubiquitous surface marker exists that unambiguously identifies latently infected 
cells from a pool of healthy cells, such a characterization is currently not feasible. Indeed this 
would require that millions of cells from HIV-infected patients on cART be sequenced individually, 
and even then HIV reservoirs in hard-to-get tissues, such GALT or lymph nodes, would be missed. 
In vitro models of HIV latency are limited to the study of latency in specific cell types, fail to 
accurately recapitulate the quiescent nature of latently infected cells, rely on artificial methods of 
inducing latency, and cannot capture the complexities of host-virus interactions. Furthermore, NHP 
models of HIV latency are difficult to conduct, costly, time and labor intensive, and rely on the use 
of SIV or SHIV to model HIV. On the other hand, humanized mice offer a uniquely malleable model 
to study HIV in the context of a functional human immune system. Therefore, in this study we 
aimed to develop a HIV reporter humanized mouse model that would allow us to specifically 
identify and isolate genuine latently HIV infected primary cells from diverse anatomical 
compartments. Our model is based on a HIV infection reporter system (HR4lox reporter system, 
designed and tested in vitro by Dr. Petitjean), implemented into the well-established humanized 
NSG mouse model [207], such as to obtain reporter hu-mice in which infected cells can be 
identified based on the expression of the reporter gene, RFP (Figure 1). Explicitly, the HIV reporter 
transgene includes a dually-floxed and inverted RFP reporter gene downstream of a CMV 
promoter, which means RFP can only be expressed after two Cre-mediated recombination events 
have taken place (Figure 1A). This transgene is introduced by lentiviral transduction into the 
HSPCs used to humanize immunodeficient NSG mice. When a recombinant HIV that encodes a 
CMV-Cre cassette (HOCC, Figure 1B) is used to infect the transgenic hu-mice, infected cells 
carrying the reporter transgene (i.e. GFP+ cells) are induced to thereafter express RFP 
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constitutively, because the virus brings Cre into these cells. We hypothesized that with such a HIV 
reporter hu-mouse model we could map the sites of HIV persistence in different anatomical 
compartments and cellular subsets of the human immune system, as well as isolate genuine 
latently infected cells for subsequent genomic, transcriptomic and epigenomic profiling. To this 
end, we first validated the reporter system components in vivo and then tested the functionality of 
the HIV reporter hu-mouse model as a whole by infecting HR4lox-mice with HOCC and assessing 
whether a) RFP+ cells from tissue samples of viremic animals could be detected and isolated by 
flow cytometry and FACS; and b) the isolated RFP+ cell populations actually were infected using a 
viral outgrowth assay (VOA) and HIV-gag qPCR. Finally, we proceeded to explore HIV latency with 
our model.  
 
Genetic manipulation of the HIV genome can result in viruses with impaired infectivity or 
dysfunctionality of the transgene [212]. Thus, although infection of HR4lox-MT4C5 cells with 
HOCC passaged on PBMCs for varying lengths of time demonstrated that the recombinant virus 
stably maintained its ability to induce expression of RFP in reporter cells in vitro (Figure 2E), the in 
vivo functional stability of the Cre recombinase encoded by the HOCC virus needed to be 
validated. Infection of standard hu-mice with HOCC resulted in detectable viremia in all but one 
animal, with sustained viremia in ~71% of the infected hu-mice (Figure 3D), confirming that the 
recombinant virus encoding Cre is infectious. In addition, Cre was detected in the circulating viral 
quasispecies up to eight weeks post-infection, implying the stability of the Cre within the HOCC 
genome during replication in vivo. We also verified that introduction of the HR4lox transgene into 
the HSPCs by lentiviral transduction did not compromise human immune system reconstitution in 
the resulting mice. Flow cytometric analysis of leukocyte reconstitution in HR4lox-mice, 
longitudinally in peripheral blood, and up to ten months post-transplantation in spleen and bone 
marrow, confirmed that the HR4lox transgene did not interfere with hematopoiesis (Figure 3A-B). 
However, as the frequencies of GFP+ human cells in our first cohorts of HR4lox-mice were low, 
which would reduce readout from the model, for subsequent humanizations, the transduced 
HSPCs were sorted by FACS to obtain an almost pure population of transgenic HSPCs prior to 
transplantation into the mice. This significantly increased the frequency of human reporter 
leukocytes in the HR4lox-mice. This was an important protocol optimization in light of the model 
being used for studying latency, where the maximum readout possible is needed because of the 
rarity of latently infected cells. Indeed any cell that does not carry the reporter transgene that 
becomes infected is an undetectable event. Unexpectedly, HSPCs sorted by FACS gave rise to 
effectively reconstitution hu-mice in an all-or-nothing manner. As this phenomenon was not 
observed with HSPCs that had only been transduced, it is conceivable that the shearing stresses 
applied to the HSPCs during FACS may affect their activation state or viability, or perhaps induce 
their differentiation, such that the cell population transplanted in the newborn mice are no longer 
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able to sustain hematopoiesis. Still, as generating HR4lox-mice with a pure population of 
transgenic HSPCs was beneficial to the model, we accepted the cost of this optimization.  
 
Productive infection experiments, revealed that GFP+RFP+ could readily be isolated from spleen, 
bone marrow and peripheral blood samples of HOCC-infected reporter mice and thereafter shown 
to produce p24 in co-culture assays (VOA) and also shown to harbor viral DNA (HIV gag PCR). 
These proof-of-principle experiments validated that it is possible to identify and purify infected cells 
from the HIV reporter mouse model based on RFP expression (Figure 5). As the expression of Cre 
in HOCC is driven by the constitutive CMV promoter, theoretically integration of viral cDNA is not 
necessary for Cre to be expressed [50, 229]. This means that in the model, RFP expression marks 
cells in which at least viral entry, reverse transcription and nuclear translocation of the viral 
genome have effectively occurred. In other words, cells containing integrated provirus as well as 
unintegrated forms of HIV, known as LTR circles, which do not lead to productive infections [50], 
can be identified by proxy of RFP. However, we believe this limitation is minor as the efficacy of 
transcription and translation from unintegrated forms of HIV is low [50, 229] and generally confined 
to certain viral genes (i.e. Nef and Tat [230]), thus the overall contribution of these viral forms 
remains questionable. Generally the highest frequency of infected (i.e. RFP+) cells were found in 
the spleen, which is expected as the spleen of NSG hu-mice has a high frequency and abundance 
of CD4+ T lymphocytes [157] and HIV replication primarily occurs in lymphoid tissues [51, 90, 92]. 
Infected cells occurred at a frequency on the order of 104 infectious units per million (IUPM) GFP+ 
CD4+ T cells and principally displayed an activated (HLA-DR+), memory (CD45RA-) phenotype 
(Figure 4), as has been widely observed in patients or tissues of SIV-infected macaques [89, 90, 
213, 220, 231]. Furthermore, work done in our lab by Dr. Mary-Aude Rochat using YU-2 infected 
NSG hu-mice established that at one month post infection, on average the spleen contained 21647 
(± 29032) copies of integrated HIV DNA per million human (CD45+) cells. The comparability of 
frequencies of RFP+ cells in our model of productive HIV infection with those from Mary-Aude’s 
study provide a certain measure of confidence that our model correctly recapitulates HIV infection 
in hu-mice, whilst capturing the pathophysiology observed in HIV-infected individuals. 
Nevertheless the intensity of the RFP signal as measured by flow cytometry was on average low, 
with the positive population just bulging out from the RFP negative population, rather than 
separating distinctly (as seen in vitro in primary HR4lox-CD34+ cells infected with HOCC stock, 
Figure 2G). This is likely a consequence of the CMV promoter used to drive RFP expression in 
infected cells, as despite it being a strong constitutive viral promoter, some studies describe only 
low levels of gene expression from this promoter in primary T lymphocytes and CD34+ cells [232-
234], as well as tissue-specific promoter silencing in both immunocompetent and immunodeficient 
mice [235, 236], possibly due to methylation [237]. The consequence of having both a low 
frequency of RFP+ cells and a weak RFP signal intensity in infected cells, is the difficulty in 
isolating these cells, which means a) negative controls must always be included for setting strict 
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sorting gates; and b) tissue samples from a number of animals need to be pooled to have enough 
cells.  
 
In the first proof of principle experiments, we had tried to include an anti-p24 antibody in the 
staining panel for flow cytometry analysis, as this would have provided a direct means for 
assessing whether RFP+ cells truly are productively infected. Intact infected cells harbor p24 
intracellularly, so staining for p24 requires fixation and permeabilization of the cells prior to 
antibody labeling. In addition, the only available fluorochrome-conjugated anti-p24 antibodies 
available are proprietary products from Beckmann Coulter and the company has only come out 
with FITC- and PE-conjugated anti-p24 antibodies, both of which are not suitable with our model 
as their emission spectra are too similar to those of GFP and RFP, respectively. Thus, in addition 
to the numerous washing steps involved in intracellular staining, we had to use a secondary 
fluorochrome-conjugated antibody to label a non-conjugated primary p24 antibody. After 
intracellular p24 staining of splenocytes from viremic HR4lox-mice, we failed to clearly detect any 
RFP+ events by flow cytometry, probably because there were too few cells for such a low-yield 
staining procedure compounded by the inherently low frequency of infected cells in vivo at any 
given time [89, 213]. Besides, intracellular staining is intrinsically limited, as certain downstream 
analyses, such as VOA, cannot be performed because of the fixation and permeabilization of 
samples. Therefore, in this study we relied on both viral cultivation (VOA) and detection of cell-
associated viral DNA (HIV-Gag PCR) to assess viral burden in different tissue compartments. To 
quantify p24 levels in the VOA culture supernatant we used a relatively novel ultra-sensitive p24 
single-molecule digital ELISA (SIMOA, Quanterix) [119]. The p24 digital ELISA provides 
comparable results to HIV nucleic acid amplification testing [238] and has an LOD of 0.0025 pg/ml 
and LOQ of 0.0076 pg/ml, however it is noteworthy that one of the thirteen HIV-negative samples 
tested produced a reading of 0.0037pg/ml [119]. Therefore, a key aspect to accepting the veracity 
of very low p24 readings is seeing a persistence, and ideally growth, of the p24 signal over time. 
Owing to the p24 digital ELISA technology, Passaes C. P. et al demonstrated that a single 
productively infected CD4+ T cell produced between 0.096 and 0.36 pg/ml of p24 and released 
0.29 pg/ml (median) of p24 into the culture supernatant after overnight co-culture with autologous 
activated CD4+ T cells [224]. Exponentially increasing p24 levels are expected in cultures where 
virus outgrowth from infected cells occurs and a propagating infection is successfully established. 
We found that VOA on cells isolated from productively infected HR4lox-mice resulted in a broad 
range of p24 levels in the culture supernatants (0.019 pg/ml to saturation, i.e. >200 pg/ml); with a 
trend towards higher p24 levels in the VOA cultures started with large amounts of cells (n > 30000) 
(Figure 5). Considering that the PBMCs of acutely HIV-infected patients principally harbor 
defective proviruses [47], this observation seems logical; i.e. the likelihood of having at least one 
cell carrying replication-competent provirus capable of establishing a spreading infection in the 
culture increases with the size of the starting pool of infected cells. Importantly, the low level p24 
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signals observed in the VOA cultures persisted overtime, suggesting they are a result of p24 
release from infected cells rather than background noise from the digital p24 ELISA. In addition, 
although only low levels of p24 were detected in the VOA for the GFP+RFP+ populations, in these 
cultures at most about 400 cells were put in culture. Importantly, besides the replication-
competency of the provirus, establishment of a propagating infection (i.e. exponential viral growth) 
from an infected cell has been shown to be dependent on a viral RNA expression threshold (i.e. 
number of HIV RNA copies) [228, 239]. In fact, Hataye et al. found that the majority of cells put in 
viral outgrowth cultures died before release of progeny virions, and in the event of release of 
virions, these frequently failed to establish propagating infections in secondary cultures [228]. 
Thus, it is likely that a large proportion of the GFP+RFP+ cells isolated from viremic HR4lox hu-
mice harbored defective proviruses, died in culture before releasing infectious viral particles, or in 
which viral transcription was not sufficient to engender exponential viral outgrowth, resulting in viral 
extinction and only low levels of p24 released from dead cells or abortive viral replication. Of note, 
it is highly improbably that the p24 detected in these assays came from virions attached to the 
surface of the isolated cells, as the Env-receptor bounds (~30 pN [240]) would not withstand the 
shearing forces applied on the cell surface during FACS, where a fluid pressure of 70psi (0.482 
N/mm2) was used, as well as the numerous washing steps involved in the sample preparations 
(pre- and post-FACS). If somehow virions did remain attached to cells, anyways we would expect 
the same amount of p24 on RFP- cells. Furthermore, the congruency of the HIV gag PCR results 
with the VOA results, except for CD4+GFP+RFP- PBMCs, further support that the GFP+RFP+ 
cells isolated from the hu-mouse model are truly infected cells. The discrepancy between the low 
p24 levels measured in the VOA culture supernatants and lack of detection of HIV gag by qPCR in 
the CD4+GFP+RFP- PBMCs of productively infected HR4lox-mice implies that the LOD of the p24 
digital ELISA may actually be higher in our hands than reported [119], or that there are technical 
issues with our whole-genome amplification or HIV gag PCR assays. Alternatively, some 
underlying biological mechanism may be at hand, such as a large fraction of infected PBMCs 
carrying only unintegrated HIV DNA [50], which could still support Cre expression (LTR 
independent) and p24 expression (early gene), but would be degraded and not detectable by PCR 
because of the labile nature of unintegrated viral forms. Ultimately, the reason for this discrepancy 
is unclear and further experiments are needed to verify whether this phenomenon is repeatedly 
observed in PBMCs, which would point towards a biological effect, or occurs randomly, which 
would support a technical effect. We believe the latter is more likely. Taken together, despite the 
drawbacks of low RFP signal intensity and small samples sizes, these results confirm that in the 
context of productive infection, the HIV reporter mouse model presented herein allows for the 
isolation of in vivo infected cells based on RFP expression. By suppressing viral replication to 
undetectable levels in infected HR4lox-mice with cART (i.e. latency scenario), we then sought to 
assess whether the model was suitable to study HIV latency.  
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In the latency scenario, we initially found that splenic RFP+ cells arose at a frequency of ~0.2% 
and displayed a naïve phenotype in the HIV reporter hu-mouse model (Figure 6B-C). However, 
FACS resulted in a low yield of GFP+RFP+ cells and strikingly neither viral replication nor HIV 
DNA could be detected in the CD4+ cells. Therefore, we repeated the experiment with a new 
cohort of aviremic HOCC-infected HR4lox-mice, pooling samples from five animals. This last 
experiment revealed that ultimately, when comparable numbers of cells for experimental and 
control samples (i.e. aviremic HOCC- or WT HIV-infected HR4lox-mice, respectively) were 
analyzed and sorted by FACS, the RFP signal intensity produced by the extremely rare RFP+ cells 
in the experimental samples was too weak to enable clear discrimination of latently infected cells 
from background noise (Figure 6D). Therefore, in hindsight, the validity of the results from the first 
set of latency studies with the HIV reporter mouse model is very questionable and thus these 
results, although initially thought to be intriguing, should be disregarded. Nevertheless, in this last 
latency experiment, although none of the isolated GFP+RFP+ cells could establish a propagating 
infection in the VOA cultures within one-month of culture, p24 was uniquely detected at low levels 
in the culture supernatant of GFP+RFP+ CD4+ splenocytes and presumably monocyte-lineage 
(i.e. CD3-CD19-) bone marrow cells (7.42 and 0.589 pg/ml, respectively), when considering a 
revised LOQ of 0.055 pg/ml (Figure 6E-F). A revised LOQ was implemented for the p24 digital 
ELISA readings as the negative control wells gave rise to p24 readings reaching up to 0.055 pg/ml, 
implying that in our hands the p24 digital ELISA had a higher level of background noise than 
reported in other studies [119, 224, 238]. The positive p24 reading from the VOA of 
CD4+GFP+RFP+ splenocytes was measured only at the last sampling time point, so it is not 
possible to determine whether, with longer culture times, p24 levels would have progressively 
increased, indicative of viral outgrowth, or been sustained at a low level, suggestive of ineffective 
reactivation and abortive replication of a latent provirus. The latter scenario is a plausible 
explanation for the single, early p24 signal observed in the culture supernatant of the CD3-CD19-
GFP+RFP+ bone marrow cells. Although these low p24 readings must be considered with caution 
due to the absence of longitudinal measurements of p24 in these two cultures, the p24 levels are 
in accord with other studies quantifying, by digital ELISA, p24 release from stimulated CD4+ T 
lymphocytes from aviremic HIV patients [73, 224, 241]. Specifically, in these studies, p24 levels 
observed in viral induction assay culture supernatants ranged from 0.017 to >100 pg/ml, with some 
cultures not giving rise to any p24 production, as well as instances of abortive (transient) viral 
replication. Importantly, the type of stimulation or LRAs used to induce latent provirus greatly affect 
the outcome of viral reactivation assays in aviremic HIV patients [59, 145, 242], which brings forth 
the question of whether the VOA conditions used herein were sufficient to effectively reactivate 
latent provirus [86, 114], and if so whether reactivated latently infected cells were unable to 
overcome a threshold in viral replication (i.e. viral RNA or p24 threshold) required for successful 
viral propagation [59, 68, 228, 243]. Finally, it is also feasible that a significant portion of RFP+ 
cells in our aviremic HOCC-infected reporter mice harbored defective provirus [47, 85, 195]. In any 
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case, ultimately p24 was only detected in the cultures containing GFP+RFP+ cell populations, 
suggesting that RFP expression in the hu-mouse model under latency conditions marks latently 
infected cells.  
 
In summary, the resolution of the HIV reporter mouse model, dictated by the intensity of the RFP 
signal produced by infected cells, is too low to effectively identify and purify HIV reservoir cells. In 
addition, a major limitation in the model is the relatively low Cre-lox recombination efficiency, which 
drastically limits the number of infection events that can be detected. Despite these limitations, the 
HIV reporter hu-mouse model offers a means to specifically mark productively infected cells in 
vivo, thereby allowing these cells to be identified, characterized and isolated by FACS. Thus, the 
model could be useful for identifying sites of early viral replication associated with the route of 
infection, or to more extensively assess cell types and tissue compartments that support viral 
replication throughout the human immune system. Furthermore, during the process of developing 
and validating this model, we gained valuable insights into key features of the model that would 
need to be modified in order to improve it, and thereby make it suitable for studying the HIV 
reservoir. These are discussed in the subsequent section.  
 
2.3.2. Further directions and optimizations 
In order to improve the sensitivity and readout of the model, both the strength of the reporter gene 
signal and the overall level of expression of the reporter transgene in the human immune system of 
hu-mice need to be increased. Firstly, to address the latter without compromising human leukocyte 
reconstitution in the hu-mice, and to circumvent the need to use FACS to obtain pure populations 
of HR4lox-transduced HSPCs, a practical modification would be to use a constitutively expressed 
cell surface receptor in the place of GFP, so that effectively transduced HSPCs can be selected by 
magnetic-activated cell sorting (MACS). MACS is generally considered to be a more gentle method 
for sorting and the lower purity of MACS sorts compared to FACS would not be an issue in our 
case, as a 100% purity of transgenic HSPCs would not be absolutely necessary [244]. Thus, 
reporter hu-mice with good engraftment and transgene expression levels could easily be 
generated. In addition, such a cell surface receptor would allow for an enrichment of transgenic 
cells from reporter hu-mice samples prior to the planned assays (e.g. FACS), thereby helping to 
reduce background noise. For this purpose, an interesting option would be to use the fusion 
protein CherryPicker from Clontech, which is composed of the fluorescent protein mCherry and the 
transferrin receptor membrane-anchor domain [245], or a similar type of membrane-targeted 
protein [246]. Such membrane-anchored fluorescent proteins would allow the evaluation of 
transduction levels and identification of transgenic cells by flow cytometry as well as selection of 
transduced cells by MACS. Secondly, to increase the strength of the reporter gene signal, 
alternative promoters used to drive the expression of the reporter gene should be tested to find the 
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promoter that mediates the highest levels of reporter gene expression in human primary cells. In 
addition, it would be beneficial to use a reporter gene in place of RFP that produces a brighter 
fluorescence signal, such as the yellow and orange fluorescent proteins YPet and mKO, 
respectively. According to a quantitative assessment of fluorescent proteins by Cranfill et al., the 
relative brightness (i.e. product of the protein’s quantum yield and extinction coefficient relative to 
that of eGFP- the bench-mark fluorescent protein) of YPet and mKO were 100.32 and 103.18, 
respectively, compared to 19.25 for mRFP and 37.52 for eGFP [247]. Using a brighter fluorescent 
reporter protein would enhance the separation between the positive and negative populations, 
thereby facilitating the purification of infected cells in our model. Of note, although the theoretical 
brightness of a fluorescent protein may be high, protein folding, the microenvironment and the 
excitation wavelength greatly influence the actual brightness of the protein’s emission wavelength 
[247]. Therefore, several fluorescent proteins should be tested in human primary cells to evaluate 
which is most likely to yield a bright signal in the model. Moreover, as GFP and RFP have 
overlapping excitation and emission spectra, spill-over of the GFP signal into the RFP channel 
during flow cytometry analysis must be compensated for, which also reduces the RFP signal. This 
further supports the use of alternative reporter genes in the HR4lox transgene. Thirdly, to increase 
the readout of the model, the barrier to Cre-mediated recombination in infected cells could 
potentially be lowered by simplifying the transgene design. The current HR4lox transgene design 
requires two Cre-mediated events (i.e. requires Cre to act twice), for induction of RFP expression, 
which could be significantly reducing recombination efficiency in infected transgenic cells. 
Alternative commonly used strategies for in vivo inducible gene expression using the Cre-lox 
technology involve implementing a floxed stop codon in front or in the middle of the reporter gene 
[209, 248, 249], or using a unidirectional inversion strategy making use of special asymmetric loxP 
sites that flank the reporter gene [250]. As there is a risk of leaky reporter gene expression with the 
floxed stop codon design arising from translational read-through [251, 252], alternatively longer or 
synthetic stop sequences could be used [253]. Finally, as Cre-mediated recombination efficiency is 
mainly dictated by the availability of Cre in the cell, the promoter used to express Cre is critical 
[209]. In the current HR4lox reporter system, Cre expression is driven by the CMV promoter, which 
may be problematic in vivo, as discussed above. Thus, again, using an alternative promoter to 
drive Cre expression in the HOCC genome may also help improve resolution in the HIV reporter 
hu-mouse model. 
 
Furthermore, we have also been exploring an alternative design for a bioluminescent HIV reporter 
system, which would similarly be implemented into the NSG humanized mouse model, to generate 
a hu-mouse model where productively HIV infected cells can be tracked in real-time by 
bioluminescence imaging (BLI). As we are still in the developmental stages of this second reporter 
model, only the concept behind the reporter system is briefly described herein. Our BLI HIV 
reporter system is based on using a highly Tat-dependent promoter to drive the expression of a 
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luciferase reporter gene. The promoter is derived from the HIV LTR, but with modifications 
introduced to reduce the promoter’s basal activity and increase Tat-dependent transcription. Tat is 
expressed early after HIV infection [230, 254], thus employing a Tat-dependent promoter to drive 
luciferase expression permits to specifically monitor productive HIV infection in transgenic cells by 
BLI (after injection of the luciferase substrate, D-luciferin). An advantage of this model is the use of 
wild type HIV, circumventing any issues of compromised infectivity and virus fitness that can arise 
with genetically modified HIV clones. The major concern with this model is achieving minimal 
unspecific luciferase expression, resulting from basal transcription from the modified LTR or read-
through transcription from upstream promoters. Thus, in order to obtain high specificity and 
minimize background noise in our BLI reporter model, it is imperative to have a promoter that is 
ideally completely Tat-dependent, as well as implement insulator sequences to minimize the effect 
of neighboring genes. To this end, I supervised Anja Forrer (MD Master’s project) in the design 
and generation of modified LTR promoters with minimal basal (Tat-independent) transcriptional 
activity and maximal Tat-dependent activity. To generate Tat-dependent promoters, host 
transcription factor binding sites in HIV WT LTR, which were not vital for promoter functionality, 
were removed and the TAR region of the HIV LTR promoter was duplicated. Thereby Anja Forrer 
created a number of different modified LTRs and tested their in vitro transcriptional activities. In 
summary, we found that duplication of the TAR region was most beneficial in increasing reporter 
gene expression in the presence of Tat. Surprisingly, all the modified LTRs also displayed 
increased levels of basal reporter gene expression. Therefore, further work is required to reduce 
basal activity of the promoter destined to be used in our BLI HIV reporter system. Moreover, in 
order to maximize the sensitivity of such a BLI reporter model, I tested different luciferases for their 
in vivo bioluminescent properties. I found that a particular red-shifted, human codon optimized 
luciferase called PLR2 and generated by Professor Bruce Branchini (Connecticut College, 
Connecticut, USA) allows for much more sensitive detection of cells in deep tissues than the 
commonly used Luc2 gene from Promega. Thus, this new luciferase reporter gene seems 
promising for our BLI HIV reporter model.  
 
In conclusion, we plan to continue working on the HR4lox reporter system to render it more 
suitable for the study of HIV latency in vivo, with the ultimate goal of isolating and characterizing 
the genomic and transcriptomic profiles of reservoir cells. In addition, we will pursue the 
development of our BLI HIV reporter hu-mouse model, building on the work done at the beginning 
of my PhD and by Anja Forrer. We envisage using the BLI model to longitudinally monitor by BLI in 
situ viral replication in the context of different infection paradigms, as well as explore the effects 
and efficacy of LRAs on the viral reservoir.  
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2.4 Materials and Methods 
Ethics statement: All animal experiments were approved by the Cantonal Veterinary Office 
(#93/2014) and performed in accordance to local guidelines (KTSchV, Zurich) and the Swiss 
animal protection law (TSchG). Procurement of human cord blood was approved by the Ethical 
Committee of the University of Zurich (EK #EK1103) and cord blood was collected with informed 
written consent from donors. 
 
Cells: MOLT-4/CCR5 cells were cultured in R-10 medium (RPMI 1640 (Sigma-Aldrich) 
supplemented with 10% FBS (Biochrom), 1% 2 mM L-glutamine and 1% penicillin-streptomycin 
(both from Life Technologies)). 293T cells were cultured in D-10 medium (DMEM (Sigma-Aldrich) 
supplemented in the same way as the R-10 medium). PBMCs were isolated from buffy coats, 
obtained from the local blood donation center in Zurich, by Ficoll (Alere Technologies AS) gradient 
centrifugation. CD4+ T cells were purified from freshly isolated PBMCs using anti-CD4 MicroBeads 
(Miltenyi Biotec) with a purity ≥90%. Cells were stored frozen in liquid nitrogen until use.   
 
Wild-type HIV production and titration: Wild-type NL4-3 or YU-2 viruses were produced by 
transient transfection of 293T cells with polyethylenimin (Sigma-Aldrich) and the pNL4-3 (NIH Aids 
reagent program, Cat. No. 114) or pYU-2 (NIH Aids reagent program, Cat. No. 1350) plasmid, 
respectively. After 3 to 18 hours incubation, the supernatant was exchanged for fresh D-10 
medium. Forty-eight hours post-transfection, the supernatant was harvested, filtered (0.22um, 
Steriflip, EMD Millipore), aliquoted and frozen at -80°C until use. Virus stocks were titrated as 
described in [255]. Briefly, CD8-depleted PBMCs from three donors were activated with 
recombinant IL-2, PHA and OKT3 antibody for two days and then challenged with serial dilutions of 
virus stock in order to determine the TCID50 by p24 ELISA. 
 
HR4lox lentiviral particle and HOCC production and titrations: HR4lox lentiviral particles were 
produced (by Dr Petitjean) by calcium phosphate co-transfection of 293T and equal amounts of the 
HR4lox lentiviral transfer plasmid, pCMV-delta-R8.2 packaging plasmid (Addgene plasmid # 
12263) and pMD2.2-VSVG envelope plasmid (Addgene plasmid # 12259). HOCC virus was 
produced (by Dr Petitjean) by calcium phosphate transfection of 293T cells with the HOCC plasmid 
(pBR-NL4-3 Nef-codon optimized-CMV-CRE). For both preparations, 12-24 hours post-
transfection the cells were washed and fresh D-10 medium without FBS was added. After 72 hours 
the supernatant was harvested, filtered and concentrated on a sucrose cushion (20% sucrose in 
PBS Ca2+ Mg2+). The virus particles were then resuspended in PBS Ca2+ Mg2+ for 4 hours at 
4°C, before being aliquoted and stored at -80°C until use. HOCC virus stocks were titrated by 
challenging 5x104 2-day activated (0.5ug/ml PHA, 20U/mL IL-2 ) PBMCs from healthy donors with 
serial dilutions of virus stock. After 5 days, cells were stained for intracellular Cre (primary mouse 
anti-Cre recombinase antibody (Abcam) plus secondary anti-mouse APC antibody) and anaylsed 
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by flow cytometry to estimate the frequency of Cre+ cells and thereby calculate the infectious units 
per mililiter (IU/mL). The TCID50/ml for HOCC virus stocks was then estimated from this IU/mL 
titer by dividing the latter by 0.7 (based on the Poisson distribution and [256]). 
 
Isolation of CD34+ cells from umbilical cord blood: CD34+ HSPCs were isolated from human 
cord blood by Ficoll (Alere Technolgies AS) gradient centrifugation and with anti-CD34 
immunomagnetic beads (Miltenyi Biotec). HSPCs and the flow-through (i.e. non-target) fractions 
were either used directly or stored frozen in liquid nitrogen until use. 
 
Transduction of umbilical cord blood-derived CD34+ HSPCs: Freshly isolated human HSPCs 
(see above) were cultured in CellGro (CellGenix) supplemented with SCF 20 ng/mL, FLT3 20 
ng/mL, TPO1 20 ng/mL, IL-3 20 ng/mL (all cytokines from Immunotools) at a concentration of 106 
cells/mL. Eighteen to 24 hours after activation, LentiBlast-B (Oz Biosciences SAS) at a 
concentration of 1:1000 and HR4lox lentiviral particles were added to the cells for approximately 
48 hours. Transduction efficiency was assessed based on GFP expression by flow cytometry and 
whenever possible, cells were directly transplanted into newborn NSG mice (see below), or 
otherwise stored frozen in liquid nitrogen until use. In later experiments, prior to transplantation, the 
transduced HSPCs were subjected to FACS (FACS Aria III 5L, BD Biosciences) to obtain a pure 
population of GFP+ (transduced) HSPCs.  
 
Generation, infection and treatment of hu-mice: Hu-mice were generated as described in [163]. 
Briefly, newborn immunodeficient NOD-SCID-IL2Rgamma-/- (NSG) mice (Jackson laboratory) were 
sub-lethally irradiated (1 Gy) and transplanted intrahepatically with approximately 1.0±0.5×105 
untransduced or transduced CD34+ HSPCs. Mice were bred and maintained in specific pathogen 
free conditions (Biologisches Zentrallabor at the University Hospital Zurich) in individual ventilated 
cages and were given autoclaved food and water. Mice were monitored once weekly according to 
a standard score sheet. Twelve to 16 weeks after transplantation, human engraftment and de novo 
human immune system reconstitution in the mice were assessed by flow cytometry (CyAn™ ADP 
Analyzer, Beckman Coulter) by staining PBMCs with anti-human monoclonal antibodies against 
the following cell-surface markers: CD45-Krome Orange (Beckman Coulter), CD3-PE, CD4-Pe 
Cy7, CD8-BV421, CD19-APC (all from Biolegend).  
 
Hu-mice were infected intraperitoneally with HOCC, NL4-3 or YU-2 at a dose of 1.0-1.2x106 
TCID50 per mouse, unless stated otherwise. For the latency studies, infected hu-mice were 
treated with Abacavir (ABC, 100 mg/kg per day), Lamivudine (3TC, 150 mg/kg per day) and 
Dolutegravir (DTG, 15 mg/kg per day) (all from ViiV Healthcare) dissolved in a sucralose solution 
replacing the normal drinking water as described in [24]. Briefly, drug tablets were manually 
pulverized, weighed to get the desired amount of active compound (assuming an average body 
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weight of 20g per mouse and consumption of 5mL per day), added to MediDrop® sucralose 
solution (ClearH2O) and mixed for at least 15 minutes using a magnetic stirrer (protocol kindly 
provided by Julien Villaudy). The cART solution was then given in place of the normal drinking 
water and exchanged twice a week to avoid issues with the drugs precipitating.  
 
Quantification of viremia: Viremia in the hu-mice was quantified using an in-house viral load 
assay implemented in our lab by Dr. Audigé based on the protocol described in [257]. RNA was 
extracted from plasma using the QIAamp® Viral RNA kit (Qiagen), eluted in 30uL AVE buffer and 
reverse transcribed using the iScript™ cDNA Synthesis Kit (Bio-Rad). A HIV-1 gag qPCR was then 
performed on the cDNA in a 50uL reaction containing 1X Maxima Hot Start PCR Master Mix 
(Thermo Scientific), 1 uM forward primer (5’-CAAGCAGCCATGCAAATGTTAAAAGA-3’ [257]), 1 
uM reverse primer (5’-TACTAGTAGTTCCTGCTATGTCACTTCC-3’ [258]) and 0.3 uM probe (5’-
FAM-TGCAGCTTCCTCATTGATGGT-BHQ-1-3’ [259]). Experiments were performed in duplicates 
on a IQ™5 real-time thermocycler (Bio-Rad Laboratories, Inc), with the following cycling protocol: 
95°C 4 min, 50x (95°C 5 s, 55°C 5 s, 60°C 30 s). Standards were prepared fresh for each qPCR 
experiment by diluting filtered supernatant from PBMCs infected with NL4-3 (aliquots stored at -
80°C) containing a known number of HIV RNA copies/ml (quantified by COBAS® 
AmpliPrep/COBAS® TaqMan HIV-1 Test, Roche), and co-extracted with the test samples. qPCR 
data was analysed with iQ™5 Optical System Software v2.1 (Bio-Rad Laboratories, Inc). 
 
Flow cytometry and FACS: For all flow cytomerty and FACS experiments besides engraftment 
checks, acquisitions were perfomed on a LSRFortessa™ II and FACSAria™ III 4L (both from BD 
Biosciences). Cell suspensions were labeled with anti-human monoclonal antibodies targeting the 
following cell-surface markers: CD45-BV510, CD3-APC-Cy7, CD4-PerCp, HLA-DR-BV421, CCR7-
PE-Cy7, CD45RA-APC (all from Sony Biotechnology Inc), and CD19-AlexaFluor-700 (in 1st panel 
with CD19) or CD19-BV711 (in 2nd panel with CD19) (both from BioLegend). PBS or FACS buffer 
(PBS containing 2% FBS and 0.05% sodium azide) were used for washing and reagent dilutions. 
Before acquisition cells were fixed with 1% Paraformaldehyde (Sigma-Aldrich). Data were 
analyzed with FlowJo 10 software (FlowJo LLC). 
 
Detecting Cre in circulating (plasma) viruses: The amount of Cre recombinase present in the 
plasma of HOCC-infected hu-mice was quantified by RT-qPCR. RNA was extracted from plasma 
using the QIAamp® Viral RNA kit (Qiagen), reverse transcribed and the cDNA subjected to a Cre-
qPCR (assay established by Dr Petitjean in Prof. Benkirane’s laboratory). 
 
Viral outgrowth assay on sorted cells and quantification of p24 antigen in culture 
supernatants: Cells isolated by FACS from infected (viremic or aviremic) HR4lox hu-mice were 
washed in PBS and then co-cultured with permissive cells under T-cell stimulatory conditions to 
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induce viral outgrowth, which was assessed by longitudinally quantifying p24 antigen 
concentrations in the culture supernatants. Two different VOAs were used in this study. The in the 
first VOA, used in all experiment except the last latency study, sorted cells were co-cultured with 1 
million CD4+ T cells from healthy donors in R-10 supplemented with 100U/mL human rIL-2 (NIH 
Aids Reagents Program Cat. No. 136) and 0.5ug/mL PHA (Sigma-Aldrich). After 72 hours, 
supernatants were collected, the remaining culture medium was exchanged to remove the PHA 
and 1 million fresh 3-day activated (rIL-2 and PHA) CD4+ T cells from the same donor were added. 
Thereafter, supernatants were collected every 3-4 days for 3 weeks. At day 9, 1 million fresh 3-day 
activated (rIL-2 and PHA) CD4+ T cells from the same donor were again added. The second VOA 
was conducted as described in [260], except that sorted cells were not cultured in limiting dilutions 
(too few cells). Briefly, sorted cells were cultured in Super T cell medium (STCM; containing 
100U/mL human rIL-2 and 1% T cell growth factor) on irradiated PBMCs from healthy donors and 
1ug/mL PHA. After 24 hours, the medium was exchanged to remove the PHA and MOLT-4/CCR5 
cells were added to help propagate reactivated virus. Five days later supernatants were collected 
and the cells split into two, seeding the second half of cells into a new plate, and fresh STCM 
added. For 4 weeks, supernatants were collected, cultures split in two and fresh STCM added 
every 4-7 days. For both VOAs, p24 antigen concentrations in the culture supernatants were 
quantified using the Simoa™ p24 Antigen Assay (Quanterix) (ultrasensitive digital immunoassay, 
LOD = 0.0133pg/mL) as described in [224]. 
 
Whole genome amplification (WGA) and detection of HIV DNA in sorted cells: WGA was 
done by multiple displacement amplification (MDA) using the illustra™ Single Cell GenomiPhi™ 
DNA Amplification Kit (GE Healthcare) as specified in the kit manual, except for the following 
optimizations: 2-10uL of cell suspension in PBS were used as starting material; lysis and 
neutralization buffer volumes were scaled up to 2uL (doubled if > 1000 cells were in the starting 
cell suspension). DNA quantification of the MDA products was done in duplicates with 1uL of 
amplified DNA using the Quant-iT™ PicoGreen™ dsDNA Assay Kit (Invitrogen). The presence of 
HIV DNA (gag) in the MDA products was assessed using our in-house HIV-1 gag qPCR assay 
(described above), carried out in duplicates on 1uL of amplified DNA. The remainder of the MDA 
products were stored at -80°C. 
 
Statistical analysis : Statistical analyses were performed using GraphPad Prism 7 (GraphPad 
Software). D’Agostino-Pearson omnibus normality test was always applied to data sets to first 
assess whether parametric tests could be used. Accordingly, data were then subjected either to t-
tests or ANOVAs (or non-parametric equivalents). Significance was considered when p-values 
were ≤0.05 
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3. CHAPTER 3 
 
 
Dissecting the contribution of APOBEC3G to HIV 
diversification and adaptation to antiviral monotherapy 
in humanized mice 
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3.1. Introduction 
Genetic diversification is key feature of HIV and essential for viral evolution, adaptation and escape 
from immune surveillance and antiretroviral therapy (ART) [173, 261]. Accordingly, viral 
diversification in HIV-infected patients is associated progressive HIV disease and underlies the 
rapid emergence of drug resistant HIV strains. HIV’s extensive sequence variation is widely 
attributed to the low fidelity of the viral reverse transcriptase (RT), which induces an estimated 
3x10-5 mutations/base pairs/cycle [20, 174, 175], HIV’s high replication rates (1010 – 1011 
virions/day [21, 176]) and recombination between co-packaged genomes [22, 23]. Another 
proposed driver of viral diversification is sublethal mutagenesis of the HIV genome induced by host 
deaminases from the APOBEC3 (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like 3) family. The APOBEC3 family consists of seven cytidine deaminases (termed A3A to A3H), 
which contribute broadly to human innate antiviral immunity and restrict HIV to varying degrees 
[71, 180-183]. A3G is amongst the most potent anti-HIV APOBEC3 enzymes, but A3D, A3F and 
A3H also display anti-HIV activity [71, 183]. A3G is incorporated into budding virions and therefore 
exerts its antiviral activity in the next round of infection (i.e. in cells newly infected with virions 
containing A3G). It restricts HIV replication by deaminating cytidine residues in the nascent HIV 
cDNA to uridine residues during reverse transcription, thereby introducing a high number of G-to-A 
mutations in the proviral genome, which generally result in defective proviruses [184]. In turn, HIV 
evolved to evade APOBEC3-mediated restriction by encoding the viral infectivity factor (Vif). Vif is 
a HIV accessory protein that efficiently inhibits encapsidation of APOBEC3 enzymes into progeny 
virions, mainly by inducing their degradation through the host ubiquitin-proteasome pathway [185, 
186]. Notably, although Vif is essential for HIV propagation in vivo [262-264], HIV variants 
encoding vif alleles with only partial APOBEC3 neutralizing activities have been identified and 
recovered from HIV infected patients [187-189]. Moreover, partially defective Vif viruses in patients 
have been associated with viral diversification [265], ART-failure [189, 190] and co-receptor usage 
evolution [266]. These findings suggest that complete APOBEC3 neutralization is not necessary 
for HIV survival as a population in vivo and that Vif polymorphisms enhance HIV’s evolutionary 
potential and adaptive capacity. However, the role of partially defective Vif alleles and APOBEC3 
activity on HIV diversification and adaptation remains highly debated. Various studies have shown 
that A3G diversifies HIV quasispecies using in vitro and in vivo models [179, 192, 265, 267-269] or 
by analyzing viral repertoires in patients [188]. However, other investigations uphold that A3G does 
not contribute to HIV’s evolutionary potential because its mutagenic effect on the viral genome is 
either lethal [193, 194], or insignificant compared to HIV’s own mechanisms of diversification [176, 
270]. Finding a clear answer to this controversial issue is complicated by the difficulty in 
unequivocally distinguishing sequence variation resulting from RT-error versus APOBEC3-activity. 
Specifically, although A3G and A3D/A3F introduce G-to-A mutations in the HIV genome within 
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preferred dinucleotides contexts (GG and GA, respectively) [184, 265, 271], RT also frequently 
introduces G-to-A substitutions, with a bias for GA targets [20, 272-274].  
 
G-to-A mutagenesis can be both deleterious and beneficial for HIV, as it can give rise to aberrant 
stop codons and defective proviruses, but can also result in mutated viruses that have a fitness 
advantage, for example, through acquisition of mutations conferring drug-resistance. For instance, 
resistance to the nucleoside reverse transcriptase inhibitor, lamivudine (3TC), results from a 
missense mutation in the HIV RT gene at the methionine residue 184 (M184), with isoleucine 
(M184I) or valine (M184V) being the two most prevalent drug resistance codons [275-278]. As the 
M184I variant results from a G-to-A mutation in A3G’s preferred dinucleotide context (i.e. GG-to-
AG), 3TC resistance is particularly susceptible to A3G’s mutagenic activity. Indeed, our 
collaborators showed that in vitro, HIV can exploit AG3 to escape from 3TC [179]. Specifically, the 
E45G-Vif HIV mutant (HIV-45G), which displays suboptimal A3G neutralization activity in vitro 
compared to wild type (WT)-Vif HIV, efficiently replicated in human peripheral blood mononuclear 
cells (PBMCs) and resulted in a diversified proviral population in which 3TC drug resistance-
associated mutations were found with high frequency. These results suggest that partially active 
Vif alleles result in increased proviral diversity, which in turn can shape the phenotype of circulating 
viruses. Therefore, we hypothesized that suboptimal A3G neutralization in vivo would result in a 
highly diversified genetic viral pool, with low levels of sublethal mutagenesis in at least some viral 
progeny, thereby conferring a high adaptive capacity to HIV as a population (Figure 1A). 
 
To dissect the contribution of A3G to viral fitness, diversification, and evolution dynamics in vivo, 
we used the humanized NOD-scid IL2Rgammanull (NSG) mouse model and generated isogenic 
HIV clones encoding vif alleles with different A3G-neutralization capacities (HIV-WT: 95%; HIV-
45G: 20%; HIV-SLQ: 0%). The well-established humanized NSG mouse model [158, 279] supports 
disseminated HIV replication and recapitulates key features of HIV pathogenesis [160, 163, 168], 
and thus provided us with a convenient and pertinent model to study the A3G-Vif axis within the 
complexity of the human immune system. Understanding the contribution of A3G to viral sequence 
diversification is important for the management of ART-failure and development of new therapies 
targeting the APOBEC-Vif axis. In this study, we found that the partially defective Vif mutant HIV 
(HIV-45G) displayed a superior adaptation phenotype in the context of 3TC monotherapy 
compared to WT HIV, despite inferior fitness in natural infections. We show that this phenotype is 
supported by high nucleotide diversity in proviral quasispecies landscapes, characterized by an 
A3G-mutational footprint, and a preferential emergence of M184I resistant variant, supporting the 
notion that sublethal A3G activity can enhance the evolutionary and adaptive potential of HIV.  
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3.2. Results 
3.2.1. HIV mutant with partially defective Vif can still replicate in vitro 
To address the role of A3G in shaping viral diversification and evolution, we generated isogenic Vif 
mutant HIV clones with variable activities against APOBEC3G in vitro. These HIV clones are 
derived from the HIV-1 NL4-3 consensus sequence and differ from one another only by a few 
nucleotides in vif: wild type Vif (HIV-WT), E45G Vif (HIV-45G) and 144AAA Vif (HIV-ΔSLQ) (Figure 
1A-B). The E45G Vif allele was initially identified in primary viral isolates [188] and differs from wild 
type Vif by a nonsynonymous mutation in the A3G-binding domain of Vif at residue 45 (i.e. 
glutamic acid substituted for a glycine). This residue has not been specifically associated with 
other Vif functions and is not involved in any of the other viral gene products [280, 281]. The 
APOBEC3 neutralization capabilities of the HIV clones used herein have previously been 
characterized using cell-based assays [188, 282, 283]. Whereas wild type (NL4-3) Vif displays 
95% A3G-neutralization activity, the E45G Vif mutant demonstrates only partial (20%) activity 
against A3G and both Vif variants can equally neutralize A3F [188, 189]. HIV-ΔSLQ carries 
inactivating alanine substitutions in the functional BC-box motif of Vif, essential for targeting 
APOBEC3 enzymes for proteasomal degradation, and therefore lacks any activity against either 
deaminase [280, 282]. To test the ability of each virus to replicate in the presence or absence of 
A3G in vitro, we infected MT4 cells, which do not express A3G [284], and mitogen-activated, 
primary mononuclear cells (MNCs) derived from healthy-donor cord blood, with our three HIV 
clones. As expected, in the absence of A3G (i.e. in MT4 cells), all three viruses replicated to similar 
levels (Figure 1C). However, in primary MNCs, which endogenously express A3G, only HIV-WT 
and HIV-45G replicated efficiently and to comparable levels (Figure 1D).  
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Figure 1. HIV-Vif variants modulate the antiviral activity of APOBEC3G in vitro. A. Mutations allow 
HIV to diversify into a pool of genetically distinguishable quasispecies, enabling adaptation to specific 
pressures. Mutagenesis can result from the low-fidelity RT enzyme or A3G-induced mutagenesis. B. 
HIV-Vif (NL4-3) variants E45G and ΔSLQ display incomplete neutralization of A3G due to interference 
with A3G-binding and assembly of the E3-Ub-ligase complex, respectively. C-D. Replication of HIV-Vif 
variants in the MT4 T-cell line (C) and primary mononuclear cells (D).  
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3.2.2. Suboptimal neutralization of A3G results in lower viral fitness in hu-mice 
To assess the impact of different degrees of A3G neutralization on HIV replication in vivo, we 
infected humanized mice (hu-mice) with the three HIV clones described above and sampled 
peripheral blood on a bi-weekly basis from 30 up to 85 days post-infection (dpi) (Figure 2A-B and 
Figure 3). This allowed us to monitor plasma viremia, as well as CD4+ and CD8+ T cell population 
dynamics over the course of infection. Of note, our hu-mouse model recapitulates endogenous 
expression patterns of human APOBEC3 enzymes, with CD4+ T cells from the spleens of hu-mice 
expressing comparable levels of A3D, A3F, A3G and A3H as observed in human peripheral blood 
CD4+ T cells [166]. As A3H is resistant to NL4-3 Vif [285], to negate any confounding antiviral 
effects induced by A3H in our model, all hu-mice herein were reconstituted with HSPCs from 
donors with inactive A3H haplotypes (e.g. haplotypes I, III, IV and VI [284, 286, 287]). 
 
Mirroring our in vitro results and published data [280, 282], HIV-ΔSLQ was unable to establish a 
productive infection in the hu-mice (Figure 2B), confirming that APOBEC3s are effectively 
expressed and active in our hu-mouse model in absence of Vif. On the other hand, HIV-WT and 
HIV-45G displayed robust viral replication at 30 dpi (Figure 2B), referred to as baseline herein, and 
infection rates were comparable between the two viruses (Fisher's exact test: p=0.0994). However, 
despite comparable (p=0.1673) baseline plasma viral loads in both groups (HIV-WT: 3.97±5.94 
x104 copies/mL; HIV-45G: 8.94±10.3 x104 copies/mL), over time HIV-45G viral replication was 
attenuated compared to HIV-WT. Specifically, beyond 44 dpi, viremia progressively declined in the 
HIV-45G infected hu-mice, whereas viremia rose or remained stable in the HIV-WT infected hu-
mice (Figure 3A-B). This corresponded to an average reduction in viremia from baseline to 
endpoint (i.e. 58, 75 or 85 dpi) of 0.77 log in the HIV-45G group compared to an average increase 
in viremia of 0.43 log in the HIV-WT group (p=0.0039). Taken together, these results suggest that 
HIV-45G exerts sufficient anti-A3G activity to propagate in vivo, but less effectively than HIV-WT. 
Furthermore, longitudinal flow cytometric analysis of PBMC populations revealed that there were 
no significant differences in the change in CD4+ T cells levels and CD4+/CD8+ T cell ratio over 
time between hu-mice infected with HIV-WT or HIV-45G (Figure S1). Monitoring CD4+ T cell levels 
and the CD4+/CD8+ T cell ratio provides insight about the pathogenicity of HIV, thus these results 
indicate that despite different replication kinetics the viruses were similarly pathogenic.  
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Figure 2. In vivo experimental design and approach for sequencing HIV quasispecies in plasma and 
splenocytes. A. Design of three independent experiments to study the replication of HIV-WT, HIV-45G and HIV-
ΔSLQ in humanized mice without 3TC (Exp. 1, 3) and with 3TC treatment (Exp. 2, 3). B. Viremia at 30 days post 
infection (i.e. baseline viremia) in HIV-WT, HIV-45G and HIV-ΔSLQ infected mice across the three experiments. 
The dotted line represents the limit of detection of the viral load assay (400 cp/mL). C. Schematic depicting 
approach to sequence HIV quasispecies in plasma and splenocytes.  
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Figure 3. HIV-WT and HIV-45G replication in hu-mice in the absence or presence of 3TC. A. & 
C. Change in viremia relative to baseline over time in untreated (A) and treated (C) hu-mice. B. & D. 
Overall change in viremia relative to baseline at the end of infection (mean±SD) in untreated (B) and 
treated (D) hu-mice. E.-F. Rebound viremia (E) and rate of rebound (F) in treated hu-mice. Pale lines 
represent individual mice and bold lines represent group means. 
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3.2.3. Under selective pressure by 3TC, suboptimal neutralization of A3G is associated 
with superior viral fitness in hu-mice 
To elucidate how a partially active Vif can exploit A3G-mediated mutagenesis to escape from 
antiretroviral pressure in vivo, we infected hu-mice with either HIV-WT or HIV-45G and 30 dpi we 
treated the hu-mice with 3TC for 4-6 weeks (Figure 2A). 3TC was used to apply a specific selective 
pressure on the viruses and was chosen because 3TC-resistance is well characterized [275-277]. 
Over the first two weeks of 3TC monotherapy, as expected, we observed a phase of viral 
restriction characterized by a decrease in viremia in 11/11 HIV-WT and 10/11 HIV-45G infected 
hu-mice (Figure 3C). Of note, the lone HIV-45G infected hu-mouse (#120) that did not respond to 
3TC treatment, showed signs of wasting and had to be euthanized at 44 dpi and was thus 
excluded from further analyses. The average initial decline in viremia was similar for both HIV-WT 
and HIV-45G infected mice (p=0.2462), with overall an average reduction in viremia of 0.7±0.34 
log and ≥ 72% of hu-mice in both groups displaying a decrease in viremia greater than 0.5 log. 
Virologic nadirs (i.e. lowest measured plasma viral load) were also comparable (p=0.4848) 
between treated hu-mice infected with HIV-WT (1.71±1.84 x104 copies/mL) and HIV-45G 
(2.47±2.97 copies/mL). These results indicate that both viruses were initially similarly sensitive to 
3TC monotherapy. However, viral escape rapidly ensued with a rebound in viremia in 8/11 HIV-WT 
and 10/10 HIV-45G infected hu-mice. Nevertheless, at endpoint, average HIV-45G viremia 
surpassed initial baseline (i.e. pre-treatment) levels, whereas average HIV-WT viremia had 
decreased relative to baseline (p=0.0045) (Figure 3D). Moreover, the average amplitude and rate 
of rebound in viremia (from virologic nadir) were significantly greater in the HIV-45G group 
compared to HIV-WT group (p=0.0068 and p=0.0052, respectively) (Figure 3E-F). These findings 
indicate that HIV-45G was fitter than HIV-WT under selective pressure by 3TC, suggesting that 
suboptimal A3G-neutralization increases HIV’s ability to diversify and adapt to a selective 
pressure. 
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Table 1. Baseline, nadir and rebound viral loads in treated hu-mice. BL= baseline, VL= viral load, 
dpi = days post infection. a Rebound is defined by the highest viral load after nadir. 
Mouse BL VL (log)
Nadir 
VL (log)
Log Decrease 
(BL to nadir)
BL to nadir 
(dpi)
Log Increase 
(nadir to rebound)a
Nadir to 
Rebound (dpi)
#2321 4.109 2.602 1.509 30-58 0 58-58
#2284 5.107 4.196 1.507 30-58 0 58-58
#118 5.494 4.319 1.175 30-75 0 75-75
#117 4.858 4.787 0.071 30-44 0.276 44-58
#2320 5.318 4.266 1.052 30-44 0.371 44-58
#126 5.345 4.196 1.149 30-44 0.399 44-58
#136 4.785 4.564 0.221 30-44 0.216 44-75
#2286 5.140 4.152 0.988 30-44 0.858 44-58
#116 3.350 2.602 0.748 30-44/58 0.681 44/58-75
#125 3.942 3.549 0.393 30-44 0.795 44-75
#139 4.340 2.792 1.547 30-44 0.974 44-75
Mouse BL VL (log)
Nadir 
VL (log)
Log Decrease 
(BL to nadir)
BL to nadir 
(dpi)
Log Increase 
(nadir to rebound)a
Nadir to 
Rebound (dpi)
#129 5.035 4.446 0.589 30-75 0 75-75
#2282 5.467 4.923 0.544 30-40 0.903 40-51
#130 5.489 4.858 0.631 30-44 0.709 44-58
#2256 5.111 4.416 0.695 30-44 0.724 44-58
#2288 4.597 4.012 0.585 30-44 1.119 44-58
#2322 5.269 4.175 1.094 30-40 0.757 40-58
#2319 4.397 3.418 0.979 30-40 0.941 40-58
#122 4.338 3.760 0.578 30-44 1.008 44-75
#119 3.848 3.193 0.654 30-44 1.145 44-75
#141 4.083 3.236 0.847 30-44 2.061 44-75
HIV-45G + 3TC
HIV-WT + 3TC
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3.2.4. 3TC-treated hu-mice display increasing sequence diversity in RT and rapid 
emergence of 3TC resistance mutations in plasma over time 
As HIV-45G displayed important differences in replication and adaptability to 3TC compared to 
HIV-WT in hu-mice, we sought to identify whether these phenotypes were shaped by A3G-driven 
mutagenesis. To this end, we identified and quantified the HIV quasispecies present in the infected 
hu-mice by performing deep sequencing on 250 base pairs (bp) of HIV RT in serial samples of 
plasma viral RNA (vRNA; i.e. cell-free circulating virions), as well as cell-associated HIV transcripts 
(HIV RNA) and proviruses (HIV DNA) in the splenocytes at endpoint (Figure 2C). To account for 
PCR error and amplification biases in our sequencing workflow, we included unique molecular ID 
tags (UMIDs) in the primers used for cDNA synthesis (see methods and Figure S2) [288], allowing 
us to quantitatively sequence single genome nucleic acids. We then characterized the HIV RT 
gene of the quasispecies identified in the different viral nucleic acid compartments (plasma vRNA, 
splenocyte-associated HIV RNA and DNA), in order to elucidate whether the viral genotypes 
differed between HIV-WT and HIV-45G infected hu-mice.  
 
Firstly, to determine whether viral sequence diversity in plasma corresponded with the different 
fitness phenotypes, we longitudinally measured nucleotide diversity (π), mutation rate (i.e. 
substitutions per base pair) and fractions of G-to-A mutations in the RT gene of plasma vRNA 
quasispecies. Nucleotide diversity is a measure used to express the degree of nucleotide 
polymorphisms within a given population [289]. In our case, this population is the pool of 
quasispecies in each infected hu-mouse. In untreated hu-mice infected with either virus, nucleotide 
diversity was comparable and remained unchanged over time (Figure 4A-B). In line with these 
observations, mutagenesis was also stable throughout the course of the experiment, without any 
significant accumulation of mutations over time (Figure S3A, C, E). Conversely, in both treated hu-
mouse groups, after two weeks of 3TC (i.e. 44pdi) nucleotide diversity was significantly higher 
compared to baseline levels (π at 44dpi, HIV-WT: 0.00270; HIV-45G: 0.00293), however no further 
increase in diversity was thereafter observed, suggesting a saturation of diversification in the 
circulating quasispecies. In addition, diversity was comparable between treated groups at any time 
point (Figure 4C-D). The dynamics of mutagenesis in RT of treated hu-mice mirrored this trend 
(Figure S3B). As the different APOBEC3 deaminases preferentially induces G-to-A mutations in 
distinct dinucleotide motifs (A3G: GG-to-AG; A3D/A3F: GA-to-AA) [290], we quantified the fraction 
of GGs and GAs that were mutated in plasma vRNA (Figure S3D, F). This revealed that both HIV-
WT and HIV-45G were predominantly and comparably impacted by GG-to-AG mutations in the 
treated hu-mice.  
 
As the amino acid residue 184 in HIV RT alone determines susceptibility to 3TC, we also 
calculated nucleotide diversity excluding mutations at the residue 184, which we refer to as non-
M184 nucleotide diversity (Figure 4E-F). Non-M184 nucleotide diversity was comparable between 
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groups and remained stable over time. At 44 dpi, non-M184 nucleotide diversity was 0.00105 and 
0.00121 for hu-mice infected with HIV-WT and HIV-45G, respectively, which means that 39% and 
41% of the diversity observed in the plasma quasispecies of treated hu-mice is driven by 
mutagenesis at residue 184 in HIV RT. This suggests that in the context of 3TC treatment, viral 
diversification in the plasma is strongly driven by drug resistance development and that 3TC is 
imposing an evolutionary bottleneck on the viruses.  
 
Secondly, as 3TC resistance development is particularly susceptible to A3G-mediated 
mutagenesis, we wanted to test whether development of resistance to 3TC was different in HIV-
45G infected hu-mice compared to those infected with HIV-WT. As discussed above, the residue 
184 in HIV RT determines 3TC susceptibility, with the wild type methionine (M184) rendering the 
virus susceptible to 3TC and resistance predominantly including the M184I and M184V mutations 
(Figure 5A). These mutations confer up to 1000-fold resistance to 3TC [275-277] and can both 
result from RT-error. But as the M184I mutation results from a G-to-A mutation in A3G’s preferred 
dinucleotide context (i.e. ATGG-to-ATAG), it is particularly prone to arise from A3G-induced 
mutagenesis. Therefore, we determined the frequency of drug susceptible (M184) sequences and 
drug resistance mutations (M184I/V) in the plasma quasispecies of treated hu-mice over time 
(Figure 5B-C). Interestingly, at baseline, HIV-WT and HIV-45G infected hu-mice had comparably 
low levels of drug resistant variants in their plasma (HIV-WT: 1.34±2.22% M184I and 0.56±1.45% 
M184V; HIV-45G: 2.92±3.79% M184I and 0.18±0.31% M184V). While the baseline levels of M184I 
resistance mutations were higher than M184V in HIV-WT (p=0.0450) and HIV-45G (p=0.0256) 
infected hu-mice, these were comparable between the two groups (M184I: p=0.1954; M184V: 
p=0.3863). Over time, M184I and M184V levels rapidly expanded in all but one treated hu-mouse 
(#2321). Of note, this hu-mouse displayed a progressive loss in human engraftment in the 
periphery over time, which mirrored the decline in viremia to undetectable levels by 58 dpi seen in 
this mouse, and at sacrifice we could not detect any human cells in the spleen. Linear regression 
analyses of the frequencies of drug susceptible and resistant sequences over time, revealed that in 
HIV-45G infected hu-mice the M184I mutation emerged at 8.7-times the rate of M184V (i.e. 
comparison of slopes; p=0.0035) (Figure 5C). On the other hand, despite similar trends in 
emergence of resistance mutations, in HIV-WT infected hu-mice, the M184I and M184V mutations 
emerged at statistically similar rates (Figure 5B).  
 
Furthermore, in order to verify the stability of the Vif genotypes, in a small subset of mice (HIV-WT: 
N=4; HIV-45: N=1; HIV-WT + 3TC: N=4; HIV-45 + 3TC: N=5) we also performed deep sequencing 
on 269 bp of HIV vif in plasma vRNA between baseline and 58 dpi. Sequencing of vif in HIV-WT 
groups revealed a minority of E45G sequences at baseline in 7/8 hu-mice (wild type E45 Vif: 
98.03±2.07%; mutant E45G Vif: 1.97±2.07%) (Figure S4A-B). However, there was no significant 
expansion of these minority E45G sequences over time (HIV-WT 30 dpi vs 58 dpi: p>0.9999), nor 
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in response to 3TC-treatment (HIV-WT 30 dpi vs 58 dpi: p>0.9999). Conversely, at baseline, 2/6 
hu-mice infected with HIV-45G had a minority of sequences that encoded wild type Vif (mouse 
#2256: 1/230 cDNAs, 0.4%; mouse #2322: 2/290 cDNAs, 0.7%) (Figure S4A-B) and 5/6 of these 
hu-mice showed expansion or emergence of wild type Vif at 58 dpi. This suggests viral adaptation 
over the course of infection due to selective pressure exerted by A3G in HIV-45G infected hu-mice. 
Figure 4. 3TC treatment longitudinally drives viral diversification in plasma. A.-D. Nucleotide diversity over 
time in untreated hu-mice infected with HIV-WT (A) or HIV-45G (B) and in 3TC treated hu-mice infected with HIV-
WT (C) or HIV-45G (D). E.-F. Nucleotide diversity excluding mutations at the amino acid residue 184 (M184) in 
3TC treated hu-mice infected with HIV-WT (E) or HIV-45G (F). 
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3.2.5. Diversification in the splenic viral compartments of infected hu-mice 
Within a host, HIV can exhibit distinct diversification in different tissue compartments [263, 291]. In 
addition, a purifying selection pressure may limit the amount of diversity found in the circulating 
viral quasispecies compared to cell-associated proviruses [269]. Thus, we sequenced cell-
associated HIV transcripts and proviruses in the spleens of hu-mice at the end of infection (i.e. 58, 
75 or 85 dpi depending on the experiment, see Figure 2A). Splenocytes were available from 34 
animals (HIV-WT: N=6; HIV-45G N=6; HIV-WT + 3TC: N=11, HIV-45G + 3TC: N=10). We obtained 
sequencing data for HIV RT in cell-associated HIV transcripts for all 34 spleens and sequencing 
data for HIV RT in proviruses for 21/34 spleens. This limited proviral sampling may be due to 
mutations that interfered with primer annealing and amplification.  
 
In untreated HIV-WT infected hu-mice, nucleotide diversity was comparable across all nucleic acid 
compartments at endpoint (π, plasma vRNA: 0.00057; cell-associated transcripts: 0.00103; HIV 
DNA: 0.00128) (Figure 6A). In contrast, in untreated HIV-45G infected hu-mice, proviral diversity 
Figure 5. Drug resistance development in plasma of 3TC treated hu-mice. A. Description and color-
coding of the drug susceptible and drug resistant mutations at HIV RT codon 184. B. Frequencies of drug 
susceptible (M184) and drug resistant (184I, 184V) sequences in plasma of treated hu-mice infected with 
HIV-WT or HIV-45G over time. C. Linear regression of data shown in (B), with the best-fit values of the 
slopes indicated on the right. F-test for comparisons of slopes. ns = non-significant. Pale lines represent 
individual mice and bold lines represent group means. 
  
A 
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(π=0.01347) was higher than in cell-associated transcripts (p=0.0162) and 10.5-fold greater than 
proviral diversity in the HIV-WT group (p=0.0377). HIV-45G proviral diversification resulted from an 
estimated average mutation rate of 9.06±6.54 x10-3 substitutions/bp, in contrast to only 6.61±3.79 
x10-3 substitutions/bp in the proviruses of HIW-WT infected hu-mice. In the treated groups, proviral 
diversity was significantly greater than in the RNA compartments for both viruses (π plasma vRNA, 
HIV-WT: 0.00242, HIV-45G: 0.00274; π cell-associated transcripts, HIV-WT: 0.00247, HIV-45G: 
0.00329; π HIV DNA, HIV-WT: 0.00551, HIV-45G: 0.00682), but diversity was comparable 
between corresponding compartments of the two virus (Figure 6B). Furthermore, as hypermutated 
proviral sequences (i.e. proviruses that harbor extensive G-to-A mutations in APOBEC3 target 
sites) are largely evolutionary dead-ends (i.e. give rise to replication incompetent proviruses) [193], 
they can result in an overestimation of viral diversification. Therefore, we used the online tool 
Hypermut 2.0 to identify hypermutant proviruses (see methods section) and thereby quantify 
proviral nucleotide diversity excluding hypermutants. In untreated mice, hypermutants contributed 
to 24.4±21.2% and 52.2±30.4% of proviral diversity in HIV-WT and HIV-45G mice (p=0.3429), 
respectively. In treated mice, hypermutants contributed to 27.9±19.2% of HIV-WT proviral diversity 
and 24.2±28.6% of HIV-45G proviral diversity (p=0.6964).   
 
To determine what is driving the viral diversification, we measured the fraction of GG dinucleotides 
mutated to AG and GA dinucleotides mutated to AA in the different quasispecies compartments 
(Figure 6C-F). These analyses revealed that in both untreated and treated mice, diversification 
was driven by GG-to-AG mutations, with only few GA-to-AA mutations observed. In untreated hu-
mice, HIV-45G proviruses carried a greater fraction of GG-to-AG mutations (13.3%) than HIV-WT 
mice (0.5%, p=0.0401, Figure 6C). Strikingly, in the context of 3TC, this difference was lost (HIV-
45G: 9.3% vs HIV-WT: 3.9%, p=0.1998, Figure 6D). As G-to-A mutations, particularly those in GG-
to-AG or GA-to-AA dinucleotide contexts may result in premature stop codons, we also quantified 
the number of putative stop codons per 1000 codons sequenced (Figure 6G-H). Overall, the 
number of stop codons were highest in the proviral compartments compared to the RNA viral 
compartments, in line with a purifying selection of hypermutated proviruses. In untreated hu-mice, 
there was less than one stop codon per 1000 sequenced codons in all three HIV-WT 
compartments (plasma vRNA: 0.01; cell-associated transcripts: 0.05; proviruses: 0.17), whereas 
the HIV-45G proviruses and cell-associated transcripts contained a significantly greater number of 
putative stop codons than in the HIV-WT counterparts (proviruses: 8.3, p=0.0442; cell-associated 
transcripts: 0.92, p=0.0022). In treated hu-mice, stop codon rates in proviruses were comparable 
(p=0.3660) in HIV-WT (1.1 per 1000) and HIV-45G (6.1 per 1000) groups, but the number of stop 
codons was greater in HIV-45G cell-associated transcripts than those of HIV-WT (HIV-WT: 0.1, 
HIV-45G: 0.6; p<0.0001) (Figure 6H). This discrepancy may be due to a limited sampling of the 
proviral quasispecies. Taken together, these results suggest A3G-driven mutagenesis contributes 
strongly to viral diversification, but that increased mutagenesis can also results in higher levels of 
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defective proviruses and HIV transcripts. Footprints of A3G mutagenesis were prominent at the 
proviral level of untreated HIV-45G hu-mice, whereas the selective pressure (i.e. bottleneck) 
imposed by 3TC may be masking differences in the treated groups. 
Figure 6. Characterization of quasispecies in the plasma and spleen compartments of hu-mice. 
A.-B. Nucleotide diversity of quasispecies found in the plasma and spleen compartments in untreated 
(A) and 3TC treated (B) hu-mice at the end of infection. C.-F. Fractions of GG dinucleotides mutated to 
AG, or GA dinucleotides mutated to AA in plasma and spleen compartments in untreated (C, E) and 
treated mice (D, F). G.-H. Numbers of codons mutated to stop codons for every 1000 codons 
sequenced in viral compartments in untreated (G) and treated hu-mice (H).  
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A 
Figure 8. Characterization of proviral variants in treated hu-mice. A. Depiction of the 
mutational landscape of proviral variants in treated hu-mice. The individual horizontal lines 
represent distinct proviral sequences and substitutions are depicted as colored bars at affected 
positions. 
Figure 7. Number of unique variants across the plasma and spleen viral compartments. 
Numbers of distinct variants in untreated (I) and (J) treated hu-mice at the end of infection.  
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 B 
Figure 8. (Cont.) Characterization of proviral variants in treated hu-mice. B. Frequencies of proviral 
variants in treated hu-mice. Drug susceptible or resistance mutations are color-coded. Proviral variants 
represented in splenocyte transcripts (blue circle) or plasma vRNA (yellow star) are indicated. Variants with 
premature stop mutations are indicated (red X). Hypermutants (see methods) are indicated by black arrows. 
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3.2.6. Characterization of viral landscapes found in the plasma and splenic viral 
compartments of infected hu-mice 
To understand the dynamics between archival (DNA) and expressed (RNA) viral landscapes in the 
spleen and plasma of infected hu-mice, for each animal we identified, quantified and characterized 
the viral variants present in each compartment (Figures 7-9). Herein, a viral variant corresponds to 
a distinct viral population characterized by RT sequences that are identical in sequence but have a 
different UMID. Data for all three viral compartments were available for 17/21 hu-mice (for the 
remaining four hu-mice only cell-associated HIV RNA and DNA data were available). We identified 
a total of 2948 distinct HIV RT variants. The number of variants differed starkly between viral 
nucleic acid compartments (Figure 7). Strikingly, the highest number of variants was observed in 
cell-associated HIV transcripts (HIV-WT: 113±71/sample; HIV-45G: 171±100; HIV-WT + 3TC: 
96±82; HIV-45G + 3TC: 120±100) and overall proviruses contained the lowest number of variants, 
displaying about one order of magnitude fewer variants than cell-associated transcripts (untreated: 
HIV-WT: 11±2, HIV-45G: 15±9; treated: HIV-WT: 13±7, HIV-45G: 16±8). These results are 
unexpected and we lack a plausible biological explanation to explain these. Given that in acutely 
HIV-infected patients, PBMCs were shown to principally harbor defective proviruses [47], we 
expect a greater number of variants in the proviruses, which are then absent in the transcribed 
viral populations due to purifying selection of defective viruses. Thus, we postulate that these 
unexpected results may be the consequence of limited recovery of splenic proviral quasispecies, 
especially as we observed a greater divergence between proviral variants than between the RNA 
variants (i.e. proviral variants generally differed by several mutations, whereas the majority of RNA 
variants differed by only one base pair). 
 
We observed distinct mutations reflecting extensive adenosine substitutions in a dinucleotide 
context suggestive of APOBEC3 activity in the proviral variants of treated hu-mice (Figure 8A). 
Interestingly, despite antiretroviral pressure, we found both drug susceptible and drug resistant 
proviruses in treated hu-mice (Figure 8B). The 3TC susceptible variants were often intact without 
premature stop codons (HIV-WT: 15/25 M184 variants; HIV-45G: 34/45 M184 variants). These 
drug-susceptible proviruses probably reflect the quasispecies present prior to 3TC treatment. 
Overall, in the proviruses of treated hu-mice, there were comparable levels of drug susceptible 
sequences (HIV-WT: 46.19±27.03%; HIV-45G: 28.06±25.28%, p=0.2373) as well as drug resistant 
M184I (HIV-WT: 33.31±24.03%; HIV-45G: 40.13±32.95%, p=0.6831) and M184V (HIV-WT: 
20.46±27.41%; HIV-45G: 31.31±38.93%, p=0.5796) sequences. In addition, the numbers of 
proviruses with premature stop codons were comparable between both groups (HIV-WT: 
37.2±5.8%; HIV-45G: 42.5±13.0%; p=0.3786). Furthermore, to identify potential evolutionary 
bottlenecks (i.e. selective pressure imposed by 3TC and purifying selection), we mapped the 
fraction of proviruses that gave rise to cell-associated transcripts and plasma virions in the treated 
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hu-mouse groups (Figure 8B). In the absence of bottlenecks, every provirus would be transcribed 
with equal efficiency, resulting in equal numbers of cell-free virions. However, we observed that 
only 46.3% (HIV-WT) and 39.8% (HIV-45G) of proviruses were transcribed (p=0.4924), with 31% 
(HIV-WT) and 32% (HIV-45G) being represented in cell-free virions (p=0.8742). We observed 
fewer proviral variants expressed in plasma compared to the number expressed as cell-associated 
transcripts only for HIV-45G infected hu-mice (p=0.0387). This indicates that HIV-45G proviruses 
were less likely to produce circulating viruses, possibly due to APOBEC3-driven mutagenesis 
resulting in lethal defects at the protein level.  
 
Furthermore, to determine whether variants were comparably distributed among the cell-free and 
cell-associated compartments, for each hu-mouse, correlation analyses were performed for all 
variants found in that animal, in each compartment (Table 2). If the correlation coefficient was 
greater than 0.6 (R2>0.60), we defined the correlation between the two nucleic acid compartments 
as strong. There was a strong correlation between the distribution of variants in proviruses and 
cell-associated transcripts in 14/21 hu-mice (HIV-WT: 4/4; HIV-45: 2/4; HIV-WT + 3TC: 3/6; HIV-
45G + 3TC: 5/7) (Table 2 and Figure 9). The same hu-mice showed a strong correlation between 
proviral and plasma vRNA variant distributions. Additionally, all distributions within cell-associated 
transcripts correlated very strongly (i.e. mean R2=0.96±0.07) with plasma vRNA. These findings 
are suggestive of the existence of a purifying selection from proviruses to plasma virions, but also 
that there is good mixing between the splenic and plasma viral compartments studied.  
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Table 2. Correlations between splenocyte-associated proviruses and HIV transcripts, and 
plasma viral RNA landscapes. 
Figure 9. Viral quasispecies landscapes in splenocyte and plasma compartments. From inside to 
outside, concentric circles depict the frequencies of distinct quasispecies variants among splenocyte-
associated proviruses (DNA), splenocyte-associated HIV transcript (RNA) and plasma viral RNA (vRNA) 
landscapes. Each of 2948 unique quasispecies sequences is indicated by a distinct color and the 5 most 
frequent variants (and nucleotide mutations) are labeled by their respective colors (see inset). Proviral 
landscapes that weakly correlate with viral RNA landscape are outlined in black.  
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3.3. Discussion 
Evidence of APOBEC3 G-to-A hypermutation footprints in the HIV genomes and Vif variants with 
suboptimal APOBEC3-neutralization activities in patients [187-189] suggest that the APOBEC3G-
Vif axis contributes to viral diversification, yet this theory remains highly debated. In this study, we 
used humanized mice infected with isogenic HIV clones differing in their ability to counteract A3G, 
but displaying comparable replication in the absence of A3G in vitro, to dissect the effects of A3G-
mediated mutagenesis on viral replication, diversification and adaptation to the nucleoside analog 
reverse transcriptase inhibitor lamivudine (3TC). We first characterized the phenotype of the 
viruses either in natural (i.e. untreated) infections or in the context of 3TC monotherapy by 
longitudinally quantifying viremia and PBMCs subsets. To gain insights into the mechanisms 
driving viral fitness and evolution, we sequenced the viral reverse transcriptase gene (HIV RT) 
from cell-free plasma virions, as well as cell-associated viral transcripts and proviruses in the 
spleens of infected hu-mice, allowing us to characterize quantitatively the viral quasispecies 
present longitudinally in the plasma and at endpoint in the splenocytes. 
 
In this study, we observed clear differences in fitness between the Vif-mutant HIV with only partial 
(20%) activity against A3G (HIV-45G) and the wild type Vif HIV (HIV-WT; 95% activity against 
A3G) replicating in hu-mice, and characterization of the viral quasispecies in the plasma and 
splenic compartments provided evidence of A3G’s underlying role in these phenotypic 
manifestations. Specifically, we found that HIV-45G established a robust infection in hu-mice, but 
over time exhibited attenuated viral replication compared to HIV-WT (Figure 3A-B). This attenuated 
fitness phenotype was characterized by a 10.5-fold greater diversity in the splenic proviruses of hu-
mice infected with HIV-45G compared to those infected with HIV-WT (Figure 6A). Importantly, the 
proviral diversity in HIV-45G infected hu-mice was predominantly sustained by GG-to-AG 
mutations (i.e. characteristic A3G mutational footprint), which resulted in a ~48-fold greater stop 
codon rate (i.e. number of stop codons per 1000 codons) than that observed in the proviral 
compartment of HIV-WT infected hu-mice (Figure 6C, G). Hypermutated proviruses contributed to 
approximately half of the proviral diversity seen in the HIV-45G hu-mice. Interestingly, some 
hypermutated proviral variants were also expressed as splenocyte-associated transcripts and 
circulating virions. These results suggest that partially neutralized A3G in HIV-45G infections 
contributes to a more diversified pool of infectious viruses, in line with other studies [192, 267]. 
Moreover, the proviral mutation rate observed in HIV-45G infected mice (~9x10-3 substitutions/bp) 
is much higher than the estimated in vitro error rate of HIV RT (3 x10-5) [20, 174, 175], making it 
difficult to attribute this high level of GG-to-AG substitutions to RT-error alone. In addition, the high 
HIV-45G proviral mutation rate observed in this study is comparable to mutation rates found in 
treatment-naïve patient PBMCs (4.1 ±1.7 x10-3), where both RT- and APOBEC3-associated 
mutagenesis were identified [292]. Finally, characterization of the distribution of viral variants 
between proviruses (HIV DNA) and cell-associated viral transcripts (HIV RNA) in the spleen, and 
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cell-free virus in the plasma (plasma vRNA), revealed a tendency for HIV-45G proviruses to be 
underrepresented in the transcribed viral pools (Table 2 and Figures 8-9). These findings are in 
line with a purifying selection of hypermutated genomes occurring from proviral DNA, to cell-
associated viral RNA and finally cell-free viral RNA, such that only viable viruses mostly devoid of 
hypermutation are released into the plasma [166, 269, 292, 293]. Indeed, in the plasma 
quasispecies we observed comparable nucleotide diversity and mutation rates for both viruses 
over time, with no evidence for the accumulation of mutations or increase in diversity over time, 
despite extensive footprints of G-to-A mutations in splenic proviruses in HIV-45G infected hu-mice 
(Figures 4, 7A and S3). Previously, our collaborators showed that hypermutated proviruses can be 
rescued by recombination (i.e. template switching during reserve transcription) between 
heterogonous RNA genomes in virions produced in co-infected cells in vitro [179]. Thus, 
recombination between hypermutated and intact genomes may be a mechanism by which 
hypermutated proviruses contribute to viral diversification in vivo. Furthermore, the transcription 
and translation of portions of defective proviruses has been documented in patients [294] and such 
proviruses may contribute to HIV pathogenesis by chronically stimulating host-immune responses 
[295, 296]. Taken together these results indicate that A3G-mediated mutagenesis diversifies the 
proviral repertoire, with diverging consequences for HIV. As proviruses with A3G-mutagenic 
footprints are often defective (hypermutated) and cannot be properly transcribed or packaged into 
virions, A3G-mediated mutagenesis attenuates viral fitness over time. Yet these hypermutated 
genomes may still contribute to viral evolution through recombination, as well as sustain an 
immune environment favorable for HIV replication (i.e. activation of resting CD4+ T cells). 
 
To assess the contribution of A3G-mediated mutagenesis to HIV adaption, we introduced a 
selective pressure into our model by treating infected hu-mice with 3TC, one month post-infection. 
As 3TC-resistance is solely conferred by substitution of the methionine codon 184 (M184) in HIV 
RT predominantly with an isoleucine (M184I) or a valine (M184V), and the M184I variant results 
from a G-to-A mutation in A3G’s preferred dinucleotide context (i.e. GG-to-AG), this anti-HIV drug 
is well suited to study whether A3G plays a role in HIV evolution in vivo. Specifically, if A3G 
significantly contributes to viral adaptation, we expect to see differences in the emergence of the 
M184I variant between hu-mice infected with HIV-WT and HIV-45G. Indeed, we found that in hu-
mice, although both viruses were initially comparably sensitive to restriction by 3TC, the partially 
defective Vif mutant HIV adapted faster to 3TC and was thereafter fitter than HIV-WT (Figure 3C-
F). This suggests that in vivo, suboptimal neutralization of A3G confers an enhanced evolutionary 
potential onto the virus. Analysis of the plasma quasispecies revealed that in both HIV-WT and 
HIV-45G infected hu-mice, there were comparably low levels of drug resistant variants at baseline 
(i.e. prior to the start of 3TC therapy) and that rebound in viremia was concurrent with the 
emergence of the drug-resistant M184I/V variants in the plasma, with a predominance of the 
M184I mutation (Figure 5). These findings mirror what is seen in patients on 3TC monotherapy 
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[277, 278]. Importantly, in the hu-mice infected with HIV-45G, we observed an 8.3-times faster 
emergence of the M184I variant compared to the M184V variant. This was not the case for hu-
mice infected with HIV-WT. As the M184I variant is prone to arise from A3G-mediated 
mutagenesis, this further supports the notion that A3G can boost viral adaptation in vivo. Although 
a study by Keulen et al. attributed the early appearance of the M184I variant to HIV RT’s G-to-A 
mutational bias [273], in this study A3G’s GG-to-AG mutagenic effect on HIV was not considered. 
Also, since then, our collaborators have shown that A3G specifically drives the emergence of the 
M184I mutation (and not the M184V or other minority 3TC-resistant variants) in proviruses in ex 
vivo-infected PBMCs [179], whilst other groups have shown that HIV’s RT has a bias for GA 
targets [20, 272, 274].  
 
Theoretically, we expect higher viral diversity in hu-mice infected with HIV-45G and treated with 
3TC since HIV’s high rate of error prone replication, as well as A3G’s mutagenic activity would be 
contributing to it. Surprisingly, diversification in the cell-free plasma vRNA was comparable 
between both viruses, increasing over the first two weeks of treatment and then remaining stable 
until the end (Figure 4). Plasma vRNA diversity was largely a result of GG-to-AG mutations (Figure 
S3). Two mechanisms may be affecting diversification in RT in the circulating viral pool and 
masking differences between the viruses: the purifying selection of hypermutated genomes and 
the bottleneck imposed specifically on RT by 3TC. The overall increase in diversity seen in the 
treated groups compared to the untreated hu-mice groups supports this notion, as well as the fact 
that diversity was largely (~40%) driven by mutagenesis at residue 184 in HIV RT (Figure 4). 
Furthermore, we observed an emergence and expansion of WT vif in the plasma quasispecies of 
HIV-45G infected hu-mice (Figure S4), suggesting a selective pressure from A3G.  
 
Moreover, our genotypic analyses first focused on plasma quasispecies as these can readily be 
sampled longitudinally, however, the main sites of HIV replication occur in lymphoid tissues [51], 
such as the spleen, which we can only access when we sacrifice the mice at the end of the 
experiments (i.e. endpoint). Thus, we also sequenced the cell-associated proviral and HIV 
transcript quasispecies present in splenocytes and compared these to the cell-free plasma viral 
quasispecies at endpoint. Surprisingly, nucleotide diversity, mutation rates and number of variants 
were comparable between the two viruses across all corresponding compartments at endpoint 
(Figures 6-7). Both HIV-WT and HIV-45G proviruses were predominantly and comparably, affected 
by GG-to-AG mutations. In addition, comparable proportions of hypermutated sequences 
contributed to proviral diversification in both groups and unlike in the untreated groups, premature 
stop codons were not more common in the HIV-45G proviruses than the HIV-WT proviruses. Thus, 
it is possible that in the context of 3TC treatment, A3G’s contribution to diversification is masked by 
the bottleneck imposed on the RT gene by 3TC [297]. Indeed, Mansky et al showed in vitro that 
3TC treatment increases HIV’s mutation frequency [298]. Alternatively, as we showed that for both 
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viruses, less than 47% of proviruses were transcribed and less than 33% were found in the 
circulating viral pool (Figures 8-9), it is likely that a purifying selection of hypermutated genomes 
limits our ability to capture the extent of A3G-induced diversification when we can only 
longitudinally characterize cell-free plasma quasispecies. For example, Cuevas et al, showed that 
in treatment-naïve patients, mutation rates in cell-free plasma quasispecies were 44-times lower 
than in the PBMC-associated proviruses, with a large proportion of hypermutated viral genomes 
not reaching the plasma [292]. As we could only assess cell-associated viral RNA and DNA 
quasispecies in the spleen at one time point (well after 3TC-resistant variants predominated), we 
cannot exclude the possibility that, like in plasma, in the context of 3TC, HIV-45G only has superior 
kinetics of viral diversification in the spleen. In this regard, we speculate that a longitudinal 
characterization of cell-associated quasispecies in PBMCs and cross-sectional study of spleen 
quasispecies may provide more information on how A3G shapes viral diversification. However, 
given the limited volume of blood that can be collected in hu-mice, in this study it was not possible 
to include such an analysis of PBMCs. It may be that even with a modified sequencing workflow, 
the amount of PBMCs that can be serially collected from hu-mice would not suffice for accurate 
and high-resolution sequencing of the viral quasispecies therein.  
 
Furthermore, as viruses in diverse anatomical compartments have been shown to influence one-
another [291, 299, 300], we cannot rule out the impact of proviral landscapes seeded in other 
tissues and cellular reservoirs, on the circulating plasma quasispecies and the phenotypes 
observed. For example, in secondary lymphoid tissues, such as lymph nodes and gut-associated 
lymphoid tissue, replication dynamics and modes of transmission influence distinct proviral 
landscapes in patients and hu-mice [92, 299, 301, 302]. Indeed, quantitative comparisons of viral 
variants in the plasma and splenocytes of 3TC-treated hu-mice at least partly support the notion 
that viral replication in other tissues, such as in lymph nodes, gut or bone marrow, may be shaping 
viral evolution in our model. Specifically, although the viral landscapes in the different 
compartments correlated strongly in the majority of animals (Table 2), we found that splenic 
proviral landscapes can be distinct from the cell-free plasma compartments (Figure 9). Thus, viral 
quasispecies from other tissue compartments could be influencing the plasma viral repertoire and 
thereby explain the different adaption phenotypes observed for the two viruses.  
 
Lastly, APOBEC3-induced mutations often result in defective proviruses (i.e. contain premature 
stop codons or inactivating hypermutation) incapable of encoding for a replication-competent virus 
[47, 114]. Yet, surprisingly, rather than being evolutionary dead-ends, we show that some 
hypermutated proviruses are not only transcribed in infected splenocytes, but can be packaged 
and found in circulating virus (Figure 8B). The role of hypermutated quasispecies in vivo has yet to 
be fully elucidated, but in vitro studies have found virions containing aberrant stop codons within 
gag [269] and shown that defective viral sequences can contribute to sequence diversity and 
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resistance mutations through recombination events during coinfection [179]. Therefore, we 
postulate that a more diverse proviral landscape resulting from incomplete neutralization of A3G, 
even if littered by hypermutated proviruses, can increase the potential number of viral variants that 
can contribute to adaptation. Additionally, as discussed earlier, defective proviruses may also drive 
chronic immune activation, which is favorable to HIV replication [296]. 
  
In conclusion, we demonstrate that suboptimal neutralization of A3G by a partially defective Vif 
variant improves the fitness of HIV in the presence of a selective pressure. Using high-resolution 
sequencing of plasma and splenocyte compartments, we show that this phenotype results from 
increased diversification in proviral and circulating quasispecies, characterized by an A3G-
mutational footprint. Moreover, distinct dynamics and quasispecies landscapes between plasma, 
spleen and other viral compartments may influence systemic viral fitness and require further 
investigation. We believe the depth and accuracy of our sequencing approach are key and 
distinguish our work from previous studies investigating the role of A3G in humanized mice [166, 
263].  
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3.4. Materials and Methods  
 
Ethics statement: Animal experiments were approved by the Cantonal Veterinary Office 
(#26/2011 & #93/2014) and performed in accordance to local guidelines (TschV, Zurich) and the 
Swiss animal protection law (TschG). Procurement of human cord blood was approved by the 
Ethical Committee of the University of Zurich (EK #EK1103) and cord blood was collected with 
written informed consent from donors. 
 
Cells and reagents: Cell lines were obtained from NIH Aids reagent program. 293T cells and 
TZM-bl cells were cultured in DMEM medium (Lonza) supplemented with 10% FBS (Lonza), 1% 
Penicillin-Streptomycin (Life technologies). MT4 cells and primary mononuclear cells (MNCs) 
derived from cord blood were cultured in RPMI medium (Lonza) supplemented as above. MNCs 
were activated with PHA at 1ug/mL for 48 hours prior to use in infection assays. 3TC tablets 
(Epivir, GlaxoSmithKlein, UK) were weighed, pulverized and admixed to food pellets as previously 
described [163].  
 
Viral stocks: Viral stocks were produced by transient transfection of 293T cells with 
polyethylenimin (Sigma-Aldrich) and the pNL4-3 plasmid (NIH Aids reagent program, Cat. No. 
114), or plasmids encoding the various Vif-mutants (HIV-45G and HIV-ΔSLQ) within the backbone 
of pNL4-3. The HIV-45G and HIV-ΔSLQ mutants were generated as previously described [186, 
188, 303]. After 3 to 18 hours incubation, the supernatant was exchanged for fresh D-10 medium. 
Forty-eight hours post-transfection, the supernatant was harvested, filtered (0.22um, Steriflip, EMD 
Millipore), aliquoted and frozen at -80°C until use. The tissue culture infectious dose 50 (TCID50) 
of the viral stocks were determined by infection of TZM-bl cells seeded in 96-well plates (104 
cells/well) with serial dilutions of the viral stocks. Forty-eight hours post-infection the cells were 
washed, lysed and fixed and β-galactosidase measured in the plates using the Galacto-Star B-
Galactosidase Reporter Gene System (Applied Biosystems). Plates were scored for the number of 
negative wells and TCID50 was then calculated using the Spearman-Karber formula. 
 
Generation of humanized mice: Hu-mice were generated as previously described [163]. Briefly, 
newborn immunodeficient NOD-scid IL-2Rγ-null (NSG) mice (Jackson laboratory) were sub-lethally 
irradiated (1 Gy) and transplanted intrahepatically with approximately 2.0±0.5×105 cord blood-
derived CD34+ cells. Twelve to sixteen weeks after transplantation, human engraftment and de 
novo human immune system reconstitution in the mice were assessed by flow cytometry (CyAn™ 
ADP Analyzer, Beckman Coulter) by staining PBMCs with anti-human monoclonal antibodies 
against the following cell-surface markers: CD45-Krome Orange (Beckman Coulter), CD3-PE, 
CD4-Pe Cy7, CD8-BV421, CD19-APC (all from Biolegend). Animals were housed under specific 
pathogen free conditions.  
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Infection and 3TC treatment of humanized mice: Hu-mice were infected intraperitoneally with 
the various HIVs at a dose of 2×105 TCID50 per mouse. Plasma viremia was monitored 30 days 
post-infection and thereafter on a biweekly basis using the Cobas® Amplicor technology (Roche, 
Switzerland) (Figure S1A). The detection limit of the assay is 400 HIV RNA copies/mL. At 30 days 
post-infection (i.e. baseline), some infected hu-mice were treated with 3TC. Only hu-mice with a 
detectable viremia at baseline were included in the analyses. At the end of the experiments, hu-
mice were euthanized and spleens were harvested, processed and stored frozen in 10% 
DMSO/FBS in liquid nitrogen. 
 
Amplification of HIV from plasma viral RNA: Viral RNA was extracted from 200μL frozen 
plasma samples using the QIAamp Viral RNA Minikit (Hilden) as per manufacturer’s instruction. 
For amplification of samples for deep sequencing, cDNAs were synthesized using custom primers 
in a reverse transcription reaction. (Refer to Table S1 for primer sequences; Integrated DNA 
Technologies). From 5’ to 3’, our first generation RT cDNA primer (4372) included a 16 bp HIV-
specific sequence (accession: AF324493.2: 3336-3351), 8 bp randomized sequence (UMID) and 
23bp HIV-specific sequence (AF324493.2: 3305-3327). Viral cDNA was synthesized using the 
ThermoScript RT-PCR System (Thermo Fisher Scientific). Briefly, RNA and primer were denatured 
at 65°C for 5 min. Thermoscript reaction mix was added to the RNA and primer (50°C for 60 min, 
85°C for 5 min). Viral cDNA was column purified (Zymo Clean and Concentrator) and amplified in a 
first round PCR using primers 1922 (AF324493.2: 2929-2946) and 1923 (AF324493.2: 3337-
3356). First round PCR used Pfx50 polymerase (94°C for 2 min, followed by 23 cycles of 93°C for 
15 sec, 48°C for 30 sec, 68°C for 60 sec and a final extension of 68°C for 10 min) (Thermo Fisher 
Scientific). First round products were purified (Zymo Clean and Concentrator) and a second PCR 
was performed to add Illumina-based adapters using custom primers 1690 and one of 734 primers 
with distinct MiSeq barcode identifiers (Table S1). The second round PCR used PfuUltra II Fusion 
HS Polymerase (95°C for 2 min, followed by 25 cycles of 93°C for 20 sec, 50°C for 20 sec, 72°C 
for 15 sec and a final extension of 72°C for 10 min) (Agilent Technologies). Second round products 
were confirmed by electrophoresis and purified by SPRIselect magnetic bead selection (Beckman 
Coulter). 
 
To amplify vif sequences from plasma vRNA, a distinct cDNA synthesis primer was used (4373). 
From 5’ to 3’, primer 4373 included a 16 bp T7 sequence, an 8bp randomized sequence and 23 bp 
HIV-specific sequence (AF324493.2: 5386-5406). Viral cDNA was synthesized using the 
ThermoScript RT-PCR System and purified as described above. cDNAs were amplified in the first 
round PCR using primers 2402 (AF324493.2: 4993-5012) and 2401 (T7). First round products 
were purified and amplified in a second round PCR using primers 2403 and one of 80 primers with 
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distinct MiSeq barcode identifiers and complementarity to the T7 sequence. Products and cycling 
conditions were the same as RT products.  
 
Amplification of HIV transcripts from splenocyte RNA: Spleens were thawed and 
homogenized in 1mL Trizol LS Reagent (Thermo Fisher Scientific). RNA was precipitated and 
extracted from aqueous phases per manufacturer’s protocol. RNA was treated with rDNase I to 
remove residual DNA (Ambion). Organic phases were saved for DNA extraction. cDNAs were 
synthesized using the second generation RT cDNA primer (4633). From 5’ to 3’, the second 
generation primer included a 16 bp T7 sequence, 8 bp randomized sequence (UMID) and 23 bp 
HIV-specific sequence (AF324493.2: 3305-3327). Viral cDNA was synthesized and column purified 
as described above. Viral cDNA was amplified in the first round PCR using primers 1922 and 2401 
and PfuUltra II Fusion HS Polymerase (95°C for 2 min, followed by 23 cycles of 93°C for 20 sec, 
48°C for 20 sec, 72°C for 15 sec and a final extension of 72°C for 10 min). First round products 
were purified as described above and amplified in a second round PCR using primer 1690 and one 
of 80 primers with distinct MiSeq barcode identifiers and complementarity to the T7 sequence 
(Table S1). Second round PCRs used PfuUltra II Fusion HS Polymerase (95°C for 2 min, followed 
by 25 cycles of 93°C for 20 sec, 48°C for 20 sec, 72°C for 15 sec and a final extension of 72°C for 
10 min). Second round products were purified as described above.  
 
Amplification of HIV proviruses from splenocyte DNA: Genomic DNA from splenocytes was 
extracted from Trizol LS organic phases by an optimized protocol using back extraction buffer (4M 
guanidium thiocyanate, 50mM sodium citrate, 1M Tris). For amplification of proviruses, a single 
molecule extension was performed to create single-stranded proviral sequences with UMIDs. 
Primer 4633 was used to amplify the proviral sequences using PfuUltra II Fusion HS Polymerase 
(95°C for 2 min, followed by 1 cycle of 93°C for 20 sec, 48°C for 20 sec, 72°C for 15 sec and a 
final extension of 72°C for 15 min). Products larger than 300 bp were column purified (Zymo Size-
Selection). First and second round PCRs were done using the same primers used for splenocyte 
HIV transcripts. Proviral sequences were amplified using PfuUltra II Fusion HS Polymerase (first 
round: 95°C for 2 min, followed by 25 cycles of 93°C for 20 sec, 48°C for 20 sec, 72°C for 15 sec 
and a final extension of 72°C for 10 min; second round: 95°C for 2 min, followed by 30 cycles of 
93°C for 20 sec, 48°C for 20 sec, 72°C for 15 sec and a final extension of 72°C for 10 min). 
Purifications between rounds were done as described above.  
 
MiSeq Library Preparation and MiSeq Instrumentation: Sequencing libraries were run on the 
Illumina MiSeq to sequence paired-end reads. To prepare libraries, bead-purified PCR products 
containing Illumina adapters (376 bp RT amplicons and 393 bp vif amplicons) were quantitated by 
Qubit dsDNA HS Assay Kit (Invitrogen, Carlsbad, CA). To sequence 250 bp of the RT region, a 
6pM final library was run with a 20% spike-in of PhiX Control V3 (Illumina, San Diego, CA) for 
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2x150 cycles using MiSeq Reagent Kit v2 (250 cycles) or MiSeq Reagent Kit v3 (600 cycles). 
Custom sequencing primers were used for the forward (1692), index (plasma, 3890; splenocyte 
transcript/proviral, 4577), and reverse (plasma, 3889; splenocyte transcript/proviral, 4578) reads. 
To sequence 269 bp of vif, a 6pM final library was run with a 15% spike-in of PhiX Control V3 for 
2x150 cycles. Custom sequencing primers were used for the forward (4580), index (4577) and 
reverse (4578) reads.  
 
For HIV RT we sequenced a total of 83 HIV RNA samples (69 vRNA, 14 HIV transcripts) from 14 
animals with the first generation RT ID primer 4372 and 61 HIV RNA samples (42 vRNA, 19 HIV 
transcripts) from 20 animals with the second generation RT ID primer 4633. We obtained 
11’855’691 high quality pairwise HIV RT reads, which represented 333’258 UMIDs (#4372: 
136,241; #4633: 197,017). We also sequenced a total of 21 HIV DNA samples from 21 different 
mice with the second generation RT ID primer 4633. We obtained 1‘878‘208 pairwise HIV RT 
reads that represented 5‘547 UMIDs. For HIV vif, we sequenced 27 plasma samples and obtained 
579’466 reads and identified 6’983 distinct UMIDs.  
 
Bioinformatic Pipeline for Sequence Analyses: Custom Unix and Perl scripts were written to 
process FASTQ files. First, paired-end reads were merged using the Paired-End reAd mergeR 
[304]. Reads were aligned to pNL4-3 RT or vif (AF324493.2) and filtered. Consensus sequences 
for sequences defined by a distinct UMID were identified using in-house scripts (Figure S3B). 
Additional custom scripts were written to quantify 3TC resistance mutations at RT codon 184 and 
to compute mutation rates. DNASP v5 polymorphism software was used to calculate the average 
number of nucleotide differences per site between two sequences, or nucleotide diversity (π) [305]. 
To identify hypermutants, the Hypermut 2.0 program 
(https://www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html) was used. Briefly, Fisher’s 
exact test calculated a probability associated with hypermutation based on frequency of G-to-A 
changes at APOBEC3 target sites (GRD->ARD, R: A or G, D: A, T or G) and non-target sites. If 
p<0.05, the sequence was defined as a hypermutant. 
 
Statistics: Data were analyzed with nonparametric, two-tailed tests, unless the dataset passed 
normality testing. Significance testing is reported as exact p-values in the text or using asterisks to 
represent p-values in the figures (i.e. “ * ”= p ≤ 0.05; “ ** ” = p ≤ 0.01; “ *** ” = p ≤ 0.001; “ **** ”= p ≤ 
0.0001). Results are reported as mean ± standard deviation (SD) and figures depict group mean 
and SD, unless stated otherwise. All statistics were performed using the built-in analysis packages 
from GraphPad Prism v7.0 Suite (GraphPad Software). 
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3.5. Supplementary Material 
Figure S1. Cellular dynamics in hu-mice over time. A.-B. Flow cytometric analyses of human 
engraftment levels (i.e. %CD45+) at 30 days prior to and after infection in hu-mice intended for treated 
and untreated groups. C.-F. Change in CD4+ T cell frequencies (C, E) and CD4+/CD8+ T cell ratio (D, F) 
from the day of infection to endpoint in untreated (left-hand side panels) and treated (right-hand side 
panels) hu-mice. Gray shading represents days on 3TC treatment. Pale lines represent individual mice 
and bold lines represent group means. 
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Figure S2. Sequencing of HIV in infected hu-mice. A. Schematic depicting the use of a cDNA 
synthesis primer with a unique molecular tag (UMID), to label and track HIV nucleic acids for 
sequencing. B. Workflow for sequencing HIV nucleic acids. C.-D. Number of samples per UMID for 
the first generation of RT-primer 4372 (C) and second generation of RT-primer 4633 (D). Red bars 
reflect UMIDs that have only 1 mismatch to the HIV specific sequence and thus have a bias in 
amplification. These were excluded from downstream analyses. E. Number of individual nucleic acid 
molecules sequenced per sample in plasma and splenocytes for HIV RT and Vif genes.   
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Figure S3. Overall and specific G-to-A mutations in plasma quasispecies over time. A.-B. Overall 
mutation rates in plasma viral RNA of untreated (A) and 3TC treated (B) hu-mice. C.-D. Fraction of GG 
dinucleotides mutated to AG in untreated (C) and treated (D) hu-mice. E.-F. Fraction of GA dinucleotides 
mutated to AA in untreated (E) and treated (F) hu-mice. Mean±SD depicted. 
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Figure S4. Stability of Vif genotypes in plasma over time. A.-B. Frequencies of Vif-E45 (purple) and Vif-
45G (orange) genotypes in plasma of untreated (A) and treated (B) hu-mice (from Exp. #3) at 30 and 58 days 
post infection. 
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Primer HIV Target Sequence (5' to 3')
4372 RT (1st gen) TTGCCCAATTCAATTTNNNNNNNNATTTCTGTATGTCATTGACAGTC
4373 Vif TAATACGACTCACTATAGGGNNNNNNNNATTTCTTATAGCAGATTCTGA
4633 RT (2nd gen) TTGCCCAATTCAATTTNNNNNNNNATTTCTGTATGTCATTGACAGTC
Primer HIV Target Sequence (5' to 3')
1922 RT (For) ATAATACTRCATTTACCATAC
1923 RT (Rev) CTGACTTGCCCAATTCAATT
2402 Vif (For) GTGACATAAAAGTAGTGCCA
2401 RT/Vif (T7) (Rev) TAATACGACTCACTATAGGG
Primer HIV Target Sequence (5' to 3')
1690 RT AATGATACGGCGACCACCGAGATCTACACTCTTTCGGCCTTTTAGAAAACAAAATC
2403 Vif AATGATACGGCGACCACCGAGATCTACACTCTTTCGACACCATATGTATATTTCAA
Primer HIV Target Sequence (5' to 3')
2128 RT CAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGAGTCTGACTTGCCCAATTCAAT
2129 RT CAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGAGTCTGACTTGCCCAATTCAAT
2130 RT CAAGCAGAAGACGGCATACGAGATACATCGGTGACTGGAGTCTGACTTGCCCAATTCAAT
2131 RT CAAGCAGAAGACGGCATACGAGATGCCTAAGTGACTGGAGTCTGACTTGCCCAATTCAAT
2132 RT CAAGCAGAAGACGGCATACGAGATTGGTCAGTGACTGGAGTCTGACTTGCCCAATTCAAT
2133 RT CAAGCAGAAGACGGCATACGAGATCACTGTGTGACTGGAGTCTGACTTGCCCAATTCAAT
2134 RT CAAGCAGAAGACGGCATACGAGATATTGGCGTGACTGGAGTCTGACTTGCCCAATTCAAT
2135 RT CAAGCAGAAGACGGCATACGAGATGATCTGGTGACTGGAGTCTGACTTGCCCAATTCAAT
2136 RT CAAGCAGAAGACGGCATACGAGATTCAAGTGTGACTGGAGTCTGACTTGCCCAATTCAAT
2137 RT CAAGCAGAAGACGGCATACGAGATCTGATCGTGACTGGAGTCTGACTTGCCCAATTCAAT
2138 RT CAAGCAGAAGACGGCATACGAGATAAGCTAGTGACTGGAGTCTGACTTGCCCAATTCAAT
2139 RT CAAGCAGAAGACGGCATACGAGATGTAGCCGTGACTGGAGTCTGACTTGCCCAATTCAAT
2140 RT CAAGCAGAAGACGGCATACGAGATTACAAGGTGACTGGAGTCTGACTTGCCCAATTCAAT
2141 RT CAAGCAGAAGACGGCATACGAGATTTGACTGTGACTGGAGTCTGACTTGCCCAATTCAAT
2142 RT CAAGCAGAAGACGGCATACGAGATGGAACTGTGACTGGAGTCTGACTTGCCCAATTCAAT
2143 RT CAAGCAGAAGACGGCATACGAGATTGACATGTGACTGGAGTCTGACTTGCCCAATTCAAT
2144 RT CAAGCAGAAGACGGCATACGAGATGGACGGGTGACTGGAGTCTGACTTGCCCAATTCAAT
2145 RT CAAGCAGAAGACGGCATACGAGATCTCTACGTGACTGGAGTCTGACTTGCCCAATTCAAT
2146 RT CAAGCAGAAGACGGCATACGAGATGCGGACGTGACTGGAGTCTGACTTGCCCAATTCAAT
2147 RT CAAGCAGAAGACGGCATACGAGATTTTCACGTGACTGGAGTCTGACTTGCCCAATTCAAT
2148 RT CAAGCAGAAGACGGCATACGAGATGGCCACGTGACTGGAGTCTGACTTGCCCAATTCAAT
2149 RT CAAGCAGAAGACGGCATACGAGATCGAAACGTGACTGGAGTCTGACTTGCCCAATTCAAT
2150 RT CAAGCAGAAGACGGCATACGAGATCGTACGGTGACTGGAGTCTGACTTGCCCAATTCAAT
2151 RT CAAGCAGAAGACGGCATACGAGATCCACTCGTGACTGGAGTCTGACTTGCCCAATTCAAT
2152 RT CAAGCAGAAGACGGCATACGAGATGCTACCGTGACTGGAGTCTGACTTGCCCAATTCAAT
2309 RT CAAGCAGAAGACGGCATACGAGATATCAGTGTGACTGGAGTCTGACTTGCCCAATTCAAT
2310 RT CAAGCAGAAGACGGCATACGAGATGCTCATGTGACTGGAGTCTGACTTGCCCAATTCAAT
2311 RT CAAGCAGAAGACGGCATACGAGATAGGAATGTGACTGGAGTCTGACTTGCCCAATTCAAT
2312 RT CAAGCAGAAGACGGCATACGAGATCTTTTGGTGACTGGAGTCTGACTTGCCCAATTCAAT
2313 RT CAAGCAGAAGACGGCATACGAGATTAGTTGGTGACTGGAGTCTGACTTGCCCAATTCAAT
2314 RT CAAGCAGAAGACGGCATACGAGATCCGGTGGTGACTGGAGTCTGACTTGCCCAATTCAAT
2315 RT CAAGCAGAAGACGGCATACGAGATATCGTGGTGACTGGAGTCTGACTTGCCCAATTCAAT
2316 RT CAAGCAGAAGACGGCATACGAGATAAAATGGTGACTGGAGTCTGACTTGCCCAATTCAAT
2317 RT CAAGCAGAAGACGGCATACGAGATATTCCGGTGACTGGAGTCTGACTTGCCCAATTCAAT
2318 RT CAAGCAGAAGACGGCATACGAGATGCTGTAGTGACTGGAGTCTGACTTGCCCAATTCAAT
2319 RT CAAGCAGAAGACGGCATACGAGATGAATGAGTGACTGGAGTCTGACTTGCCCAATTCAAT
2320 RT CAAGCAGAAGACGGCATACGAGATTCGGGAGTGACTGGAGTCTGACTTGCCCAATTCAAT
2321 RT CAAGCAGAAGACGGCATACGAGATCTTCGAGTGACTGGAGTCTGACTTGCCCAATTCAAT
2322 RT CAAGCAGAAGACGGCATACGAGATTGCCGAGTGACTGGAGTCTGACTTGCCCAATTCAAT
2562 RT CAAGCAGAAGACGGCATACGAGATTGCTTCGTGACTGGAGTCTGACTTGCCCAATTCAAT
2563 RT CAAGCAGAAGACGGCATACGAGATACGCGTGTGACTGGAGTCTGACTTGCCCAATTCAAT
2564 RT CAAGCAGAAGACGGCATACGAGATGGGAGCGTGACTGGAGTCTGACTTGCCCAATTCAAT
2565 RT CAAGCAGAAGACGGCATACGAGATCCGACAGTGACTGGAGTCTGACTTGCCCAATTCAAT
2566 RT CAAGCAGAAGACGGCATACGAGATAGTGCAGTGACTGGAGTCTGACTTGCCCAATTCAAT
2567 RT CAAGCAGAAGACGGCATACGAGATACCGCTGTGACTGGAGTCTGACTTGCCCAATTCAAT
2568 RT CAAGCAGAAGACGGCATACGAGATCAAGCAGTGACTGGAGTCTGACTTGCCCAATTCAAT
2569 RT CAAGCAGAAGACGGCATACGAGATTAGCGCGTGACTGGAGTCTGACTTGCCCAATTCAAT
2570 RT CAAGCAGAAGACGGCATACGAGATTACCCTGTGACTGGAGTCTGACTTGCCCAATTCAAT
2571 RT CAAGCAGAAGACGGCATACGAGATAAATACGTGACTGGAGTCTGACTTGCCCAATTCAAT
2572 RT CAAGCAGAAGACGGCATACGAGATCTATCTGTGACTGGAGTCTGACTTGCCCAATTCAAT
2573 RT CAAGCAGAAGACGGCATACGAGATTTATGCGTGACTGGAGTCTGACTTGCCCAATTCAAT
4444 RT CAAGCAGAAGACGGCATACGAGATACATATGTGACTGGAGTCTGACTTGCCCAATTCAAT
4445 RT CAAGCAGAAGACGGCATACGAGATACGTCTGTGACTGGAGTCTGACTTGCCCAATTCAAT
4446 RT CAAGCAGAAGACGGCATACGAGATACTAGCGTGACTGGAGTCTGACTTGCCCAATTCAAT
4447 RT CAAGCAGAAGACGGCATACGAGATACTATAGTGACTGGAGTCTGACTTGCCCAATTCAAT
4448 RT CAAGCAGAAGACGGCATACGAGATAGTCTAGTGACTGGAGTCTGACTTGCCCAATTCAAT
4449 RT CAAGCAGAAGACGGCATACGAGATATTGAGGTGACTGGAGTCTGACTTGCCCAATTCAAT
4450 RT CAAGCAGAAGACGGCATACGAGATATATCAGTGACTGGAGTCTGACTTGCCCAATTCAAT
4451 RT CAAGCAGAAGACGGCATACGAGATATGATTGTGACTGGAGTCTGACTTGCCCAATTCAAT
4452 RT CAAGCAGAAGACGGCATACGAGATATGCTGGTGACTGGAGTCTGACTTGCCCAATTCAAT
4453 RT CAAGCAGAAGACGGCATACGAGATCACGCAGTGACTGGAGTCTGACTTGCCCAATTCAAT
4454 RT CAAGCAGAAGACGGCATACGAGATCATCAGGTGACTGGAGTCTGACTTGCCCAATTCAAT
4455 RT CAAGCAGAAGACGGCATACGAGATCGCAGTGTGACTGGAGTCTGACTTGCCCAATTCAAT
4456 RT CAAGCAGAAGACGGCATACGAGATCATAGCGTGACTGGAGTCTGACTTGCCCAATTCAAT
4457 RT CAAGCAGAAGACGGCATACGAGATCTAGTAGTGACTGGAGTCTGACTTGCCCAATTCAAT
4458 RT CAAGCAGAAGACGGCATACGAGATGACACAGTGACTGGAGTCTGACTTGCCCAATTCAAT
4459 RT CAAGCAGAAGACGGCATACGAGATGTCTACGTGACTGGAGTCTGACTTGCCCAATTCAAT
4460 RT CAAGCAGAAGACGGCATACGAGATGAGATCGTGACTGGAGTCTGACTTGCCCAATTCAAT
4461 RT CAAGCAGAAGACGGCATACGAGATGCACGTGTGACTGGAGTCTGACTTGCCCAATTCAAT
4462 RT CAAGCAGAAGACGGCATACGAGATTGATCAGTGACTGGAGTCTGACTTGCCCAATTCAAT
4463 RT CAAGCAGAAGACGGCATACGAGATTATCTCGTGACTGGAGTCTGACTTGCCCAATTCAAT
4464 RT CAAGCAGAAGACGGCATACGAGATTCGCTCGTGACTGGAGTCTGACTTGCCCAATTCAAT
4465 RT CAAGCAGAAGACGGCATACGAGATTCTCGTGTGACTGGAGTCTGACTTGCCCAATTCAAT
4466 RT CAAGCAGAAGACGGCATACGAGATTGCGATGTGACTGGAGTCTGACTTGCCCAATTCAAT
Reverse Transcription (cDNA synthesis) Primers
First Round PCR Primers
Second Round PCR Primers (Forward Only)
Second Round PCR Primers (Reverse with MiSeq Barcodes) (N=74)
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Primer HIV Target Sequence (5' to 3')
4634 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGAGTAATACGACTCACTATAGGG
4635 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATACATCGGTGACTGGAGTAATACGACTCACTATAGGG
4636 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGCCTAAGTGACTGGAGTAATACGACTCACTATAGGG
4637 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTGGTCAGTGACTGGAGTAATACGACTCACTATAGGG
4638 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCACTGTGTGACTGGAGTAATACGACTCACTATAGGG
4639 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATATTGGCGTGACTGGAGTAATACGACTCACTATAGGG
4640 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGATCTGGTGACTGGAGTAATACGACTCACTATAGGG
4641 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTCAAGTGTGACTGGAGTAATACGACTCACTATAGGG
4642 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCTGATCGTGACTGGAGTAATACGACTCACTATAGGG
4643 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATAAGCTAGTGACTGGAGTAATACGACTCACTATAGGG
4644 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGTAGCCGTGACTGGAGTAATACGACTCACTATAGGG
4645 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTACAAGGTGACTGGAGTAATACGACTCACTATAGGG
4646 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTTGACTGTGACTGGAGTAATACGACTCACTATAGGG
4647 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGGAACTGTGACTGGAGTAATACGACTCACTATAGGG
4648 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTGACATGTGACTGGAGTAATACGACTCACTATAGGG
4649 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGGACGGGTGACTGGAGTAATACGACTCACTATAGGG
4650 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCTCTACGTGACTGGAGTAATACGACTCACTATAGGG
4651 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGCGGACGTGACTGGAGTAATACGACTCACTATAGGG
4652 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTTTCACGTGACTGGAGTAATACGACTCACTATAGGG
4653 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGGCCACGTGACTGGAGTAATACGACTCACTATAGGG
4654 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCGAAACGTGACTGGAGTAATACGACTCACTATAGGG
4655 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCGTACGGTGACTGGAGTAATACGACTCACTATAGGG
4656 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCCACTCGTGACTGGAGTAATACGACTCACTATAGGG
4657 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGCTACCGTGACTGGAGTAATACGACTCACTATAGGG
4658 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATATCAGTGTGACTGGAGTAATACGACTCACTATAGGG
4659 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGCTCATGTGACTGGAGTAATACGACTCACTATAGGG
4660 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATAGGAATGTGACTGGAGTAATACGACTCACTATAGGG
4661 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCTTTTGGTGACTGGAGTAATACGACTCACTATAGGG
4662 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTAGTTGGTGACTGGAGTAATACGACTCACTATAGGG
4663 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCCGGTGGTGACTGGAGTAATACGACTCACTATAGGG
4664 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATATCGTGGTGACTGGAGTAATACGACTCACTATAGGG
4665 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATAAAATGGTGACTGGAGTAATACGACTCACTATAGGG
4666 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATATTCCGGTGACTGGAGTAATACGACTCACTATAGGG
4667 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGCTGTAGTGACTGGAGTAATACGACTCACTATAGGG
4668 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGAATGAGTGACTGGAGTAATACGACTCACTATAGGG
4669 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTCGGGAGTGACTGGAGTAATACGACTCACTATAGGG
4670 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCTTCGAGTGACTGGAGTAATACGACTCACTATAGGG
4671 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTGCTTCGTGACTGGAGTAATACGACTCACTATAGGG
4672 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATACGCGTGTGACTGGAGTAATACGACTCACTATAGGG
4673 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGGGAGCGTGACTGGAGTAATACGACTCACTATAGGG
4674 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCCGACAGTGACTGGAGTAATACGACTCACTATAGGG
4675 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATAGTGCAGTGACTGGAGTAATACGACTCACTATAGGG
4676 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATACCGCTGTGACTGGAGTAATACGACTCACTATAGGG
4677 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTAGCGCGTGACTGGAGTAATACGACTCACTATAGGG
4678 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATAAATACGTGACTGGAGTAATACGACTCACTATAGGG
4679 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCTATCTGTGACTGGAGTAATACGACTCACTATAGGG
4680 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTTATGCGTGACTGGAGTAATACGACTCACTATAGGG
4681 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATACATATGTGACTGGAGTAATACGACTCACTATAGGG
4682 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATACGTCTGTGACTGGAGTAATACGACTCACTATAGGG
4683 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATACTAGCGTGACTGGAGTAATACGACTCACTATAGGG
4684 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATACTATAGTGACTGGAGTAATACGACTCACTATAGGG
4685 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATAGTCTAGTGACTGGAGTAATACGACTCACTATAGGG
4686 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATATTGAGGTGACTGGAGTAATACGACTCACTATAGGG
4687 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATATATCAGTGACTGGAGTAATACGACTCACTATAGGG
4688 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATATGATTGTGACTGGAGTAATACGACTCACTATAGGG
4689 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATATGCTGGTGACTGGAGTAATACGACTCACTATAGGG
4690 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCACGCAGTGACTGGAGTAATACGACTCACTATAGGG
4691 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCATCAGGTGACTGGAGTAATACGACTCACTATAGGG
4692 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCGCAGTGTGACTGGAGTAATACGACTCACTATAGGG
4693 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCATAGCGTGACTGGAGTAATACGACTCACTATAGGG
4694 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCTAGTAGTGACTGGAGTAATACGACTCACTATAGGG
4695 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGACACAGTGACTGGAGTAATACGACTCACTATAGGG
4696 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGTCTACGTGACTGGAGTAATACGACTCACTATAGGG
4697 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGAGATCGTGACTGGAGTAATACGACTCACTATAGGG
4698 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGCACGTGTGACTGGAGTAATACGACTCACTATAGGG
4699 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTGATCAGTGACTGGAGTAATACGACTCACTATAGGG
4700 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTATCTCGTGACTGGAGTAATACGACTCACTATAGGG
4701 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTCGCTCGTGACTGGAGTAATACGACTCACTATAGGG
4702 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTCTCGTGTGACTGGAGTAATACGACTCACTATAGGG
4703 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTGCGATGTGACTGGAGTAATACGACTCACTATAGGG
4704 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTGCCGAGTGACTGGAGTAATACGACTCACTATAGGG
4705 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTACCCTGTGACTGGAGTAATACGACTCACTATAGGG
4722 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGTTACAGTGACTGGAGTAATACGACTCACTATAGGG
4723 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGGATTCGTGACTGGAGTAATACGACTCACTATAGGG
4724 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATACAGATGTGACTGGAGTAATACGACTCACTATAGGG
4725 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTATTGCGTGACTGGAGTAATACGACTCACTATAGGG
4726 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATGTCTATGTGACTGGAGTAATACGACTCACTATAGGG
4727 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATTCTCAGGTGACTGGAGTAATACGACTCACTATAGGG
4728 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATATAGAGGTGACTGGAGTAATACGACTCACTATAGGG
4729 RT/Vif (T7) CAAGCAGAAGACGGCATACGAGATCTACAAGTGACTGGAGTAATACGACTCACTATAGGG
Primer Target Sequence (5' to 3')
1692 RT For ACACTCTTTCGGCCTTTTAGAAAACAAAATC
3890 RT Index ATTGAATTGGGCAAGTCAGACTCCAGTCAC
3889 RT Rev GTGACTGGAGTCTGACTTGCCCAATTCAAT
4577 RT/Vif (T7) Index CCCTATAGTGAGTCGTATTACTCCAGTCAC
4578 RT/Vif (T7) Rev GTGACTGGAGTAATACGACTCACTATAGGG
4580 Vif For CGAGATCTACACTCTTTCGACACCATATGTATATTTC
MiSeq Sequencing Primers
Second Round PCR Primers (Reverse with MiSeq Barcodes) (N=80)
Table S1. Primers for reverse transcription, PCR amplification and Illumina MiSeq Sequencing. 
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4. VARIA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This study assesses the leukocyte reconstitution in NSG hu-mice, transplanted with cord-blood 
derived CD34+ cells over time. The main finding are that human engraftment levels were stable for 
up to 32 weeks in the periphery, spleen and bone marrow, and that this long-term engraftment was 
supported by the maintenance of primitive hematopoietic stem cells in the bone marrow over time.  
 
Personal contributions: I was involved in the isolation of the cord-blood derived CD34+ cells, 
generation of the humanized mice and the weekly animal health checks.  
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This study is submitted and assesses the anti-HIV activity of different interferon alpha (IFNa) 
subtypes, which differ in their binding affinities to IFNARs 1 and 2, in primary cells. The main 
findings are that the different IFNa subtypes do not differ qualitatively, but rather quantitatively, in 
their ability to restrict HIV replication. Namely, when high enough doses of each IFNa were used, 
their anti-HIV effects were comparable. Also, the interferon-stimulated genes (ISGs) response in 
primary CD4+ T cells after treatment with different IFNa subtypes revealed a similar regulation of 
ISGs across all conditions, with gene expression patterns clustering with donors rather than the 
IFNa subtype treatment. 
 
Personal contributions: I was involved in the analysis of interferon-stimulated gene expression 
data and generation of Figure 4A.  
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5. CONCLUSIONS AND FUTURE DIRECTIONS 
 
As outlined in the introduction, a major barrier to HIV cure is HIV’s ability to establish latent 
infections, whereby the virus can persist in a silent state for years, despite effective suppression of 
viral replication with cART. This latent reservoir appears to be seeded throughout the host, in 
different anatomical compartments and is unaffected by host-immune responses and cART. Yet, 
upon interruption of cART, viral rebound and progression of HIV infection rapidly occur in almost all 
HIV-infected patients (even after decades of effective viral suppression by cART), due to the ability 
of latently HIV-infected cells to revert to a productive state and re-establish a systemic infection [9-
11, 13, 16, 67, 306]. Thus, to stop the HIV pandemic, a cure is needed and is likely to require the 
complete clearing of the latent HIV reservoir. In order to achieve this, we need more insights into 
HIV latency.   
 
As we lack a ubiquitous and specific means to identify latently infected cells in aviremic HIV-
infected patients and access to patient samples is very limited, characterization of the cell types 
and the mechanisms contributing to HIV latency are largely restricted to ex vivo viral outgrowth 
assays (VOAs) on patient PBMCs and in vitro models of latently infected cells. However, HIV 
infection is a systemic disease, with HIV replication mainly occurring in deep lymphoid tissues 
where the lymphocyte subsets and immune landscape differ substantially from the peripheral blood 
[51, 60, 90, 91, 93, 94, 217, 307]. Furthermore, HIV compartmentalization has been observed in 
patients [52, 53, 82, 197], showing that HIV diversity, replication and reservoirs in given tissues 
differ according to the anatomical compartment. Together this suggests that studying the 
peripheral blood HIV reservoir in patients is not very reflective of latently infected cells in other 
anatomical compartments. Additionally, in vitro models of latently infected cells do not fully 
recapitulate the ex vivo response characteristics of reservoir cells in patients [145]. It is noteworthy 
that the ex vivo response of PBMCs from aviremic patients to different LRAs also greatly varies 
between donors [242]. The lack of a representative model of systemic HIV latency greatly impedes 
efforts in HIV cure, with the implication that so far, no pharmacological intervention has been able 
to block, or even significantly delay, viral rebound in patients after cART interruption [142]. 
Strikingly, even though IL-2 alone or in combination with IFN-gamma, induced a reduction in the 
frequency of latently infected PBMCs in patients, viral rebound still rapidly occurred after cART 
interruption [134]. Taken together, these findings highlight how crucial it is to gain more insight into 
genuine HIV reservoirs seeded beyond the blood compartment. Hereby I do not seek to devalue in 
vitro models of HIV latency and the key insights these have provided, but rather my intention is to 
highlight that as HIV seeds a systemic and heterogeneous reservoir, systemic investigations and 
combinatorial latency reversing approaches will be required if we hope to cure HIV-infected 
patients.  
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In the first part of this thesis, we endeavored to develop an in vivo model to study HIV latency 
systemically. We used the NSG hu-mouse model as a basis for our model, as hu-mice are well-
established and accepted models for studying HIV pathogenesis and persistence [160, 161]. In 
addition, as the HSPCs used to reconstitute the mice can be genetically modified prior to 
transplantation [205, 208], hu-mice provide a uniquely mutable system to work with. To be able to 
specifically identify latently infected cells in our HIV reporter hu-mouse model, we incorporated an 
HIV-inducible RFP reporter transgene (i.e. HR4lox transgene) into the NSG hu-mouse model. 
Specifically, the transgene has two parts: a cassette containing a CMV promoter and floxed 
(inverted) RFP, followed by a PGK promoter and GFP cassette, which means transgenic cells are 
constitutively GFP+ and only constitutively express RFP after two Cre-mediated recombination 
events take place at the lox sites flanking the RFP gene. By using a HIV variant that encodes a 
CMV promoter-Cre cassette (i.e. HOCC), Cre-lox recombination becomes dependent on HIV 
infection. Thus in HOCC-infected HR4lox hu-mice, GFP+RFP+ cells comprise a mixture of 
productively and latently infected cells, whereas in HOCC-infected but cART-suppressed HR4lox 
hu-mice (i.e. latency scenario), GFP+RFP+ cells identify latently infected cells. Although our HIV 
reporter hu-mouse model allowed us to isolate infected cells in the productive infection scenario, in 
the context of cART the resolution of the system was too low to unambiguously identify and sort 
reservoir cells. Nevertheless, we are convinced the in vivo model developed herein is a promising 
approach for obtaining genuine latently HIV-infected cell from diverse anatomical compartments 
and is therefore a good basis for further optimization. The two main issues with our model appear 
to be: i) the use of the CMV promoter for gene expression, which may be silenced by methylation 
in vivo; and ii) the high barrier to effective Cre-lox recombination imposed by the lox site design in 
the HR4lox transgene. In the discussion section of chapter 2, I elaborate on modifications that 
might improve the resolution of this HIV latency model. In addition, the use of an alternative 
reporter gene to RFP may help reduce attenuation of the reporter signal, which currently can arise 
due to spectral overlap with the GFP signal in transgenic cells and tissue autofluorescence. Once 
we have improved our HIV reporter hu-mouse model, our ultimate goal is to characterize the cell 
types harboring silent HIV in as many tissues as possible and carryout single cell RNA 
sequencing, which may reveal new ways to specifically target latency maintenance and reversion 
in vivo.  
 
Another critical barrier to HIV eradication is HIV’s ability to rapidly diversify after transmission. This 
key attribute of HIV means that it exists in its host as a pool of genetically diverse and continually 
evolving quasispecies that undermine the development of an effective anti-HIV host immune 
response and anti-HIV vaccine, and supports the emergence of drug-resistant strains [173, 261]. 
Although high in vivo rates of replication and RT-mediated mutagenesis, as well as recombination 
between co-packaged genomes are mechanism explicitly used by HIV for diversification, whether 
APOBEC3-mediated mutagenesis contributes to HIV-1 diversification in vivo remains highly 
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debated. Thus, in the second part of this thesis, we also explored the contribution of APOBEC3G 
(A3G)-induced mutagenesis to viral diversification and adaption using the NSG hu-mouse model. 
A3G is a cytidine deaminase that is part of the human innate immune system and potently restricts 
HIV replication (in the absence of the viral accessory protein Vif) by catalyzing extensive G-to-A 
substitutions in the nascent viral cDNA during reverse transcription [184]. As A3G’s mutagenic 
activity on HIV often introduces premature stop codons or missense mutations in the viral genome 
[47, 114], some studies support the notion that A3G-mediated mutagenesis only results in 
defective (hypermutated) proviruses [176, 193, 194, 270]. On the other hand, A3G has the 
potential to contribute to HIV sequence diversification if the level of genome editing is sublethal or 
if hypermutated viral genomes are rescued by recombination with intact viral sequences [179, 192, 
267]. Elucidating whether A3G plays a role in viral evolution is relevant to understanding the 
emergence of drug-resistances, especially as patients carrying HIV mutants with partially defective 
vif alleles are more likely to fail ART [189, 190, 265, 266]). In addition, it is also important for the 
design and development of novel antiviral treatments aimed at blocking Vif-APOBEC3 interactions 
(reviewed in [308]), as partial inhibition of Vif may turn out to be counterproductive and favor viral 
diversification and escape.  
 
In this study, we show that in hu-mice infected with a HIV clone encoding a Vif mutant with 
suboptimal A3G-neutralizing capabilities, the splenic proviral quasispecies were more diversified 
than in hu-mice infected with WT HIV. This increased proviral diversity was characterized by 
footprints of A3G-mutagenesis and a portion of mutated proviral variants were also represented as 
cell-associated viral transcripts in the spleen and cell-free virions in the plasma. In addition, the Vif 
mutant virus’s adaptation to monotherapy with the reverse transcriptase inhibitor lamivudine (3TC) 
was superior compared to WT HIV. This enhanced fitness phenotype was uniquely associated with 
a preferential emergence of the 3TC-drug resistance mutation M184I, which results from a G-to-A 
substitution in an A3G-favored dinucleotide context, over other 3TC-resistance mutations. Taken 
together, our data support that sublethal A3G-mutagenesis can occur in vivo and that A3G can 
shape the proviral landscape, thereby accelerating the development of drug resistances.  
 
I believe that the use of hu-mice and isogenic HIV clones differing in their ability to counteract A3G 
are key strengths of this study. As HIV diversification is shaped by the interplay between the virus 
and the host immune system, it is crucial to study viral diversification in a system that captures the 
complexity of the human immune system, especially considering that the expression and activity of 
A3G is not homogenous throughout tissues and cell types [309, 310]. Indeed, we initially found that 
the Vif mutant HIV replicated as well as the WT virus in vitro, indicating that in vitro assays do not 
reflect accurately the APOBEC3-Vif axis. Moreover, as it is difficult to unequivocally assess 
whether G-to-A mutations arise from RT-error or APOBEC3-activity, the use of isogenic HIV clones 
is an interesting approach to dissect the contribution of A3G over RT-error to HIV diversification. 
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Specifically, the partially defective Vif mutant HIV used herein contains a single point mutation in 
the A3G-binding domain of Vif. This amino acid has not been specifically associated with Vif 
functions other than A3G-binding and is not part of any of the other HIV gene products [280, 281]. 
Thus, difference observed in hu-mice infected with either of the two viruses should be the result of 
partially unchecked A3G-activity. Moreover, the use of UMIDs in our sequencing methods is 
another key strength of this work, as it allowed us to sequence viral quasispecies in an unbiased 
manner and with high-resolution.  
 
Overall, in this thesis, we sought to address key characteristics of HIV that preclude its eradication, 
namely HIV latency and HIV diversification. To this end, we made extensive use of hu-mice, which 
are powerful tools for study human diseases.  
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